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Peripheral arterial disease (PAD) refers to the obstruction or blockage of arteries of the lower 
extremity vessels. PAD is characterised by accelerated arterial calcification and impairment 
in angiogenesis, both of which associate with adverse cardiovascular outcomes. The 
pathogenesis of lower extremity PAD remains poorly described but is regarded secondary to 
atherosclerosis due to fatty plaque build-up within the arterial wall. Despite the many clinical 
advances available to treat PAD, impairment in microcirculation continues to put patients at 
constant risk of ischemia; increasing their risk of developing limb amputations which 
subsequently affects their quality of life.  Therapies for PAD are centred around alleviating 
stenosis and promoting tissue revascularization following ischemia, and while atherosclerosis 
is recognised as the main cause of PAD, acute or chronic limb ischemia may be the result of 
various other cardiovascular risk factors.  Calcification is implicated as a contributor to PAD, 
but the mechanisms underlying this are not fully elucidated. Firstly, I sought to determine the 
effect of elevated calcium on ischemia-driven angiogenesis. Human coronary artery 
endothelial cells were cultured and incubated with calcification medium (CM) (CaCl2 
2.7mM, Na2PO4 2.0mM) for 24h and conditioned to either normoxia or hypoxia. The 
Hindlimb ischemia model was used to assess the role of high calcium on ischemia-driven 
angiogenesis in vivo, on 8-week-old and 24-week-old mice, with high calcium levels (OPG-/-) 
and wildtype (C57BL6/J, control) mice. Blood flow reperfusion was assessed by Laser 
Doppler Perfusion Imaging (LDPI). In vitro, CM upregulated mRNA expression of 
calcification inductive genes, Bmp2 and Runx2. CM significantly decreased tubule formation 
in normoxia, with further reduction in hypoxia (13%); and reduced cell migration in 
normoxia alone. CM increased the expression of key angiogenic markers Hif-1α and Vegfa 
mRNA levels in normoxic conditions, which coincided with an increase in their protein 
expression in normoxia; and reduction in hypoxia. Incubation with CM reduced cell viability 
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and induced cell death in EC. 8-week-old OPG-/- mice showed elevated serum calcium levels 
and ALP activity, an important diagnostic marker of calcification. LDPI showed striking 
reductions in blood-flow reperfusion of 8-week OPG-/- mice compared to controls at day 14; 
which was further impaired in an aged cohort of mice, with a significant reduction in blood 
flow at day 10. Mechanistically, ischemic limbs of 8-week old OPG-/- mice showed 
significant upregulation HIF-1α and reduced CD31 neovessels. Clinical scoring revealed 
significantly worse outcomes for both limb function and tissue ischemia in the OPG-/- mice 
versus controls, assessed by Tarlov scores, with higher values indicating a worse outcome. 
Furthermore, to assess the effect of calcification milieu on inflammatory-driven angiogenesis, 
cells were stimulated with both CM and TNF-α in vitro to induce inflammation. Overall, CM 
had no additive effect in driving inflammatory-driven angiogenesis, with no effects on HIF-
1α and VEGFA expression. CM however induced the expression of inflammatory markers 
ICAM, VCAM, MCP1 and NF- κB (P65) expression in treated cells compared to controls. 
When this was modelled in vivo using the peri-arterial femoral cuff placement, OPG-/- mice 
with high calcification milieu displayed no changes in angiogenic marker expression though 
displayed significantly elevated inflammatory-marker expression. This is the first 
demonstration that high-levels of calcium negatively regulates ischemia-driven angiogenesis. 
These findings have implications for the development of therapies that can suppress 
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1. Introduction to Cardiovascular Diseases  
Cardiovascular diseases (CVD) are the leading cause of death worldwide accounting 
for an estimated 31% of global deaths. CVD is the main cause of death in Australians, killing 
1 person every 11 minutes1. According to the World Health Organisation (WHO), 
approximately 17.3 million people died from CVD in 2008, with predictions that around 23.6 
million individuals will die from CVD, mainly heart disease by the year 20302. The most 
common cause of CVD is atherosclerosis, or the accumulation of fatty plaques in the arterial 
wall which results in the narrowing of blood vessels. Atherosclerosis is a three pathology 
disease and is associated with coronary artery disease, peripheral arterial diseases and 
cerebrovascular disease3.  
 
1.1 Pathogenesis of Atherosclerosis  
Atherosclerosis is a complex inflammatory process that occurs due to the 
accumulation of lipids within the artery wall. This occurs in large and medium-sized arteries 
and leads to ischemia of the heart, brain or extremities, which can ultimately lead to 
Myocardial Infarction (MI), stroke and peripheral vascular diseases4. In atherosclerotic 
plaques, vascular calcification (VC) can appear in two morphologies of either (1) micro or 
spotty early calcification and (2) macro or sheet like late-stage calcification5. 
Microcalcifications are said to be more inflammatory and may perpetuate inflammatory cycles 
leading to plaque instability. Conversely, macrocalcifications are thought to have plaque 
stabilizing properties5. Furthermore, VC in the form of spotty intimal microcalcifications is 
driven by numerous factors such as endothelial injury, increased generation of reactive 
oxygen species (ROS), the accumulation of oxidised lipids and apoptosis of vascular smooth 
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muscle cells (VSMCs), which provide a nidus for hydroxyapatite mineral deposition (site of 
mineralisation).  
The initial step during atherosclerotic plaque development that leads to vascular 
endothelial inflammation is subendothelial deposition of low-density lipoprotein-cholesterol 
(LDL). LDL becomes modified to oxidized LDL (oxLDL) by various CVD risk factors due 
to an increase in oxidative stress within the vascular wall. oxLDL triggers the activation of 
NF-κB signalling, which promotes the expression of adhesion molecules including vascular 
cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), and 
other chemokines including monocyte chemoattractant protein (MCP1) and interleukin 8 (IL-
8) on the vascular surface of endothelial cells6 (Figure 1.1 A). As a result, binding of 
VCAM-1 and ICAM-1 to their ligands α4: β1 and CD11a:CD18 on monocytes triggers the 
recruitment and transmigration of monocytes into the vascular wall. This results in the 
differentiation of monocytes into pro-atherogenic macrophages or foam cells, which are able 
to scavenge oxLDL and act to amplify the inflammatory process via the secretion of 
cytokines (IL-1β, IL-12, TNF-α) Figure 1.1 B) 6.  
 
The inflammatory response is continued by further recruitment of monocytes, which 
eventually leads to intimal thickening and increases in plaque volume. This promotes 
neovascularization of the atherosclerotic lesions and the formation of fatty streaks, which are 
the earliest lesions seen in atherosclerosis. As the plaque develops and grows, this leads to the 
recruitment of additional cell types such as VSMCs, which undergo proliferation to stabilise 
the fibrous plaque Figure 1.1 C) 6. As the inflammatory response is exacerbated, other 
inflammatory markers such as von Willebrand factor (vWF) and tissue factor (TF) are 
secreted, which stimulate fibrin deposition and platelet binding creating a pro-thrombotic 
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environment. Overtime, foam cells may undergo apoptosis resulting in the release of cell-
debris and lipids, which result in the formation of a necrotic core Figure 1.1 D) 6.  
Atherosclerosis is a systematic disease that is not limited to a single arterial territory 
and can affect arteries of different vascular beds simultaneously, with varying degree of 
progression. It is a is a widespread, chronic and progressive disease affecting larger to 
medium-sized arteries and commonly occurs in the brain (carotid, vertebral, and cerebral 
arteries, heart (coronary arteries disease) or in the lower extremities (the iliac and femoral 
arteries)7. Furthermore, its presence at different sites is associated with increased risk of 
development in other vascular beds. Therefore because of the systemic nature of the disease, 
treatment with statins, antiplatelet agents have proven beneficial, irrespective of the vascular 
bed affected. For the purpose of this thesis, atherosclerosis was investigated in the setting of 





















Figure1.1 1.1: Schematic representation of the pathophysiology of Atherosclerosis in 
PAD (Adapted from6). 
 (a) Low density lipoprotein-cholesterol (LDL) is deposited within the endothelium and 
undergoes oxidative modification to oxidized LDL (oxLDL, which stimulates endothelial 
cells (ECs) to express adhesion molecules VCAM-1 and chemokines (MCP1, IL-8). 
Monocytes are recruited into the vessel and undergo differentiation into pro-atherogenic 
macrophages; (b) Macrophages scavenge oxLDL and leukocytes are recruited into the vessel 
wall; (c) the increasing plaque volume promotes plaque neovascularization and recruitment 
and proliferation of SMCs which stabilize the fibrous plaque. A pro-thrombotic environment 
is created due to deposition of fibrin and activated platelets, with increased expression of 
tissue factor (TF) and von Willebrand factor (vWF); (d) foam cells may undergo apoptosis 






1.2 Peripheral Arterial Disease (PAD) 
Peripheral arterial disease (PAD) refers to the occlusion or narrowing of the arteries 
supplying blood to the lower extremities, exclusive of the coronary and cerebrovascular 
vessels3. It is a progressive occlusive disease and is the main macrovascular complication in 
type 2 diabetes; and is estimated to affect over 200 million adults worldwide8, 9. PAD is 
the leading cause of cardiovascular morbidity and mortality associated with limb loss10-12 
and is a major risk factor for MI (MI) 13. Interestingly, the prevalence of PAD is 2.1 
times that of patients with a history of MI12, and has a similar relative risk as coronary 
artery patients and cerebrovascular disease patients14. The exact pathogenesis for PAD 
remains unclear, but it is generally regarded as secondary to atherosclerosis15. Patients with 
PAD often present with multilevel disease, characterised by fatty plaque build-up and high 
levels of diffused calcium deposits in the media of their peripheral arteries. Rupture of the 
atherosclerotic plaque in the arterial wall results in obstruction of blood flow thereby 
reducing perfusion to organs16.  
 
 Pathophysiological Response to Atherosclerosis in PAD  
PAD is primarily caused by atherosclerosis and is associated with thrombus formation 
within arteries of the lower limb that results to tissue ischemia. Atherosclerosis-induced PAD 
is a complex mechanism that involves numerous cell types, proteins, and pathways. The main 
cell types involved include ECs, VSMCs,  fibroblasts, monocytes, resident stem cells, 





 Risk factors for PAD  
PAD coexists with cardiovascular and vascular diseases17. The most recognised 
cause underlying PAD development is atherosclerosis18. Risk factors for PAD are parallel 
to those of atherosclerosis14, including age (>50), smoking, diabetes mellitus, hypertension 
and dyslipidemia19-21. Age is the hallmark marker of PAD, and around 35% of adults aged 
60-65 years of age show symptoms of intermittent claudication (the physical pain 
experienced upon walking)17. Disease severity is four-fold higher in PAD patients engaging 
in heavy smoking and two-fold with diabetes17, 22. Diabetes mellitus is associated with 
increased risk of PAD, as 1% increase in glycosylated haemoglobin correlates with a 25% 
increase for PAD17. Diabetic patients also face a 10 times greater risk of amputation than 
non-diabetic patients. Dyslipidaemia, defined as elevated levels of cholesterol within the 
body also contributes to PAD development.  
 
 Symptoms for PAD  
The two most prevalent clinical manifestations of PAD are critical limb ischemia 
(CLI), and intermittent claudication (IC)11. Intermittent claudication (IC) is the earliest 
and most commonly observed symptom of PAD and refers to the physical symptoms of 
pain exerted in the lower limb muscles of both legs (calf) upon exercise and walking, 
which is rapidly relieved at rest 11, 12. With IC patients, the severity of symptoms 
increases by 25%, with 5% of these patients facing limb amputation within 5 years 23. 
CLI is the most severe and long-term clinical manifestation of PAD; that occurs due to 
hypoperfusion of the lower limbs and is commonly observed in diabetic patients11, 19. 
Patients suffering from CLI experience severe pain at rest, and present with ulcerations 
and gangrene formation in the foot with disease progression11, 19. However, unlike 
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claudication, CLI patients have a substantially increased risk of limb amputation and 
other fatal or non-fatal vascular events like MI  and stroke11,23,19. Overal, PAD patients 
are highly affected and face difficulties performing daily activities, due to reduced 
functional capacity in their limbs. Therefore, treatment goals for PAD are critical to help 
alleviate these physical symptoms and increase the quality of life for all PAD sufferers 
23.  
 
 Diagnosis for PAD 
PAD patients who present with asymptomatic PAD are faced with a poor long-term 
prognosis, with a 15 times increase and a 10 year higher risk of mortality compared to non-
PAD patients23. Currently, the gold standard diagnosis for documenting the presence and 
severity of lower extremity PAD is via two non-invasive doppler techniques using the Ankle 
Brachial pressure index (ABI) and Toe Brachial pressure index (TBI)3, 15, 24.  
ABI measures are used to illustrate how well blood is perfused in limbs and compares 
blood pressure readings between ankle pressure and brachial arm pressure. This is a quick 
and effective test that can be used to assess blood pressures in a 10-15 min time frame24. 
Normal ABI values range from 0.90 to 1.30, and ABI values of 0.50-0.85 are indicative of 
intermittent claudication in PAD patients3, 24. ABI values >0.30 can be seen in patients with 
resting claudication pain or gangrene3, 24. The efficiency of ABI testing however is reduced 
with the presence of calcified lower leg vessels as seen with type II diabetic or chronic 
kidney disease patients3, 24. This is because calcified vessels are less compliant, more rigid 
and incompressible, therefore raise ABI making blood pressure more difficult to detect. In 
such cases, TBI becomes useful as its more predictive of substantial arterial disease3. 
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TBI pressures provide more definitive diagnosis for patients with rigid and 
noncompliant blood vessels. TBI measurements are performed similarly to ABI, where tiny 
blood pressure cuffs are placed around the toe, and blood pressure is measured using a 
photoplethysmograph (PPG) infrared light sensor; with TBI value of 0.8 or greater deemed 
normal. To enable proper diagnosis, following ABI and TBI readings, further confirmation is 
done via other imaging modalities including angiography, computed tomography (CT) and 
magnetic resonance imaging (MRI)15.  
 
 Current Therapies and Treatments for PAD  
 Currently, treatment options for PAD are focused on revascularization techniques to 
alleviate vessel stenosis and occlusions; and to reduce the harmful effects of ischemia on the 
limb, and thus prevent  secondary cardiovascular events such as MI  and stroke14, 25 15. Long-
term recurrent CLI in PAD patients may result in lower extremity revascularization, and thus 
these patients may require extensive treatment to alleviate stenosis. Current therapies used for 
PAD management are centred on a two-way approach, the first focused on reducing CVD 
risk factors followed by interventions such as pharmacotherapy, endovascular therapy, or 
surgery to reduce lower extremity symptoms3, 11. Exercise programs and other lifestyle 
modifications have also proven to be effective in reducing PAD symptoms in IC patients by 
reducing pain upon walking11. Other revascularisation therapies used to treat CLI include 





1.2.5.1 Lifestyle and Risk Factor Modification 
Risk factor modification is key in the early treatment and prevention of PAD. This is 
centred on reducing risk factors that cause PAD such as diabetes, smoking, hypertension and 
hyperlipidaemia24. Studies have shown that smoking cessation reduces the progression and 
development of IC and critical limb ischemia in PAD patients3, 26. Physical activity is also 
important in managing PAD symptoms, and despite the pain caused by IC in these patients, 
studies have shown that walking was able to increase collateral circulation in patients 
suffering from IC27 and also increased walking distance28. Overall, the treatment options for 
PAD are beneficial in reducing risk factors and for the development of other 
cardiovascular diseases; and to help increase quality of life of individuals. There is 
however the need to identify possible mechanisms of action in PAD that can be targeted 
for the development of new therapeutic strategies. 
 
1.2.5.2 Pharmacotherapy 
Therapeutic treatment strategies with medication to treat PAD-associated intermittent 
caludication are aimed to reduce pain and to increase walking distance in PAD patients17. 
These serve as secondary-preventative measures for reducing PAD-associated risk factors. 
There are numerous drugs that have been studied to treat PAD symptoms, with statins and 
anti-platelet therapy being mostly explored3, 14. Statins, mainly Simvastatin and Atorvastatin 
were found to have a 24% risk reduction rate for PAD17. Statins have also demonstrated 
reduced claudication in PAD patients17. In addition, the use PCSK9 inhibitors on top of high 
intensity statin medications have demonstrated significant benefits in lowering LDL 
cholesterol in PAD; as reported in the FOURIER large randomised controlled trial 29, 30. 
 11 
 
 Anti-platelet therapy is known to reduce the risk of adverse cardiovascular outcomes 
with CVD by approximately 25%26. Platelet therapy using acetylsalicylic acid demonstrated a 
23% reduction in total mortality of CVD and MI17. Furthermore, aspirin is one of the most 
widely used and studied antiplatelet therapy drugs. The Clopidogrel versus Aspirin in 
Patients at Risk of Ischemic Events (CAPRIE) trial investigated the efficacy of clopidogrel 
and aspirin in reducing the primary outcome (cardiovascular mortality, MI, and stroke) in a 
subgroup of patients with symptomatic PAD. This study found that clopidogrel caused a 
23.8% relative risk reduction in the primary outcome compared to aspirin therapy31. 
Furthermore, Rivaroxaban in the Cardiovascular Outcomes for People Using Anticoagulation 
Strategies (COMPASS) trial extends anti-thrombotic benefits in PAD32.   
 
1.2.5.3 Surgical  
Endovascular procedures used in treating PAD are aimed to revascularise obstructed 
arteries26. Endoluminal stent placement and endarterectomy are minimally invasive 
procedures used to treat stenosis. These procedures utilize the femoral approach whereby 
catheters are inserted into the blocked artery; and are procedures have shown promising 
results for PAD treatment17, 23. Balloon angioplasty is another commonly used surgical 
procedure, which involves placing a tiny balloon at the vessel narrowing and expanding the 
balloon to open up the blockage24, 26. Stents are instruments made of expandable mesh wires 
that are inserted into the endothelium of the vessel and are left in situ to hold the blocked 
artery open and thus allow blood flow through the vessel. Atherectomy is a procedure that is 
often conducted following angioplasty, that is used to clear fatty plaques within occluded 
vessels using special devices attached onto the catheter that is placed within the vessel. This 
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is a procedure that is more beneficial for patients with heavily calcified plaques. The presence 
of calcification within the peripheral arteries is a major limiting factor for the treatment of 
PAD as observed in numerous clinical studies, this warrants for the development of more 
effective treatment options to treat PAD 33-37. 
 
1.3 Current Angiogenic Therapies  
Currently, there is a growing demand for the development of angiogenic therapies due 
to the high prevalence of ischemic diseases. Angiogenic therapies are aimed to augment 
physiological angiogenesis and suppress pathological inflammatory angiogenesis38, 39. 
Current anti-angiogenic therapies used for cancer pathologies and proliferative eye diseases 
have proven effective in randomised control trials38. Therapeutic stimulation is the most 
commonly used form of angiogenic therapy, that is aimed to increase blood flow reperfusion 
following ischemic insult to tissues in following MI, peripheral vascular diseases and in other 
cardiovascular conditions. While there are many different modes of therapeutic angiogenesis 
such cell transfer, the use of recombinant agents and gene therapy; majority of these 
treatment options are still in their infancy. Furthermore, despite the many clinical advances 
with these pro-angiogenic therapeutic agents, many patients remain refractory following 
treatment. 
Therapeutic angiogenesis is aimed to enhance new blood vessel development via the 
administration of specific pro-angiogenic growth factors. The most commonly trialled agents 
to enhance angiogenesis involve the administration of recombinant pro-angiogenic growth 
factors such as fibroblast growth factors (FGF1/2) and other isoforms of VEGFA 40, 41 42. 
Clinical trials using recombinant VEGFA165 have proven effective in one study were  
VEGFA165 improved myocardial perfusion in patients who were not suitable for coronary 
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revascularization, whilst also increasing collateral density in these patients42. In another phase 
1 clinical trial, recombinant VEGF caused improvement in myocardial perfusion at rest43. 
FGF administration was shown to stimulate the growth of dense capillary networks in the 
myocardium of patients with three-vessel coronary disease, which resulted in increased local 
blood supply to the tissues44, 45.  
However, these current anti-angiogenic agents remain ineffective as they cannot specifically 
target inflammatory-driven angiogenesis while preserving physiological angiogenesis. This 
results in several side effects of nausea, vomiting, reduced wound healing and other 
gastrointestinal perforations42. And while much focus is placed on the currently available 
risk factors for PAD, there is compelling clinical evidence to demonstrate the 
devastating effects of calcification on lower extremity revascularisation in PAD, and this 
is the main focus for this PhD.  
 
1.4 Mechanisms of Neovascularization in PAD 
Following occlusion, the body works to stimulate mechanisms to stimulate blood 
flow to the occluded site. In PAD, hypoxia is a potent inducer of angiogenesis and may 
occur due to compromised vascular supply to tissues following vascular occlusion. This 
triggers the expression of pro-angiogenic signalling cascades to drive neovascularisation. 
In response to ischemia, the body works to revascularize the affected tissues via 
activation of 3 macrovascular adaptation processes known as  (1) angiogenesis, (2) 




 Angiogenesis  
Angiogenesis is described as the formation of new blood vessels due to sprouting of 
new capillary networks from pre-existing capillary beds11, 19, 46, 49. Angiogenesis is the 
hallmark physiological process that occurs postnatally and is involved in wound healing 
and repair, menstrual cycle and growth and development. It is also a very crucial process 
for tissue revascularization post-ischemia, in particularly following a MI, stroke and in 
peripheral vascular disease. Angiogenesis also occurs in pathological conditions such as 
tumour development and other cardiovascular diseases11, 19, 50, 51.  
 Vasculogenesis  
Vasculogenesis occurs in early stages of embryonic development and refers to de novo 
assembly of primary vascular plexus in the developing embryo from the differentiation of 
mesoderm-derived precursors known as angioblasts38. During vasculogenesis, primary 
vascular plexus is formed by differentiation mesoderm-derived angioblasts into endothelial 
cells. This process is primarily driven by pro-angiogenic factors VEGF and its receptors 
(VEGFR1 & VEGFR2), fibroblast growth factor (FGF), transforming growth factor (TGF) 
and angiopietin-1 and Tie-248. VEGFA acts in a paracrine manner by binding to its receptor 
VEGFR2 on the surface of angioblasts to stimulate EC differentiation, which later results in 







Arteriogenesis describes the remodelling of pre-existing collateral arteries to increase 
tissue perfusion following vessel obstruction11, 19,49.This process is primarily dependent on 
the presence of pre-existing vessels, and is the only process known to help reduce the effects 
of arterial occlusion21, 52. Arteriogenesis occurs outside of the affected area, and is primarily 
induced by an increase in shear stress 53. Hemodynamically, arterioles are capable of 
becoming large conductance vessels that regulate sufficient blood flow following events of 
MI or limb ischemia. However, following stenosis or occlusion of a vessel, blood flow is 
redistributed towards the pre-existent artery with the lowest resistance. As a result, there is a 
20-30x increase in blood flow through the pre-existent collateral artery, which is considered 
as shear stress21, 53. Endothelial cell activation is also thought to occur in response to shear 
stress. Activation of specific shear stress receptors on ECs induces an intracellular signalling 
cascade, which then regulates the recruitment of monocytes that differentiate into 
macrophages. This results in increased proliferation and migration of collateral arteries.  
 
1.5 Blood vessels 
Blood vessels consist of arteries, arterioles, capillaries, venules, and veins. Arteries 
are large blood vessels that carry oxygenated blood away from the heart to the cells, tissues, 
and organs. Veins however are responsible for carrying deoxygenated blood back to the 
heart. Arterioles are smaller branches of an artery that lead to form capillaries. Venules are 
small branches of a vein and serve as the connecting link between capillaries and veins. 
Capillaries are the smallest form of blood vessel in the body, and their main function is 
serving as an interconnecting network between arterioles and venules to allow for oxygen and 





Blood vessels are comprised of three main distinct layers known as the tunics. The 
tunica intima is the innermost layer lining blood vessels and contains a monolayer of 
endothelial cells (ECs) which line the vessel and are surrounded by collagen-rich 
extracellular matrix (ECM), a protection scaffold for the vessel54. The middle layer or tunica 
media is mainly comprised of VSMCs and plays a key role in regulating blood vessel tone by 
contraction and dilation. The outermost layer is known as the tunica adventitia which consists 
of collagen-rich extracellular matrix and connective tissue and contains other cells such as 





Figure 1.2: Schematic of the normal structure of blood vessels. 
Tunica Media is the innermost layer lined by endothelial cells (ECs) Tunica media, consist of a layer 
of vascular smooth muscle cells (VSMC) for regulating vascular tone. The tunica externa is the 
outermost layer of blood vessels and is predominantly connective tissue consisting of blood vessels 
and immune cells. (Image adapted from: Blausen.com staff (2014). "Medical gallery of Blausen 








1.6 The Endothelium and Endothelial Disfunction 
The endothelium lining the vascular system plays an important role in maintaining 
vascular homeostasis and serves as an inert barrier between the blood and vessel wall and 
separates blood from the VSMCS55. It contains a delicate monolayer of cells known as 
endothelial cells (ECs), which are the primary cells that line the vessel wall. These cells serve 
many functions such as regulating vascular tone, permeability and the angiogenic processes, 
proliferation, migration and apoptosis; whilst also mediating a range of reparative responses 
including  inflammation which occurs in response to injury56.  
 
The main function of the endothelium is to protect against disease, and impairment of 
this leads to endothelial dysfunction. Endothelial dysfunction occurs due to changes in 
endothelial cell phenotype towards a proinflammatory and prothrombotic  state within the 
vascular wall57. Impaired endothelial function has been suggested as an early characteristic of 
PAD and in particular diabetic vasculopathy and stage 1 chronic kidney disease 58. ECs secrete 
a variety of factors which regulate vascular motor activity14. Additionally, studies have 
reported PAD patients experiencing reduced endothelial function in their limbs. This is most 
likely due to several mechanisms such as inflammation, reduced nitric oxide synthesis, 
oxidative stress and elevated  levels of lipid serum14. Endothelial dysfunction is also known to 
exacerbate clinical symptoms of PAD, by interfering with arteriogenesis or the formation of 
collateral vessels57. Therefore, endothelial dysfunction is considered a key hallmark of 
vascular diseases such as PAD, and maintaining proper integrity of the endothelium is very 





 The Angiogenic Cascades 
Endothelial cells are key initiators in blood vessel formation60-62. In adults, the 
process of angiogenesis is highly regulated by several stimulators and inhibitors of 
angiogenesis which create a delicate balance for blood vessel formation on inhibition47. 
Impairment of this balance is recognised as a key common feature underlying many 
pathological diseases including cancer, rhematoid aarthritis, type II diabetes mellitis and 
cardiovascular diseases where there is either excessive or  insufficient blood vessel growth47.  
The angiogenic response is mainly triggered by hypoxia. The initial step is the 
release and binding of pro-angiogenic growth factors hypoxia-inducible factor (HIF-1α), 
which activates the transcription of vascular endothelial growth factor (VEGFA), 
resulting in VEGFA-mediated increase in vascular permeability (Figure 1.3)21, 52. VEGF 
transcription is also stimulated by other growth factors such as fibroblast growth factor 
(FGF-2) and platelet derived growth factor (PDGF) 21, 60. This activates endothelial cells 
and promotes the release of various proteinases and enzymes, mostly matrix 
metalloproteinases which cause degradation of the extracellular basement membrane and 
thus causing alterations in the cell membrane structure and redistribution of intracellular 
adhesion molecules. This drives endothelial cell migration and proliferation that results 





Figure 1.3: Schematic illustrating the angiogenic cascade in endothelial cells.   
The main steps of the angiogenic pathway include the release and binding of pro-angiogenic 
factor, endothelial cell activation, extracellular matrix degradation, EC proliferation and 




 Angiogenesis Is Driven by Two Distinct Yet-overlapping Pathways  
Angiogenesis is a multi-step process involving well define stages that are orchestrated 
by numerous growth factors, cellular events, cytokines and signalling cascades. Depending 
on the pathophysiological context, angiogenesis is regulated via two distinctly different yet 
overlapping pathways63. Ischemia-driven angiogenesis by HIF-1 α is primarily mediated by 
hypoxia64. Conversely, inflammatory-driven angiogenesis and is driven by NF-kB (P65) 
signalling pathway65. There is conditional regulation of angiogenesis by VEGF to regulate 
both ischemia-driven and inflammatory-driven angiogenesis. Notably, VEGF is an important 
stimulator of angiogenesis in both ischemia and inflammatory conditions; modulated by HIF-
1α and NF-κB, respectively. VEGF is known to possess a response element for both NF-κB 
and HIF-1α in its promoter region; thus, allowing for conditional regulation via activation of 
both signalling pathways independently.  
 
 
1.6.2.1 Ischemia-Driven Physiological Angiogenesis is Regulated 
Via the HIF-1a Signalling Pathway 
Physiological-ischemia-driven angiogenesis is a crucial process for growth and 
development, wound healing and the menstrual cycle. This occurs post-ischemia and is 
triggered due to a chronic imbalance in oxygen supply to the tissues; resulting in a highly 
hypoxic environment; as seen following a myocardial infarct, and in disease states with vessel 
occlusion such as perivascular diseases21, 66. As a result, ischemia-driven angiogenesis is 
stimulated to induce neovascularisation of the ischemic tissue and thus restore blood flow in 
the affected area67. Reduced blood supply can also result due to imbalance between pro- and 
anti-angiogenic factors67.  
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The molecular mechanism of ischemia-driven angiogenesis is regulated primarily via 
the hypoxia-inducible factor pathway (HIFs). HIFs form a heterodimer comprising of two 
subunits, HIF-1a and HIF-1b, which are regulated depending on the intracellular 
concentration of oxygen in the tissue66. There are two isoforms of HIFS, HIF-1a  and proteins  
are regulated transcriptionally, the stability and activity of HIF-1a are reliant upon post-
translational regulation66.  
In aerobic conditions when oxygen tissue supply is sufficient, HIF-1a is regulated 
within the cytosol by propyl hydroxylase domain proteins (PHD1, PHD2 and PHD3), which 
cause hydroxylation of the proline residues (Pro402, Pro564 on  HIF-1a) and (Pro405, Pro531 
on HIF-2a ), situated within the oxygen-dependent degradation domain of an inducible a-
subunit of HIFs66, 67. This therefore allows binding of the Von-Hippen Lindau (VHL) tumour 
suppressor protein, E3 ubiquitin ligase complex, which targets HIF-1a for ubiquitination and 
proteasomal degradation (Figure 1.4)46, 67.  
Conversely, under anaerobic conditions where there is depletion in intracellular 
oxygen concentration, the PI3K/Akt signalling pathway is activated, inducing of gene 
transcription of E3 ubiquitin ligases Siah 1 & Siah 2, which target and promote degradation of 
PHD enzymes, leading to HIF-1a stabilisation and accumulation (Figure 1.4)66, 67. As a result, 
this allows HIF-1a to be translocated into the nucleus where it complexes with the HIF-1b 
subunit and binds to the hypoxia response element (HRE). It then facilitates the expression of 
pro-angiogenic mediators such as VEGF and its receptors (VEGFR1 and VEGFR2), basic 
fibroblast growth factor (bFGF), angiopoietin, stromal derived-factor 1 (SDF-1 or CXCL12), 
platelet derived growth factor (PDGF) and matrix metalloproteinases (MMPs) 32,67. As a result 
of these mechanistic interactions, these angiogenic factors stimulate endothelial cellular 
processes of proliferation, migration, extracellular matrix degradation and pericyte activation, 





Figure 1.4:  Mechanistic diagram for HIF-1a regulation during hypoxia-mediated angiogenesis.  
Under normoxic conditions, PHD1-3 hydroxylates proline residues on HIF-1α allowing von Hippel-
Lindau proteins to bind thereby targeting HIF-1α for ubiquitination and proteasomal degradation by  
The von Hippel-Lindau (VHL) complex.  In hypoxia, low oxygen levels stimulate the increase of Siah 
ubiquitin ligases (Siah 1/2) which inhibit PHDs thus preventing HIF-1α from ubiquitination and 
degradation. This increases HIF-1α stability and allows it to accumulate and translocate into the 
nucleus where it complexes with HIF-1ß and bind to the hypoxia response element (HRE) driving 






1.6.2.2 Ischemia-Driven Angiogenesis and VEGFA Signalling  
The VEGF family of ligands and receptors play a key role during angiogenesis and 
are regulated via the activation of HIF-1a. The VEGF family comprise of five members 
(VEGFA, VEGFB, VEGFC and VEGFD and placenta growth factor (PGF), and VEGFA is 
the most potent pro-angiogenic member of its family68. It is produced by endothelial cells 
following hypoxic stimulation and helps to regulate angiogenesis by controlling EC 
proliferation, apoptosis and migration which ultimately leads to the development of a vascular 
network68. It’s important role in angiogenesis has been highlighted in murine gene knockout 
studies where mutations of a single VEGFA allele results in embryonic fatality69. VEGF are a 
family of ligands highly expressed under hypoxic conditions and regulate vascular 
permeability in inflammatory responses and other pathological diseases60, 70.  
Mechanistically, VEGFA binding to its receptor VEGFR-2 on endothelial cells causes 
phosphorylation and dimerization of the receptor, in turn activating multiple downstream 
signalling pathways (Figure 1.5). These include the phosphatidylinositol 3’-kinase 
(PI3K/Akt), P38/mitogen-activated protein kinase (MAPK), and phospholipase C gamma 
(PLCg)/MAPK pathways. Specifically, PI3K activation results in phosphorylation of Akt, 
promoting EC survival. Secondly, activation of P38 by Akt in turn activates MAPK 
signalling activation which regulates EC migration. Lastly, activation of PLCg stimulates the 
activation of the ERK pathway, leading to EC proliferation. Ultimately, stimulation and 
activation of these pathways leads to EC proliferation, migration, and tubule formation 
(Figure 1.5).  
Other downstream signalling pathways that are also activated during angiogenesis 
following VEGFA signalling involve endothelial nitric oxide (eNOS). eNOS is located 
downstream of the HIF-1a-VEGFA pathway71. During hypoxia, eNOS produces nitric oxide 
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(NO) to help enhance EC proliferation, migration and to increase VEGFA expression; which 








Figure 1.5: VEGFA Signalling Pathway  
Binding of VEGFA to its receptor VEGFR2 results in dimerization which results to activation of 
multiple signalling pathways. PI3K stimulates subsequent activation of Akt phosphorylation which 
promotes endothelial cell survival. Activation of p38 leads to activation of P38 MAPK signalling, 
which promotes EC migration. VEGFA-VEGFR2 binding also results in activation of the PLC-y 
pathway that cleaves PIP2 to IP3, which results in activation downstream activation of ERK1/2 which 
regulates EC proliferation. This pathway also stimulates the release of calcium from the endoplasmic 
reticulum that results to increased vascular permeability. Calcium release is also responsible for the 
synthesis of nitric oxide from nitric oxide synthase.  
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1.6.2.3 Inflammatory-Driven Angiogenesis Is Regulated Via NF-kB 
Activation  
Angiogenic regulation and homeostasis is importance for maintaining healthy 
physiological processes. During angiogenesis, there lies a delicate balance between pro-
angiogenic and anti-angiogenic factor regulation, and disturbances in this can result in 
pathological forms of angiogenesis. Cases where this is increased include disease states of 
cancer, macular degeneration, rheumatoid arthritis, haemangioma and psoriasis46,73. 
Conversely, impairment or insufficient angiogenesis is commonly present in disease states 
such as diabetes, cardiovascular diseases, ischemic heart diseases and peripheral arterial 
disease46,73.  Therefore, there is a crucial need for homeostasis to be maintained to prevent the 
occurrence of numerous pathological conditions.  
In contrast to ischemia-driven angiogenesis, pathological angiogenesis is driven by 
inflammation. Inflammatory-driven angiogenesis may be triggered by direct or indirect 
stimulation66. Direct stimulation involves increased expression of inflammatory cytokines on 
ECs to regulate EC proliferation and migration, leading to angiogenesis67. In contrast, 
indirect stimulation involves the release and recruitment of macrophages to the inflamed site 
in response to an inflammatory stimulus, which then triggers the secretions of a host of pro-
angiogenic factors including VEGFA, TNF-α, bFGF and interferon gamma (IFNg) to 
promote angiogenesis67. Other key promoters of inflammatory driven angiogenesis include 
TNF-α, NF-kB, cell adhesion molecules (CAMs) including vascular cell adhesion molecule-1 
(VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant 
protein-1 (MCP1)74.  
The NF-kB pathway is regulated by two signalling pathways, the canonical or 
classical pathway and the non-canonical or alternative pathway; however inflammatory-
driven angiogenesis is mainly driven by the canonical pathway65, 66, 74. Mechanistically, the 
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canonical pathway is activated by inflammatory stimulus such as TNF-a and interleukins. 
The NF-kB complex comprises of two subunits, P50 and P65. Under normal conditions, in 
response to an inflammatory stimulus, the IκB kinase (IKK) enzyme complex is activated and 
phosphorylated, which results in phosphorylation of the inhibitor of κB (IκB) proteins, 
specifically IκBα, which gets targeted for ubiquitination and subsequent proteasomal 
degradation. This results in sequestering and translocation of the NF-kB dimer P50/P65 into 
the cytosol, where it binds to the NF-kB response element thereby initiating the transcription 
of pro-angiogenic factors such as VEGFA, VCAM, ICAM, and matrix metalloproteinases 

























Figure 1.6: Schematic illustrating inflammatory-driven angiogenesis mediated by NF-kB 
signalling. During inflammatory-driven angiogenesis, pro-inflammatory stimuli such as TNF-α, IFN-
g , or LPS stimulate phosphorylation of IκBα by the IKK complex, resulting in ubiquitination and 
proteasomal degradation of IκBα. This leads to translocation of the p50/p65 NF-κB dimer into the 
nucleus, where is binds to the NF-kB response element to activate the production of NF-KB target 
genes such as VEGFA to further drive the inflammatory response.  
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 Adhesion Molecules and Cytokines in Acute Inflammation  
Adhesion molecules are a group of heterogeneous cell surface proteins that regulate 
cell-to-extracellular matrix interactions as well as cell-to-cell interactions75. These proteins 
are expressed by most cells and play important roles in the regulation of inflammatory 
responses within tissues. However, these proteins may also contribute to pathological 
inflammation by promoting chronic inflammatory processes as seen in atherosclerosis, type II 
diabetes and other CVDs75.  
 
1.6.3.1 Vascular Cell Adhesion Molecule 1 (VCAM-1) 
VCAM-1 also known as CD106 (cluster of differentiation) is an immunoglobulin-like 
adhesion molecule that is constitutively expressed on blood cells including monocytes, 
lymphocytes, and eosinophils76. However unlike ICAM-1, VCAM-1 exhibits low expression 
on unstimulated ECs and thus its expression is profoundly stimulated by pro-inflammatory 
stimulus such as TNF-α, IL-1β, liposaccharides (LPS), oxidised LDL (oxLDL) and high 
glucose77. Its expression is also known to be upregulated and detected mainly at 
atherosclerotic-prone sites of the endothelium75. VCAM-1 expression is also known to be 
stimulated by NF-κB signalling. VCAM-1 functions by binding to α4β1 integrin expressed on 
lymphocytes, monocytes, and eosinophils; thereby binding these cells to the endothelium 
during early atherogenesis and causing the arrest of rolling monocytes77.  
 
 
1.6.3.2 Intracellular Cell Adhesion Molecule 1 (ICAM-1) 
ICAM-1 also known as CD54 (cluster of differentiation) is a transmembrane protein 
of the immunoglobulin superfamily that is constitutively expressed during physiological 
 30 
conditions on endothelial cells; and is important in regulating adaptive and innate immune 
responses76. ICAM-1 expression is upregulated in response to inflammatory cytokines such 
as TNF-α, IL-1β, IL-6, interferon-γ and LPS76. ICAM-1 functions by binding to two integrins 
of the β2 family on the surface of leucocytes, including CD11a/CD18 and CD11b/CD1875. 
Furthermore, during an inflammatory response, ICAM-1 binding to its integrin triggers 
rolling and transmigration of leucocytes into the sub-endothelium76.  ICAM-1 expression can 
also be regulated by transcription factors NF-κB (specifically the p65 subunit), as NF-κB is 
always required for its activation75.  
 
 
1.6.3.3 Monocyte Chemoattractant Protein (MCP1) 
Chemokines are a sub-class of cytokines which are produced by the damaged 
endothelium and promote monocyte recruitment to the site of injury through chemotaxis78. 
MCP1 also known as CCL2 is a chemoattractant chemokine that is secreted by numerous cell 
types including endothelial cells, SMCs, fibroblasts, epithelial, smooth muscle, mesangial, 
monocytes and microglial cells78. MCP1 is highly expressed in atherosclerotic lesions and 
plays an important role for the recruitment of monocytes into the arterial wall during 
inflammatory responses76. MCP1 levels are also known to be elevated by SMCs, 
monocytes/macrophages within the activated vessel wall during inflammation. MCP1 is 
regulated transcriptionally by NF-κB signalling and by the mitogen activated protein kinase 
(MAPK) pathway. Mechanistically, MCP1 binding to its receptor CCR2 on monocytes 
results in activation of intracellular signalling cascades which drive the migration of 




1.7 Vascular Calcification  
Vascular calcification (VC) is a phenomenon of soft tissue calcification and is defined 
as mineral deposition in the vascular wall in the form of hydroxyapatite (calcium-
phosphate)79, 80. VC was previously presumed to be a passive process caused by shifting of 
calcium from the bone to the arterial wall; but is now increasingly recognized to be driven by 
complex cellular mechanisms. The prevalence of VC is age and sex-dependent, affecting 
approximately 90% of males and aproximately 67% of women aged >6080, 81. VC is part of 
the aging process and is a major complication of chronic kidney disease (CKD) and 
hypertension, that is accelerated in atherosclerosis and type 2 diabetes15, 79. The incidence of 
VC is highly correlated with increased cardiovascular mortality and morbidity rates, due to 
reduced vessel compliance, vascular stiffening and reduced coronary perfusion82. This leads 
to ischemia, and other complications such as MI, stroke and leg amputations in PAD, and the 
later death of these patients82.   
 
 Calcification in Clinical Settings 
There are extensive clinical data available to demonstrate the presence of calcification 
in the clinical settings of PAD, type 2 diabetes and CKD. Its important to note that arterial 
calcification in these clinical settings commences insidiously and progresses slowly and may 
only become apparent over a course of time. Patients with PAD often present with multilevel 
disease, characterised by fatty plaque build-up and high levels of diffused calcium deposits in 
the media of their peripheral arteries83. In addition, lower extremity arterial calcification 
predicts poor cardiovascular outcomes and is highly associated with limb amputations15, 34, 84-
87, and was reported in peripheral arteries of diabetic and chronic kidney disease (CKD) 
patients, suggesting an association between arterial calcification and PAD34, 84, 85. Because 
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calcification affects limb vascularization, it is therefore considered a limiting factor for 
treatment and a potential driver of PAD15.  
 
The presence of lower extremity arterial calcification as seen on X-rays is highly 
associated with an increased risk of limb amputations and increased mortality rates  in 
diabetic patients compared to healthy individuals35. Additionally, medial calcification is 
known to result in decreased vessel compliance and cause vascular stiffening, and is thought 
to affect local blood flow as seen in PAD15. In one study, tibial artery calcification (TAC) 
scores was used to assess the associations of calcification with the severity of symptoms in 
PAD patients following computed tomography (CT). This study found that patients with 
elevated TAC scores had a much higher incidence of PAD symptoms and increased risk of 
limb amputations compared to those with lower scores34. In a different study, assesment of 
human femoralpopliteal arteries showed that calcified arteries had larger diameters, thicker 
walls, thinner tunica media; with more discontinuous elastic fibres compared to healthy 
arteries36. Based on this evidence, there is an undoubtebly pressing need for a better 
understanding of the associations linking VC to PAD.  
  
 Types of Vascular Calcification 
Traditionally, cardiovascular calcification is classified into four different types 
depending on the location and type of arteries affected. Clinically, the 4 types include 
atherosclerotic (intimal) calcification, medial arterial calcification (MAC) also known as 
Monckeberg’s sclerosis, cardiac valve calcification and vascular calciphylaxis61. All types 
have distinct yet overlapping pathological mechanisms. In particular, because intimal and 
medial calcification occur more frequently and associated with cardiovascualr diseases such 
as PAD, they will be described in more detailed below.  
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1.7.2.1 Intimal Calcification 
Intimal calcification is associated with atherosclerotic plaques and occurs in alongside 
lipid deposition, cellular necrosis and inflammation, macrophage invasion, vascular smooth 
muscle cell proliferation and dysfunction of matrix proteins as a result of chronic arterial 
inflammation79, 88. Overtime, as the plaque lesion progresses, osteogenesic markers are 
released and promote calcium-phosphate mineral deposition in the intimal layer of the artery 
wall in the form of hydroxyapatite (Figure 1.8). Calcium and phosphate mineral deposition 
elicits an inflammatory response by releasing tumour necrosis factor (TNF) production by 
macrophages. Based on this, the role of inflammation in the pathogenesis of VC remains 
questionable, and it has been proposed that vascular calcification may be an inflammatory-
driven process66, 89. Long-term effects of intimal calcification result in erosion and rupture of 
these unstable plaques, thus causing blood flow obstruction and reduced perfusion as seen in 
obstructive vascular diseases such as PAD15, 66, 89. Furthemore, the expression of bone-related 
regulating proteins such as  bone morphogentic proteins (BMPs) are known to be expressed 
in atherosclerotic plaques by endothelial cells, foam cells and smooth muscle cells61, 90.  
Macrophages, mast cells and VSMCs are the primary cells involved in atheroslerotic 
intimal calcification. Macrophages are known to release TNF-α in repsonse to oxidised LDL. 
Macrophages are also known to express a vaerity of ostegenic proteins including alkaline 
phosphatase, matrix gla protein, osteopontin and bone sialoprotein. Furthermore, TNF-α 
treatment of VSMCs is known to enhance osteoblastic differentiation and increase ALP 




1.7.2.2 Medial Calcification  
Medial calcification, or as it is traditionally known, Monckeberg's sclerosis is more 
commonly associated with chronic kidney disease (CKD)93. Medial calcification is associated 
with aging and occurs independent of atheroslerosis within the medial layer of the vessel 
wall. The medial layer of the vessel wall is comprised of thick layer of VSMCs and elastin-
rich extracellular matrix. Elastin is a protein that is abundantly expressed in the vascular wall 
of arteries that has crucial role in the maintainance of vascular wall intergrity and function. 
Therefore, the loss and degradation of elastin exarcebates medial calcification, which may 
often result in increased arterial stiffness, increased pulse pressue and left ventricular 
hypertrophy, all independent predictors of cardiovascular mortality80, 94-97.  
VSMCs are the key cell type involved in medial calcification. Under physiologucal 
conditions, these cells have contractile and proliferative properties and express a range of 
contractile proteins including smooth muscle α-actin (SMαA), SM-22α, SM myosin heavy 
chains SM-1 and SM-2, calponin, and smoothelin94. However, under pathological conditions, 
these cells can undergo phenotypic changes in response to local cues which downregulates 
their contractile proteins thus increasing their proliferative activity94, 98. The differentiation of 
VSMCs towards an osteblast-like phenotype or bone-like cells is the main theory proposed 
for medial calcification. This change from contractile  to osteogenic phenotype is brought 
about by the development of calcifying matrix vesicles by VSMCs, the loss of SMC markers 
(SM22α and SM α-actin); and gain of calcification markers (Runx2, Osteopontin, alkaline 
phosphatase (ALP), type II and type X collagen and osteocalcin94. All these factors in turn 






Figure 1.8: Schematic illustrating intimal vs medial calcification in the vessel wall.  
Intimal calcification occurs in association with athersclerosis plaque progression within the intimal 
layer due to lipid deposition, macrophage infiltration, inflammation and calcium-phosphate 
deposition. Medial calcification occurs within the medial layers of the vessel wall, and is driven by 









 Proposed Theories for Vascular Calcification 
Long considered a passive process of aging, VC is now considered to be an actively 
regulated process that occurs in a similar fashion to bone formation61. Nummerous theories 
have been proposed in the pathogenesis of vascular calcification, though the precise 
molecular and cellular mechanisms remain unclear.  
 
Some of the major hypotheses of VC include failed anticalcific processes due to loss 
of mineralisation inhibitors, induction of osteochondrogenesis, apoptosis, imbalance of 
calcium-phosphate homeostasis, bone remodelling and matrix degradation and modifications 
(reviewed in79). Currently there are no treatments available for vascular calcification, thus 
identification of novel mediators and molecular pathways responsible for the pathological 
mineralization process are key in providing insight into novel drug targets to treat VC. For 
the purpose of this thesis, the focus was on 2 theories – loss of mineral homeostasis and loss 







Figure 1.9: Schematic illustrating key mechanisms of vascular calcification79.  
VC is proposed to occur due to many different mechanisms including (1) Failure of anti-calcification 
processes, caused by loss of mineralisation inhibitors which leads to VC. (2) Numerous factors are 
able to induce osteogenic transdifferentiation of VSMCs, including products of matrix vesicles, which 
act as a nidus of calcium phosphate deposition within the vessel wall. (3) Cell death by apoptosis or 
necrosis can promote the release of apoptotic bodies or necrotic debris, which may act as sites for 
hydroxyapatite deposition. (4) Dysregulated mineral homeostasis can result in calcium phosphate 
hydroxyapatite deposition. (5) Nucleational complexes formed during bone remodelling can further 
promote VC. (6) Environmental stressors can promote matrix degradation/modifications, and thus 





1.7.3.1 Disruption of Calcium-Phosphate Homeostasis. 
 The physiological role of both calcium (Ca) and phosphate are well established in the 
regulation of numerous cellular signalling processes throughout the body and within the 
vasculature99. Phosphorus (P) has numerous roles in the body and is essential for ATP 
production, intracellular signalling, pH buffering and is a main constituent of bone, 
phospholipids and nucleic acids100. Normal serum phosphate concentrations range between 
1.12-1.45 mmol/L, and elevations greater than 1.8 mmol/L are correlated with increased 
CVD risk and all-cause mortality in CKD patients101. Calcium is crucial for many 
physiological processes in the body including muscle contraction, neuronal signalling and is a 
major constituent of bone; with 99% of calcium being stored in bone and the rest in blood 
and cells. Normal serum concentrations of Ca range within 2-2.5 mmol/L, and elevation of 
calcium concentration greater than 2.5 mmol results in hypercalcemia. Furthermore, 
disturbance in mineral homeostasis in hyperphosphatemia (elevated phosphate above 2.0 
mM) and hypercalcemia (elevated calcium above 2.4 mM) play a crucial role in the 
progression of vascular calcification and are highly associated with cardiovascular mortality 
in CKD patients79, 93, 99, 100 98.  
 
The intracellular mechanisms by which phosphate is regulated in VC occurs via 
VSMCs. Increased extracellular calcium promotes mineralization of VSMCs via induction of 
Pit1 receptor, to raise intracellular levels of inorganic phosphate. This stimulates the release 
of osteogenic transcription factors such as alkaline phosphatase (ALP) and Runx2, a potent 
transcription factor for VC, which enhance VSMCs osteogenic differentiation79. Furthermore, 
under elevated phosphate concentrations, VSMCs undergo apoptosis and necrosis, which 
results in the release of apoptotic bodies, serving as a site for calcium-phosphate 
precipitation79, 102. Furthermore, mineral imbalance is known to induce VSMC-derived matrix 
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vesicles (MVs), precursors of microcalcification103. It is believed that elevated extracellular 
concentrations of Ca and P induce the release of these pro-inflammatory macrophage derived 
MVs, thus contributing to VC103. However, the cellular mechanisms underlying vascular 
calcification in the context of endothelial cells remains very poorly understood.  
 
1.7.3.2 Loss of Mineralization Inhibiting Factors  
 There are 6 potent inhibitors of mineralization including Matrix Gla Protein (MGP), 
osteoprotegerin (OPG), Osteopontin (OPN), fetuin-A, Klotho, and inorganic pyrophosphate 
(PPi); which protect the vessel wall from undergoing calcification104. In atherosclerotic 
calcification and diabetic medial calcification, the expression of these endogenous inhibitors 
are severely reduced, which results in calcium overload leading to VC105.  During this 
process, VSMCs begin to express markers of both osteoblast and chondrocyte differentiation, 
which thereby further promote VC93. When calcium and phosphate exceed their solubility 
due to significantly elevated concentrations, this inhibits the production of calcification 
inhibitors, and thus promotes VC. Given the crucial role OPG plays in bone mineralisation 
and its implication in cardiovascular disease this inhibitor was chosen for the main focus of 
these studies. 
 
1.7.3.3 Osteopontin (OPN) 
OPN (Osteopontin) is a secreted multifunctional glycophosphoprotein that is 
synthesised by cells involved in osteogenesis and serves important roles for both 
physiological and pathophysiological processes. OPN’s main function is regulating 
biomineralization and serving as a physiological inhibitor of vascular calcification and 
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activating osteoclast function93. Under normal physiological conditions, OPN is lowly 
expressed in the circulation and in tissues of the vasculature, however under pathological 
conditions in response to injury, OPN is acutely upregulates and induces a range of cellular 
responses and promotes cell adhesion, proliferation, migration, and survival of endothelial 
cells, vascular smooth muscle cells and macrophages61, 106. OPN expression is not only 
elevated in disease pathologies of CVD but in other inflammatory diseases such as multiple 
sclerosis, Crohn disease, wound healing and a number of cancer pathologies106. Furthermore, 
in addition its role in regulating vascular calcification, OPN has other multifunctional roles in 
the vasculature and has been shown to enhance vascular in addition, remodelling and 
angiogenesis through the activation of matrix metalloproteinases (MMPs)107. OPN isoforms 
have been shown to differentially promote arteriogenesis in response to ischemia via 
macrophage accumulation and survival in OPN deficient mice108, thus highlighting its role in 
regulating angiogenesis.  
 
1.7.3.4 Matrix Gla Protein (MGP) 
Matrix Gla Protein also known γ-carboxyglutamate protein (MGP) is a vitamin K-
dependent protein and is a strong calcification inhibitor. MPG is primarily produced by 
chondrocytes and VSMCs in the arterial tunica media. However MGP functionality requires 
vitamin-K dependent γ -carboxylation and activation within the endoplasmic reticulum61. 
MPG carries out its function to inhibit VC by binding directly to BMP2, thus inhibiting 
BMP/BMPR2 interactions which results to further inhibition of VSMC osteoblastic 
differentiation61. Calcified vessels show increased expression of calcification markers such as 
type II collagen and osteocalcin while exhibiting reduced expression of MGP61. In addition, 
MGP null mice have been used to study calcification, and these mice demonstrate extensive 
arterial calcification in the first weeks of life even in the absence of atherosclerosis109. 
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In contrast to other inhibitors that are found within the vessel wall, Fetuin-A is a 
circulating inhibitor of calcification found in serum and is predominately synthesized by the 
liver61, 93. In vitro, Fetuin-A binds to Ca2+ to inhibit de novo hydroxyapatite crystal formation 
but does not affect the crystals once formed93. Fetuin-A is also expressed in secreted matrix 
vesicles during vascular calcification; as VSMCs are able to take up circulating Fetuin-A and 
store it in their ECM-bound matrix vesicles that are known to form a nidus for mineral 
deposition (site of mineralisation)93. In vivo, Fetuin-A null mice demonstrate extensive 
calcification in different organs including the liver, kidneys, myocardium, tongue, and skin. 
In chronic kidney patients, reduced Fetuin-A levels are highly associated with increased 
mortality rates113.  
 
1.7.3.6 Klotho 
The Klotho gene is an aging suppressor that plays important role in regulating mineral 
metabolism. Klotho protein is responsible for regulating calcium and phosphorus levels in 
blood, bones and cerebrospinal fluid of all vertebrates114. Furthermore, circulating blood 
levels of Klotho protein are reduced in blood and urine of CKD patients, a population who 
suffer from vascular calcification. Klotho null mice are widely used to study calcification in 
CKD, and have been shown to have ectopic calcification in the medial layer of the arteries, 
arterioles and in the parenchyma of other organs, and develop osteoporosis, and also suffer 
from premature aging92, 115. Furthermore, a defect in this gene in mice results in a syndrome 
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that resembles human ageing with significantly decreased lifespan, arteriosclerosis, skin 
atrophy and infertility92.  
 
 
1.7.3.7 Inorganic Pyrophosphate 
Inorganic pyrophosphate (PPi) is a potent endogenous inhibitor of vascular 
calcification that regulates its function via paracrine signalling61, 93. Pyrophosphate carries out 
its function by direct inhibition of hydroxyapatite formation and has also been shown to 
inhibit VSMC transdifferentiation into osteoblast-like cells, one possible theory for the 
pathogenesis of VC. PPi is synthesized by ectonucleotide pyrophosphatase/phosphodiesterase 
(eNPP), which drives the hydrolyses of extracellular adenosine-5′-triphosphate (ATP) to 
generate PPi and AMP. The lack of PPi and mutations in eNPP1 results in extensive medial 
calcification in humans116. 
 
1.7.3.8 Molecular Drivers of Vascular Calcification  
A number of potent transcription factors that regulate many osteoblast and 
chondrocyte functions in bone have been identified in the regulation of VC. These include 
alkaline phosphatase (ALP), runt-related transcription factor (Runx2) or core binding factor 
a-1 (Cbfa-1), bone morphogenetic proein-2 (BMP2) and members of the tumour necrosis 
factor superfamily, receptor activator of nuclear factor-κB ligand (RANKL) and it receptor 






1.7.3.9 Alkaline Phosphatase (ALP) 
Alkaline phosphatase (ALP) is a key transcription factor that is released early on 
during calcium deposition. It is often used as a clinical diagnostic marker of VC, as an early 
indicator of extracellular matrix (ECM) deposition 61, 80.  Changes in ALP levels are a 
prominent feature in bone diseases, CKD and cardiovascular diseases, specifically 
atherosclerotic lesions with vascular calcification100. ALP activity is crucial for the process of 
endochondral ossification as it helps with hydroxyapatite deposition. Furthermore, SMCs 
express high levels of ALP during medial calcification. The molecular mechanisms by which 
ALP regulates VC is via decreasing levels of inorganic pyrophosphate, a known potent 
inhibitor of calcification61.  The role of ALP in angiogenesis  has been well explored in bone 
cells; with VEGFA reported to stimulate ALP activity117,  and hypoxia shown to increase 
ALP activity118. 
 
1.7.3.10 Runt Related Transcription Factor (Runx2) 
Runx2 is a master regulator of bone differentiation that is expressed throughout 
skeletal development and is crucial for vascular invasion119. This protein serves as a very 
important transcription factor that triggers the expression of other major osteoblast-specific 
lineage genes including Osteopontin (OPN), osteocalcin and type 1 collagen90. Runx2 is also 
co-localized within calcified atherosclerotic plaques and can be found in calcified arterial 
tissues79. Runx2 activation can occur via several routes including the mitogen activated 
protein kinase (MAPK) and through the extracellular-signal regulated kinase 1/2 (ERK1/2). 
Runx2 binds to the osteoblast-specific cis-acting element 2 which is found in the promoter 
regions of all other major osteoblast-specific genes including ALP and Osteopontin. 
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Inorganic phosphate known to induce VSMC transdifferentiation into bone-like cells induces 
Runx2 expression79.  
The relationship of Runx2 with angiogenesis has not been fully described however, a 
deficiency in Runx2 is reported to result in vascularization defects, mainly due to reduced 
VEGF expression120, 121.  Runx2 has also been shown to increase HIF-1a protein expression, 
mainly because it stabilises and protects HIF-1a from degradation, in both normoxic and 
hypoxic conditions121. Overexpression of Runx2 is also associated with significant increases 
in Vegfa mRNA expression, and vice versa. This is thought to occur due to physical 
interactions of Runx2 and HIF-1a on the Runx2/RUNT domain122 and possibly through 
binding of Runx2 on the VEGF promotor region120. Since Runx2 is expressed in ECs of 
developing blood vessels123, this may explain its role in regulating angiogenesis, and 




1.7.3.11 Bone Morphogenetic Protein (BMP2) 
Bone morphogenetic proteins (BMPs) are potent osteogenic differentiation mediators 
of bone formation; and their role as inducers of vascular calcification has been well 
established124, 125. They are expressed in several cell types of atherosclerotic lesions by 
endothelial cells, smooth muscle cells and foam cells61, 125. BMP2 is a member of the 
transforming growth factor b-superfamily that is expressed in small amounts in healthy 
arterial walls63. BMP2 has been demonstrated to cause ectopic mineralization in muscle 
tissue and SMC mineralization both in vitro and in vivo126. BMP2 has been linked with 
endothelial dysfunction, due to its high expression during pathological stimuli such as 
oxidative stress and inflammation, which induce vascular calcification61, 125. In these 
pathological states, BMP2 induces differentiation of smooth muscle cells towards an 
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osteoblastic phenotype, thereby promoting calcification. In one study, it was reported that 
decreasing BMP signalling resulted in a reduction in both atherosclerotic lesion and diabetic 
medial calcification125. BMP2 is expressed in the vascular media where it exerts its 
osteoinductive effect, whereas BMP4, an isoform of BMP is more expressed in the 
endothelial cells61, 125.  
 
 
1.7.3.12 RANK-RANKL-OPG Cytokine Pathway 
Recent molecular and biological studies have suggested that bone-associated genes 
expressed in vascular tissue may play an important role in the pathophysiology of medial 
arterial calcification127, 128. These pro-calcifying and anti-calcifying regulatory cell 
biomarkers include osteoprotegerin (OPG), receptor activator of nuclear factor-κB ligand 
(RANKL) and it receptor RANK; which are all members of the TNF-related family, involved 
in the homeostasis of bone metabolism129. 
 
1.7.3.13 Receptor Activator of Nuclear Factor-ĸB (and Ligand) 
RANKL is expressed in tissues such as the heart, lung, kidney, thyroid and in cell 
types of osteoblasts, stromal cells, T cells and endothelial cells and has been found in calcified 
valves128, 130, 131. RANKL interacts with its cognate receptor RANK, a transmembrane protein 
located on osteoclast precursors, known to induce osteoclastogenesis through NFκB131, 132. 
Regulatory factor OPG functions as an inhibitor for the process of vascular calcification in the 
normal vasculature128. OPG is expressed at high levels in a variety of tissue including arterial 
smooth muscle cells and endothelial cells; unlike RANKL and RANK, which are not 





1.7.3.14 Osteoprotegerin (OPG) 
OPG is a member of the tumour necrosis factor (TNF) receptor superfamily, also 
known as tumour necrosis factor receptor superfamily member 11B (TNFRSF11B). It is a 
cytokine receptor that serves as a soluble decoy receptor for RANKL and TNF-related 
apoptosis-inducing ligand (TRAIL)133. It binds to RANKL and therefore negatively regulates 
the interaction between RANKL and RANK, thus preventing osteoclast differentiation 
(Figure 1.10)128, 130, 131. On the other hand, OPG is also able to bind to TRAIL to inhibit 
apoptosis of transformed cells and tumour cells, by enhancing endothelial cell survival and 
acting as a “survival factor134 133. Because of this, OPG is considered to be a promising 
therapeutic candidate as it prevents bone lesions and can inhibit tumour growth. Although 
OPG is predominantly released in bone, it is also expressed in other tissues such as the lung, 
heart and blood vessels. OPG is secreted by ECs and their progenitors as well as by VSMCs, 
megakaryocytes and platelets135.  OPG expression is also evident in the endothelium of early 
human atherosclerotic lesions, with another in vitro study showing OPG and RANKL 
expression in VSMCs and endothelial cells. 
 
There however lies much controversy regarding the role of OPG in disease, with 
emerging evidence that suggests that OPG does not merely serve a protective factor for 
bone, but may also be a novel biomarker for cardiovascular disease and 
arteriosclerosis136. OPG has been identified as a pro-angiogenic factor for angiogenesis137 
and is known to enhance the pro-angiogenic properties of endothelial colony-forming cells in 
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vitro and promote vasculogenesis in vivo135. However, despite this, there is growing clinical, 
epidemiological and experimental evidence for the role of OPG in disease. Elevated OPG 
serum levels have been associated with the severity of CVD such as atherosclerosis and 
myocardial ischemia134, 138, 139.  OPG levels are predictive of coronary artery disease (CAD) 
as reported in the Framingham Heart Study where participants demonstrated a positive 
association with circulating OPG levels and CVD incidence and mortality140. Furthermore, 
OPG is known to be associated with severity of osteosclerosis and increased number of 
disease vessels in type 2 diabetes mellitus141, atherosclerotic plaque calcification142, worse 
long-term cardiac outcomes in patients with acute coronary syndrome (ACS)143,  increased 
severity and progression of carotid artery disease in cerebrovascular diseases134 and has been 
shown to decrease osteoclastic differentiation in stenosis and aortic valves during valvular 
heart disease144.  
 
Published murine models for calcification using OPG knockout mice have 
demonstrated that these mice develop severe hypercalcemia and early calcium deposits 
within the media and subintima of the aorta, which is accompanied by the formation of 
typical bone matrix145, 146.  Furthermore, OPG deficient mice experience significant 
calcification in their aortas and renal arteries, with increased osteoporosis and advanced 
plaque progression; confirming both its crucial role in bone metabolism and protective role in 
VC128, 145.. Other studies using this murine knockout model of calcification demonstrated that 
when OPG deficient mice were treated with WP9QY (W9) peptide, that binds to RANKL to 
block RANKL-induced osteoclastogenesis; (W9) restored alveolar bone loss in OPG–/– mice 
by suppressing osteoclastogenesis and enhancing osteoclastogenesis147. OPG deficient mice 
have also been used to study bone marrow adipogenesis, with one study reporting greater 
number of adipocyte accumulation in the bone marrow of 12-week-old OPG–/– mice compared 
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to those occurring in bone marrow of wildtype mice148. In addition, OPG inactivation in 
apolipoprotein-E (ApoE)-knockout mice has shown to accelerate advanced atherosclerotic 
lesion progression and vascular calcification, therefore highlighting its protective role in 
disease149. However, to date, no studies have used this murine model to understand the role of 
a calcification milieu on ischemia and inflammatory-driven angiogenesis.  
 
Vascular inflammation is also known to regulate OPG expression. Pro-inflammatory 
mediators such as interleukins- α and growth factors such as platelet-derived growth factors 
(PDGFs) are able to induce OPG expression in ECs and VSMCs134, 136. Despite the evidence 
available to suggest the role of OPG in vascular pathophysiology, it still remains unclear 
whether OPG serves a favourable or detrimental effect on the vasculature. In most instances 
where OPG expression is upregulated, it has been proposed to be a compensatory vascular 
defence mechanism, to try and stop the activation of other inflammation pathways, a response 





















Figure 1.10: Mechanistic pathway illustrating the RANK-RANKL-OPG axis in vascular 
calcification. Under pro-calcific conditions, RANKL binds to its physiologic receptor, RANK, which 
in turn promotes osteoclast differentiation and mineral deposition. However, osteoprotegerin (OPG), a 
decoy ligand interferes with the interaction between RANK and RANKL and inhibits this process.   
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1.8 Evidence for Calcification and Angiogenesis  
Previous studies have demonstrated that angiogenesis may be associated with 
vascular calcification in blood vessels and heart valves62. The first evidence to suggest that 
soft tissue calcification may be associated with angiogenesis came from imaging studies from 
the 1980's, whereby silicone polymers were injected into cleared fixed human hearts, and the 
pattern of vascular filling was recorded by cinematography62. Analysis of these 
cinematographic images showed that abundant neovascularization was associated with sites 
of lesional calcification in the media and neointima of these lesions62. They further identified 
that around calcified deposits, there was increased proliferation of newly formed vessels 62. 
This data however only provides evidence for the role of angiogenesis in the initiation of 
ectopic calcification in atheromatous lesions and not in blood vessels. 
 There is growing evidence that ectopic calcification of blood vessels and cardiac 
valves are associated with angiogenesis51, 62,150. The OPG/RANK/RANKL pathway has 
been suggested to regulate angiogenesis in numerous studies51, 62,150. RANKL treatment  
stimulated angiogenesis in vivo and in vitro by acting as a chemostatic factor for ECs 
and inducing their migration and proliferation150,129, 151; increased vascular permeability 
and promoted neoangiogenesis via induction of EC migration and proliferation51, 150, 152. 
However, conflicting studies have reported RANKL to cause a reduction in EC 
proliferation, while inducing endothelial cell apoptosis, therefore suggesting RANKL to 
be an inhibitor of angiogenesis153. Furthermore, the pro-angiogenic role of OPG has been 
well described to have effects on mature ECs by enhancing EC chemotaxis and cell 
survival137, 154; while promoting cell proliferation and vascular cord formation in 
Matrigel both in vitro and in vivo135 153, 155, therefore proposing its potential role in 
maintaining EC integrity154. In addition, VEGFA has been shown to increase the mRNA 
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expression of Rank in human ECs, which upregulated their angiogenic response to 
RANKL51,150,45. It was also shown that in co-cultures of endothelial cells with osteoblasts, 
proliferation of ECs was enhanced by the production of osteoblast-derived angiogenic factors 
such as VEGFA156. Based on this evidence, the OPG/RANK/RANKL triad may have a 
potential role in regulating angiogenesis. 
During angiogenesis, BMP2 and BMP4 along with other angiogenic factors such as 
VEGF have shown to induce endothelial cell migration and proliferation61, 62. As discussed 
earlier, endothelial cell migration and proliferation are critical processes needed for 
angiogenesis. Collett and Canfield24, reported that differentiation of VSMCs is brought 
about by an inflammatory stimuli, which triggers activation of specific osteogenic signals 
such as BMP2, which thereby stimulate differentiation of VSMCs into osteoblast-like 
cells, a well proposed mechanisms of vascular calcification 61, 62, 157. There lies extensive 
data showing that BMP2 is capable of driving angiogenesis via the induction of VEGFA 
expression, particularly in cancer pathologies158, 159. However, the mechanisms by which 
BMP2 stimulates angiogenesis in endothelial cells have not been established.   
Inflammatory mediators derived from monocyte-macrophages such as TNFα, have been 
reported to contribute to the progression of VC by promoting osteoblastic differentiation of 
VSMCs, leading to mineralisation. Furthermore, calcium phosphate mineral deposition is 
known to elicit an inflammatory response, by stimulating TNF production by macrophages160, 
161. Though the mechanisms of vascular calcification have been intensely studied for many 
years, the understanding of its effects on inflammatory-driven angiogenesis in endothelial 




1.9 Hypotheses and Aims 
The regulation of angiogenesis is important for the treatment of cancer and ischemic diseases. 
Therapeutic strategies are aimed to deliver single growth factors as treatment options and 
have been shown to lack efficacy. Despite the abundance of evidence regarding the presence 
of VC in PAD, the underlying mechanisms remain unknown. Moreover, the presence of 
calcification and a highly calcific environment has not been studied as a deterrent of this 
angiogenic process.  Therefore, given the above rationale, the studies described in this thesis 
aimed to: 
a) Characterise the effect of high calcium on endothelial cell hypoxia-driven 
angiogenesis in vitro.  
b) Investigate role of a calcification milieu on ischemia-driven angiogenesis in vivo, 
using the hind-limb model of angiogenesis in OPG knockout mice. 
c) Elucidate the role of inflammatory stimuli in driving calcification-induced 
angiogenesis in endothelial cells in vitro 
d) Determine the role of calcification on inflammatory-driven angiogenesis using a peri-
arterial cuff in OPG knockout mice. 
The hypothesis of this body of work was that high calcium will negatively affect endothelial 
cell angiogenesis in vitro and that the presence of a calcific milieu will impact ischemia-

















2. IN VITRO METHODOLOGY 
Table 1: General Solutions & Reagents 
Reagent/Material (Product Code)  Manufacturer  
1-Bromo-3-chloropropane (B9673)  Sigma-Aldrich, MO, USA  
1Kb Plus DNA Ladder (10787018)  ThermoFisher Scientific, MA, USA  
1-Palmitoyl-2-linoleoyl-phosphatidylcholine (850458P)  Avanti Polar Lipids, AL, USA  
Agarose (A9539)  Sigma-Aldrich, MO, USA  
Ammonium bicarbonate (A6141)  Sigma-Aldrich, MO, USA  
Biotium-GelRedTM 10,000X in Water (GTS41003)  Adelab Scientific, SA, Australia  
BoltTM 4-12% Bis-Tris Plus Gels, 10-wells 
(NW04120BOX)  
Life Technologies, CA, USA  
BoltTM 4-12% Bis-Tris Plus Gels, 12-wells 
(NW04122BOX)  
Life Technologies, CA, USA  
BoltTM 4-12% Bis-Tris Plus Gels, 17-wells 
(NW04127BOX)  
Life Technologies, CA, USA  
BoltTM LDS Sample Buffer 4X (B0007)  Life Technologies, CA, USA  
BoltTM MES SDS Running Buffer 20X (B0002)  Life Technologies, CA, USA  
BoltTM Reducing Agent 10X (B0004)  Life Technologies, CA, USA  
Bovine serum albumin (A7906)  Sigma-Aldrich, MO, USA  
Calcium Assay Kit (701220) Cayman Chemical 
Calcium Chloride  Sigma-Aldrich, MO, USA 
Chloroform (AJA152-2.5L GL)  Ajax Finechem, NSW, Australia  
Clarity Western ECL Substrate (1705061)  Bio-Rad Laboratories, CA, USA  
Ethanol (E7023)  Sigma-Aldrich, MO, USA  
Ethanol (100%) for histopathology (FNNJJ008)  Fronine, NSW, Australia  
Fluorescence Mounting Media (S302380-2)  Dako, CA, USA  
Foetal bovine serum (AU-FBS/PG)  CellSera, NSW, Australia  
Formalin (HT501128)  Sigma-Aldrich, MO, USA  
Glacial acetic acid (AJA1-2.5L PL)  Ajax Finechem, NSW, Australia  
Glycine (G7126)  Sigma-Aldrich, MO, USA  
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Goat serum (G9023)  Sigma-Aldrich, MO, USA  
Guanidine hydrochloride (G4505)  Sigma-Aldrich, MO, USA  
Hexadimethrine bromide (H9268)  Sigma-Aldrich, MO, USA  
Hydrogen peroxide solution (216763)  Sigma-Aldrich, MO, USA  
iBlotTM 2 Transfer Stacks, regular size (IB23001)  Life Technologies, CA, USA  
iBlotTM 2 Transfer Stacks, mini size (IB23002)  Life Technologies, CA, USA  
ImmPACT® DAB Peroxidase Substrate (SK-4015)  Vector Laboratories, CA, USA  
SsoAdvancedTM Universal SYBR® Green Supermix 
(1725275)  
Bio-Rad Laboratories, CA, USA  
iScript cDNA Synthesis Kit (1708841)  Bio-Rad Laboratories, CA, USA  
Isopropanol (I9516)  Sigma-Aldrich, MO, USA  
LabAssay ALP kit  (29158601) Wako Diagnostics, VA, USA  
Lillie Mayer’s haematoxylin (AHLM)  Australian Biostain, VIC, Australia  
Matrigel® Growth Factor Reduced Basement Membrane 
Matrix (356231)  
Corning Life Sciences, NY, USA  
MesoEndo Cell Growth Medium (212-500)  Cell Applications Inc., CA, USA  
Methanol (MA004)  Chem-Supply, SA, Australia  
NE-PER® Nuclear and Cytoplasmic Extraction Reagents 
(78833)  
ThermoFisher Scientific, MA, USA  
Normal horse serum (S-2000)  Vector Laboratories, CA, USA  
Nuclease-free water (P1193)  Promega, WI, USA  
Opti-MEMTM I Reduced Serum Media (31985070)  Life Technologies, CA, USA  
Paraformaldehyde (C004)  ProSciTech, QLD, Australia  
Phosphatase Inhibitor Cocktail 2 (P5726)  Sigma-Aldrich, MO, USA  
Phosphate-buffered saline (D1408-500ML)  Sigma-Aldrich, MO, USA  
Phenylmethylsulfonyl fluoride solution (93482)  Sigma-Aldrich, MO, USA  
Phospholipid C Assay Kit (997-01801)  Wako Diagnostics, VA, USA  
Pierce BCA Protein Assay Kit (23227)  ThermoFisher Scientific, MA, USA  
Polyethylene glycol (P2139)  Sigma-Aldrich, MO, USA  
Ponceau S solution (P7170-1L)  Sigma-Aldrich, MO, USA  
Potassium bromide (PA006)  Chem-Supply, SA, Australia  
Precision Plus Protein Dual Color Standards (1610374S)  Bio-Rad Laboratories, CA, USA  
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Protease Inhibitor Cocktail (P8340)  Sigma-Aldrich, MO, USA  
Proteinase K (17916)  ThermoFisher Scientific, MA, USA  
Recombinant human VEGF 165 (293-VE-010)  R&D Systems, MN, USA  
RestoreTM Western Blot Stripping Buffer (21059)  ThermoFisher Scientific, MA, USA  
Sodium azide (SA189)  Chem-Supply, SA, Australia  
Sodium chloride (71380)  Sigma-Aldrich, MO, USA  
Sodium Phosphate (S3264-500G) Sigma-Aldrich, MO, USA  
Sodium cholate (C6445)  Sigma-Aldrich, MO, USA  
Sodium citrate tribasic dihydrate (C8532)  Sigma-Aldrich, MO, USA  
Sodium dodecyl sulfate (L3771)  Sigma-Aldrich, MO, USA  
Sodium orthovanadate (S6508)  Sigma-Aldrich, MO, USA  
Tissue-Tek® O.C.T. compound (IA018)  ProSciTech, QLD, Australia  
TRI® Reagent (T9424)  Sigma-Aldrich, MO, USA  
Trichrome Stain Kit (ab150686)  Abcam, Cambridge, UK  
Tris hydrochloride (T3253)  Sigma-Aldrich, MO, USA  
Tris(hydroxymethyl)aminomethane (AJA2311)  Ajax Finechem, NSW, Australia  
Triton X-100 (X100)  Sigma-Aldrich, MO, USA  
Trypsin-EDTA (15400054)  ThermoFisher Scientific, MA, USA  
Tumour Necrosis Factor-α _Human, (T0157) _ _ Sigma-Aldrich, MO, USA  
Trypan Blue solution (T8154)  Sigma-Aldrich, MO, USA  
Tween®-20 (P9416)  Sigma-Aldrich, MO, USA  
Vectashield® Antifade Mounting Medium with DAPI (H-
1200)  
Vector Laboratories, CA, USA  
Vector® Red Alkaline Phosphatase Substrate kit (SK-5100)  Vector Laboratories, CA, USA  
WST-1 Reagent Roche Applied Science, Mannheim, 
Germany 













2.1 Cell Culture  
Human Coronary Artery Endothelial Cells (HCAECs) (Cell Applications) were 
cultured in MesoEndo Cell Growth Media (Sigma-Aldrich), supplemented with 5% fetal 
bovine serum (FBS), 10 µg/ml streptomycin, 10 U/ml penicillin and 1 mM L-glutamine, in a 
T-75cm2. Cells were grown to 80% confluency and washed with Dulbecco's Phosphate 
Buffered Saline (PBS) (Sigma-Aldrich) before seeding in 6 well plates. Cells were serum 
starved for 24 h in Medium-199 (Sigma-Aldrich) containing 10% FBS, supplemented with 
Earle's salts, L-glutamine and NaHCO3, also containing 1.36mM calcium, a no treatment (NT) 
control.  To induce phosphate mediated calcification, CM was supplemented with calcium and 
phosphate (2.7mM CaCl2 and 2.0mM NaH2PO4) referred to as calcification medium (CM).  
Cell culture experiments were conducted under 2 different conditions: (1) 
inflammation or (2) hypoxia. Cells were incubated and maintained in a 37° C humidified 
atmosphere of 5% CO2 for 24 h for Normoxic conditions. A hypoxic environment was 
achieved by incubation in a hypoxic incubator with conditions of 1.2% O2/5% CO2 balanced 
with N2. For inflammation, cells were pre-treated for 4 h with tumour necrosis factor alpha 
(TNF-α) at a concentration of 10 ng/mL. Tissue culture media was changed every 2-3 days. 
All experiments were carried out in triplicates. All cells were used between passages 2 and 5 
only in vitro. 
 
2.2 Functional Studies  
2.2.1 Tubulogenesis Matrigel Assay 
To assess tubulogenesis, growth factor reduced Matrigel (company) was thawed and 
carefully plated at 40 μL/well into a 96 well plate, ensuring no bubbles were present. This 
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was left to polymerise at 37°C for 30 minutes. HCAECs were plated at 1 x 105 cells/mL in 
100 μL MesoEndo Endothelial Cell Media (212-500, Cell Applications Inc., California, 
USA) and under hypoxia was stimulated with (1.2% O2/ 5% CO2) conditions at 37°C for 4 – 
6 hours. HCAEC tubule formation performed for a total of 4 hours and images were imaged 
at 10X magnification and counted in a minimum of 3 fields of view per well using Image J 
(National Institutes of Health, Maryland, USA). 
 
2.2.2 Boyden Chamber Cell Migration Assay 
HCAECs were cultured and treated as previously described. Cells were harvested using 
Trypsin EDTA (Sigma-Aldrich) and resuspend in 500 μl of 3% FBS Opti-MEM medium 
(Gibco) to make up cell suspension. 600 μl of migration media (3% FBS Opti-MEM medium 
containing VEGF 10 ng/mL) was carefully added to the bottom chamber of 24 well 
Transwell, ensuring no bubbles were present. 100 μL cell suspension at a density of 1 x 105 
cells/mL was added into each transwell insert, ensuring that there are no air bubbles on or 
below the membrane. Plates were incubated overnight at 37°C. The following day, media 
was carefully aspirated from the upper chamber. Transwell inserts was removed and cells on 
the upper surface of the transwell membrane were carefully scraped away using a cotton tip. 
Transwells were then submerged in 1mL of 1x PBS for approximately 1 min to rinse, and 
then transferred into 4% paraformaldehyde in PBS for 10 min to fix. Excess medium was 
aspirated from the transwell inserts, and membranes cut out using a scalpel blade, and 
membranes were placed cell side up onto labelled slides. DAPI staining for nuclei was used 
to stain membranes. Slides were imaged at 20x magnification in the dark at five separate 
fields at same magnification with a fluorescent microscope. Analysis for cell counts were 




2.2.3 Cell Viability Assay  
A functional WST-1 cell viability assay was used to assess the effect of calcification stimuli 
on cell viability in vitro. WST-1 is a colorimetric assay by which the reduction of tetrazolium 
compound to its formazan products by mitochondrial dehydrogenase activity is measured in 
viable cells. The greater the number of viable cells and metabolically active cells present, the 
greater the amount of formazen product formed following the addition of WST-1.  
HCAECs were cultured as previously described. Cells were stained for viability with Trypan 
Blue solution (Sigma-Aldrich) and counted using a haemocytometer. Cells were seeded in a 
96 well plate at a density of 10 X 103 cells/mL for 24 h, and seeded overnight in low serum 
media M199, containing 10% FBS. Following treatment for 24 h, cell proliferation reagent 
WST-1 (Roche, Life sciences) was prepared in a 1:10 final dilution (10 µl/well WST-1 
reagent), with a total volume of 100 µL/well, and was added to cells. Cells were incubated in 
a humidified atmosphere 37°C, 5% CO2, protected from light, and following a 4 hour 
incubation period, the formazan products was quantified at 450 nm using the BIO-RAD 
iMark™ Microplate Reader. Unless otherwise stated, all experiments were carried out in 
triplicates, with data from 3 independent experiments averaged and used for analysis. 
 
2.2.4 Mechanistic Studies 
Mechanistic studies were conducted to assess the effect of calcification on both ischemia-
driven and inflammatory driven angiogenesis in vitro. Cells were plated in 6 well plates at a 
cell density of 1x105 cells/mL. For inflammatory studies, cells were incubated with TNF-α at 
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10 ng/mL for 4 hours in 10% M199 medium as described earlier and were harvested 
accordingly for western blotting analysis.    
2.2.5 Protein Extraction 
Treated cells were harvested from 6 well plates after 24 h. Media was removed, and cells 
were washed once in cold PBS. Radioimmunoprecipitation assay (RIPA) lysis buffer (20 mM 
Tris-HCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulphonyl 
fluoride, 1.5 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin, 1 mM sodium 
orthovanadate, and 0.2% Triton X-100; pH 7.4), protease inhibitor cocktail (1:100, P8340, 
Sigma-Aldrich) was added to cells in 100μL (1:100), along with protease inhibitor cocktail 
(1:100, P8340, Sigma-Aldrich), and phenylmethanesulfonyl fluoride solution (93482, Sigma-
Aldrich), and was transferred to Eppendorf tubes. Each sample was sonicated for 2 seconds 
to further lyse the sample and were centrifuged for 10 minutes at 14,000 rpm at 4oC and 
stored at -80oC. 
2.2.6 Nuclear Extraction 
To extract the nuclear fraction of incubated cells, the NE-PER Nuclear and Cytoplasmic 
Extraction kit (PIE78833, Thermo Fisher Scientific) was used. Following 24 h treatment in 6 
well plates, cells were harvested as previously described to achieve a pellet in an Eppendorf 
tube. Nuclear and Cytoplasmic tubes were labelled and pre-chilled on ice before beginning 
the assay. To begin extraction, 50 μL ice cold CER I reagent was added to each tube. Tubes 
were vortexed for 15 seconds before incubation on ice for 10 minutes. Following this, 5 μL 
CER II reagent was added, tubes were vortexed for 5 seconds and allowed to incubate on ice 
for 1 minute. Tubes were vortexed once more prior to centrifugation at 16,000 g for 5 
minutes at 4oC. The supernatant containing the cytoplasmic fraction was transferred to a new 
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tube and stored at -80oC. The pellet containing the nuclear fraction was resuspended in 25 μL 
ice cold NER reagent by vortexing for 15 seconds at 10-minute intervals for a total of 40 
minutes. Samples were kept on ice between vortexing. Samples were then centrifuged at 
16,000 g for 10 minutes and the supernatant containing the nuclear fraction was transferred to 
new Eppendorf tubes and stored at -80oC. 
 
2.2.7 Protein Estimation 
The protein concentration for each sample was determined using the Bicinchoninic (BCA) 
Protein Assay (Thermo Fisher Scientific). A standard curve using bovine serum albumin 
(BSA, A7906-100G, Sigma-Aldrich) concentrations of 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2.0 
mg/mL was constructed from 2 mg/mL BSA stock as prepared in Table 2.1. 
 
Table 2.2: Standard BSA Solutions Used in BCA Assay. 







0 0 600 
0.25 75 525 
0.5 150 450 
0.75 225 375 
1 300 300 
1.25 375 225 
1.5 450 150 
2 600 0 
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This assay was performed in a 96 well plate. 5 µL of standard and sample was added to each 
well in duplicate, and 195 µL of reagent mix consisting of 50 parts reagent A (23223, 
Thermo Fisher Scientific) and 1-part reagent B (copper (II) sulphate) (23224, Thermo Fisher 
Scientific). The plate was then incubated at 37°C for 30 minutes and absorbance of each well 
measured at 595 nm using microplate reader (Flex Station 3, Molecular Devices, San Jose, 
CA, USA) using the SoftMax Pro program (v5.3, Molecular Devices) for data acquisition and 
analysis. The protein concentration of unknown samples was interpolated from the standard 
curve using GraphPad Prism, Version 8. 
 
2.2.8 Western Blotting 
Whole cell protein lysate was used to determine changes in angiogenic and calcification 
markers. To prepare samples, protein was added to 8 μL BoltTM LDS Sample Buffer (4X) and 3 
μL BoltTM Reducing Agent (10X) that had been diluted 1:10 in distilled water from the stock 
provided. Samples were then denatured by heating at 95oC for 5 minutes before placing on ice 
for 2 minutes. 8 μL of (ladder name) Pre-stained Protein Standard (Life Technologies) and 40 
μL sample were loaded into 10, 12 and 17 well Bolt® 4% Bis-tris plus gel (Life 
Technologies). Equal protein of 10-20 μg was loaded on each gel. Gels were run at 120 V for 
1 hour and 15 minutes in Bolt® MES SDS Running Buffer Life Technologies) diluted in 
distilled H2O. Following this, proteins from the gel were then transferred onto nitrocellulose 
membranes (Life Technologies) using the iBlot Gel Transfer system (Life Technologies) run 
at 20 V for 7 minutes. Membranes were then blocked in 10% (w/v) skim milk or 5% BSA 
(Sigma Aldrich) in 1xTBST (20 mM Tris, 136 mM NaCl, and 0.1% [w/v] tween 20, pH 7.4) 
for 1 hour at room temperature on a rocking platform. Following this, membranes were 
washed 3 times in TBST for 5 minutes at room temperature. Membranes were probed with 
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antibodies as for total HIF-1a (Novus, NB100-449, 1:500), VEGFA (Abcam, ab461154, 
1:2000), Runx2 (D130-3; MBL, 1:1000), RANKL (Santa Cruz, Sc3770779, 1:500), BMP2 
(Novus, NOVNBP119751, 1:1000), total eNOS (BD, 610297, 1:1000), phosphorylated 
(S1177) eNOS (BD, 61293, 1:1000), total Erk1/2 (Cell Signalling Technology; 9102, 1:1000), 
phosphorylated (Tyr202/Tyr204) Erk1/2 (Cell Signalling Technology; 4370, 1:1000),  total p38 
MAPK (Cell Signalling Technology; 86901, 1:1000), phosphorylated p38 MAPK (T180/Y182), 
(Cell Signalling, 4511, 1:1000), total VEGFR2 (2479; Cell Signalling Technology, 1:1000), 
phosphorylated (y1175) VEGFR2 (Cell Signalling 2478, 1:1000), PHD2 (Novus, NB100-2219, 
1:1000), PHD3 (Novus, NB100-303, 1:1000). Even loading was confirmed by alpha-tubulin 
(Abcam, ab729, 1:5000) for total lysate; and Lamin B 1 Nuclear Envelope Marker (Abcam, 
ab160-048, 1:1000) for nuclear extracts. Membranes were developed by chemiluminescence 
on the Chemidoc MP Imaging System (machine details) with ECL reagents in a 1:1 ratio of 
Clarity Western Peroxide Reagent and Clarity Western Luminol/Enhancer Reagent (170-
5061, Biorad). Images were recorded using Image Lab Software (v.5.0, 170-9692, BioRad). 
Treated cells were harvested from 6 well plates 24h later. Media was removed, and 
cells washed once in cold PBS. Radioimmunoprecipitation assay (RIPA) lysis buffer (20 mM 
Tris-HCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulphonyl 
fluoride, 1.5 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin, 1 mM sodium 
orthovanadate, and 0.2% Triton X-100; pH 7.4), protease inhibitor cocktail (1:100, P8340, 
Sigma-Aldrich) was added to cells in 100 μL (1:100), along with protease inhibitor cocktail 
(1:100, P8340, Sigma-Aldrich), and phenylmethanesulfonyl fluoride solution (93482, Sigma-
Aldrich), and was transferred to Eppendorf tubes. Each sample was sonicated for 2 seconds 
to further lyse the sample and were centrifuged for 10 minutes at 14,000 rpm at 4oC and 
stored at -80oC. Protein concentrations were determined using the bicinchoninic assay 
(BCA), and total protein concentration between 10-15 μg of the protein were loaded for 
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Western blot analysis and probed with antibodies as for total HIF-1a (Novus, NB100-449, 
1:5000), VEGF (Abcam, ab461154, 1:2000), and nuclear NF-kB (P65) (Abcam, ab86299). 
Even loading was confirmed by alpha-tubulin (Abcam, ab729, 1:5000) for total lysate; and 
Lamin B 1 Nuclear Envelope Marker (Abcam, ab160-048, 1:1000) for nuclear extracts. 
Protein levels were quantified and analysed using Bio-Rad ImageLab software (Bio-Rad 
Laboratories). 
 
2.2.9 RNA Extraction 
Extraction of pure RNA was performed by adding 500μL Trizol reagent (Ambion, Life 
Technologies) to cells in 6 well plates following 1 x quick wash with old 1 x PBS. Cells were 
scraped using cell scrapers and 1/10 volume of Bromo-chloropropane (BCP) (Sigma-Aldrich) 
(50 µl) was then added, and supernatant was transferred to labelled Eppendorf tubes. Sample 
tubes were vortexed for 15 seconds then rested at room temperature for 5 minutes prior 
centrifugation at 14,000 rpm for 15 mins at 4°C on the Eppendorf Centrifuge 5424R (details). 
Colourless upper aqueous phase was transferred to a new tube and 0.5 volume of 2-propanol 
(250 µl) was added and tubes incubated overnight at -20°Celsius. The following day, samples 
were centrifuged at 14,000 rpm for 15 minutes at 4°C and supernatant was decanted. The 
remaining pellet was washed with 0.5 volume of ice-cold 75% ethanol (250 µl) and 
centrifuged at 14,000 rpm for 10 minutes at 4°C. The pellet was dried, and RNA was 
dissolved in pre-warmed RNA-nuclease free water (20 µL). Nanodrop 2000 
spectrophotometer (Thermo Scientific, CA, USA) was used to quantify all RNA 
concentrations. To assess RNA quality and purity, samples with A260/A280 ratio values 
between 1.8-2.0 were deemed acceptable.  
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2.2.10 Reverse Transcriptase- Polymerase Chain Reaction (RT-
PCR) 
Complementary DNA (cDNA) synthesis was performed using iSCRIPT buffer (Bio-RAD, 
Hercules, CA, USA) for all RNA samples at 100 ng/µL. The final volume of reaction was 10 
µL. RNA samples were prepared in duplicates and were incubated in the BIO-RAD T100™ 
Thermal Cycler at varying temperatures at different time points of; 25°C for 5 minutes, 42°C 
for 30 minutes. 85°C for 5 minutes and 15°C for infinity (∞). The cDNA was then diluted 1:3 
via the addition of 20 µL nuclease-free water and stored at -20°C until use in real-time PCR.  
Table 2.2. Reverse Transcription Reaction Mix. 
Component Volume (μL) 
iScript Reverse Transcriptase  0.5  
5X iScript Reaction Buffer  2.0  
Nuclease-Free Water  5.5  
Normalised RNA Sample  2.0  
Total  10.0  
 
2.2.11 Quick Reverse Transcriptase- Polymerase Chain Reaction 
(qRT-PCR) 
Real-time PCR were performed for the analysis of gene expression on endothelial cells. 
Universal SYBR© Green Supermix (SsoAdvanced™) was used for preparation of mastermix 
for cDNA samples, and all PCR reactions were performed in triplicate and ran on the Bio-
Rad CFX96 thermocycler. Steps included initial denaturation and enzyme activation 95°C for 
3 minutes; 40 cycles of denaturation 95°C for 30 seconds, annealing 60°C for 30 seconds, 
followed by extension 72°C for 30 seconds. A non-template control (NTC) was included to 
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monitor contamination and primer-dimer formation that could produce false positive results. 
18s was used as a housekeeping gene. The relative changes in gene expression between 
treatments was determined using the 2-ΔΔcT method. Primers sequences for each cDNA are 
depicted in table 2.4.  
Table 2.3: Quantitative Real-time PCR Reaction Mix  
Components Volume (µL) 





















 Gene Forward Primer 5’-3’ Reverse Primer 5’-3’ 
1  18S GAAGGCTGGGGCTCATTT CAGGAGGCATTGCTGATGAT 
2  RANK ATGCGGTTTGCAGTTCTTGTC ACTCCTTATCTCCACTTAGG 
3  OPG GCTTGAAACATAGGAGCTG GTTTACTTTGGTGCCAGG 
4  RANKL ACTACCAGAAACGAGTGGGAA GCATCTGTTCTCGGAAAACCT 
5  RUNX2 TGGTTACTGTCATGGCGGGTA  TCTCAGATCGTTGAACCTTGCTA 
6  BMP2 ACTACCAGAAACGAGTGGGAA GCATCTGTTCTCGGAAAACCT 
7  VEGFA TGTGAATGCAGACCAAAGAAAGA TGCTTTCTCCGCTCTGAGC 
8  HIF-1Α AACGTCGAAAAGAAAAGTCTCG CCTTATCAAGATGCGAACTCACA 
9  SIAH1 CACCAGCAGTTCTTCACCATTTAGC CAATCGTCGCCTATGACCATTTAGC 
10 SIAH2 CCCTTCCTGCCTGCCCAGCCATCG TCAGTGTCTATTAGCGCAATCG 





2.3  IN VIVO METHODOLOGY 
2.3.1 Animal Studies and Ethics.  
All animal experimental procedures were conducted with approval from the South 
Australian Health and Medical Research Institute (SAHMRI) Animal Ethics Committee 
(SAM265) and were conducted in accordance to the Australian Code for the Care and Use of 
Animals for Scientific Purposes (8th edition, 2013). OPG-/- mice (C57BL/6J background) 
were obtained from Jax Laboratories (Maine, United States). Matching wildtype littermates 
(C57BL/6J background) were utilised as controls in all the experiments. Male mice were 
divided into two groups: 8-12 weeks of age for young adults, and 12-24 weeks of aged for 
ageing cohort. All animals were housed in the animal care facility at SAHMRI and 
maintained on a standard mouse chow diet (Speciality Feeds, Glen Forrest, WA, Australia). 
 
2.3.2 Hind-Limb Ischemic Surgery (HLI) 
All animal experimental procedures were conducted with approval from the South 
Australian Health and Medical Research Institute (SAHMRI) Animal Ethics Committee 
(SAM265) and were conducted in accordance with the Australian Code for the Care and Use 
of Animals for Scientific Purposes (8th edition, 2013). OPG-/- mice (C57BL/6J background) 
were obtained from Jax Laboratories (USA). Matching wildtype littermates (C57BL/6J 
background) were utilised as controls in all the experiments. Male and female mice were 
divided into two groups: 8-10 weeks of age for young adults, and 24 weeks for ageing cohort. 
All animals were housed in the animal care facility at SAHMRI and maintained on a standard 
mouse chow diet (Speciality Feeds, Glen Forrest, WA, Australia).  
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Mice were anaesthetized by inhalation of isoflurane and euthanized by cardiac 
exsanguination post-surgery. At euthanasia, blood was collected by right ventricular puncture 
with a heparinised 1 cc/mL syringe. Blood was kept on ice until centrifugation at 3,000 rpm 
for 10 minutes. Plasma was stored in 50 μL aliquots at -80°C. The hindlimb ischemia model 
was conducted as previously described162 to ensure ischemia of the distal regions of the 
hindlimb. Following inhalation of isoflurane (2%), the proximal end of the femoral artery and 
distal end of the saphenous vein were ligated with 8-0 silk suture, and the artery and all side 
branches were dissected free and excised to induce ischemia in the foot and the gastrocnemius 
muscle; and the overlying skin sutured with 6-0 silk sutures (n = 12 per group). A sham 
operation was performed on the right hind-limb as a control. Post-surgical pain was managed 
by buprenorphine (0.1mg/kg) administration 2 days post-surgery and animals were monitored 
daily. Mice were anesthetized using isoflurane and euthanized by cardiac exsanguination at 1 
and 14 days after ischemic surgery. Angiogenesis predominates in the ischemic distal bed, so 






Figure 2.1:  Schematic Demonstration of The Hind Limb Ischemia Model Study Design.  
The proximal end of the femoral artery and distal end of the saphenous vein were ligated with 8-0 silk 
suture. The artery and all side branches were dissected free and excised to induce ischemia in the foot 
and the gastrocnemius muscle. 
  
 
2.3.3 Laser Doppler Perfusion Imaging  
Blood reperfusion of the hindlimb was determined by Laser Doppler Perfusion imaging 
(moorLDI2-IR, Moor Instruments, Devon, UK) at baseline, immediately post-surgery and on 
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Figure 2.2:  Laser Doppler Perfusion Imaging. Blue indicates low blood flow; red indicates 
high blood flow. Blood flow return was assessed in the hindlimbs of these mice on days 1, 3, 7, 10 
and day 14 endpoint, with three scans taken per mouse at each time point. Data was analysed using 
the laser Doppler imaging system (moorLDI2-IR, Moor instruments, Devon, UK). 
 
 
2.3.4 Tissue Processing 
Mice were anesthetised using isoflurane and euthanised by cardiac exsanguination 14 days 
following surgery. The gastrocnemius muscles of both the ischaemic and non-ischaemic 
hindlimbs, were halved and snap frozen at -80o C in Eppendorf tubes for RNA/protein 
analysis. The other half was placed in Tissue-Tek® optimal cutting temperature (OCT) 
compound (IA018, ProSciTech, Kirwan, QLD, Australia) within Tissue-Tek® cryomolds 
Immunocytochemistry 
 CD31 & α-actin 
RNA  
Day 14 
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HLI Surgery 
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then immediately placed on dry ice. The muscle and all other tissues were snap frozen in 
liquid nitrogen and stored at -80o C until ready to be processed for histology.  
 
2.3.5 Plasma Isolation from Whole Bloods  
Whole blood was collected in heparin sulphate tubes (Interpath 22/12/45) by right 
ventricular puncture and was kept on ice until centrifugation at 3000 rpm for 10 minutes at 
4oC. The plasma layer was collected in three 50 µl aliquots and was stored at -80oC. Plasma 
was isolated for detection of calcium levels (Calcium Assay, Cayman Chemical, 701220) and 
alkaline phosphatase activity (LabAssay ALP, WAKO, 291-58601).  
 
2.3.6 RNA Extraction, cDNA Synthesis and Quantitative Real-Time PCR 
Quantitative real-time PCR (qRT-PCR) was performed on cDNA in triplicates using 
SSoAdvanced Universal SYBR Green Supermix in a CFX Connect Real Time System (Bio-
Rad). Relative changes in mRNA expression were normalised using the ΔΔCt method to 
housekeeping gene 36B4. Genes of interest included angiogenic markers: HIF-1α, VEGFA, 
VEGFR2, RANKL, Runx2, BMP2, Siah 1, Siah 2, PHD2 and PHD3 (For full extraction 
protocol, see chapter 2, section 2.3.7. For primer sequences see Table 2.5.  
 
2.3.7 Immunohistochemistry   
OCT embedded gastrocnemius muscle tissues were sectioned to 5 µm thickness on 
the Shandon Cryotome E Cryostat (ThermoFisher Scientific); and mounted on superfrost 
plusTM Adhesion Microscope Slides (J1800AMNT, ThermoFisher Scientific). Prior to 
staining, slides were dried overnight at room temperature, fixed in 2% paraformaldehyde for 
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10 minutes, then washed with 0.1 M glycine in PBS for 3 x 2 minute to quench unreacted 
aldehydes. Tissues were washed in PBST containing 0.1% (v/v) Twenn-20 for 3x5 minutes, 
followed by blocking in 5% goat serum (G9023, Sigma-Aldrich) in PBST for 1 hour at room 
temperature.  
Tissues sections were then incubated overnight with primary antibodies in antibody 
diluent to detect Smooth muscle a-actin positive arterioles (1:1000, F3777, Sigma-Aldrich, 
St Louis, MO, USA) and laminin B (1:200) MAB1905, Merck Millipore, Burlington, MA, 
USA) to assess myocytes. The next day following primary antibody incubation, tissues were 
washed with PBST for 4 x 2 minutes and were incubated with secondary antibodies Alexa 
FluorÒ 555 (1:1000; A-21434; Invitrogen, Carlsbad, CA, USA) in antibody diluent for 1 
hour at 37 degrees, which was followed by 6 x 2-minute washes in PBST. Sections were 
again blocked with 5% goat serum for 1 hour at room temperature, and stained for CD31 
positive neovessels (1:50, ab28364, abcam, Cambridge, UK). Slides were washed for 4 x 2 
minutes in PBST then incubated with Alexa FluorÒ 647 (1:500; A-32733; Life technologies, 
Carlsbad, CA, USA) secondary antibody in antibody diluent respectively, for 1 hour. Slides 
were finally washed in PBST for 6 x 2 minute each and mounted with Fluorescence 
Mounting Media (S302380-2, Dako), and a cover slip was applied to each slide. Control 
sections probed with only secondary antibodies were also run to assess and adjust for the 
degree of background staining during the imaging process. These were mounted with Prolong 
Antifade Mounting Media with DAPI (P36935, Life Technologies) so that cell nuclei could 
be detected.  
All slides were allowed to dry in the dark for 24 hours and were imaged on the Nikon 
Eclipse Ni-U microscope using NIS-Elements software (Melville, NY, USA) with five high-
magnification fields (20X) of view taken for each section using the Cy5 (CD31), FITC (α-
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SMA) and Cy5 (laminin) filters. For analysis, CD31+ neovessels SMA+ arterioles and 
myocytes were manually quantified using ImageJ software.  
2.3.8 Clinical Scoring  
To assess tissue ischemia and limb function, mice were observed after surgery using a 
slightly modified version of the well-established Tarlov Clinical Scoring System as 
previously described163 at each perfusion assessment. For limb function clinical scoring was 
scaled as (0=normal gait movement, 1= plantar but no toe flexion, 2=no flexion, 3= dragging 
foot). For tissue ischemia, scoring was based on (0=no damage, 1=discoloration 1 nail, 2= 
discoloration of 2 nails, 3= discoloration of 1 toe, 4=discoloration of 2 toes, 5=foot necrosis, 















Table 4.1: Tarlov Functional scoring system. (A) Original Tarlov scores used to assess animal 
locomotor recovery from spinal cord injury, and limb-function of mice post-hindlimb surgery as 
previously described163. (B) Modified Tarlov Scoring System Used to score mice post-HLI surgery in 
aged mice. Mice were scored for limb function (LF) or tissue ischemia (TI) based on the above 
scores. All data was recorded into an excel spreadsheet and scores were tallied per mouse. 
2.3.9 Murine Peri-Arterial Femoral Cuff Surgery 




1 Plantar but no toe flexion 
2 No flexion 
3 Dragging of foot 
  
Tissue Ischemia 
0 No damage 
1 Discoloration ->1 nail 
2 Discoloration -> 2 nails 
3 Discoloration of 1 toe 
4 Discoloration of 2 toes 
5 Foot Necrosis 
6 Leg necrosis 
7 Auto-amputation of leg 
Tarlov Score 
    0 No movement 
    1 Barely perceptible movement, non-
weight bearing 
    2 Frequent movement, non-weight 
bearing 
    3 Supports weight, partial weight 
bearing 
    4 Walks with mild deficit 
    5 Normal but slow walking 
    6 Full and fast walking 
Ischemia Score 
 
    0 Auto-amputation > half lower limb 
    1 Gangrenous tissue > half foot 
    2 Gangrenous tissue < half foot, with 
lower limb muscle necrosis 
    3 Gangrenous tissue < half foot, 
without lower limb muscle necrosis 
    4 Pale foot or gait abnormalities 
    5 Normal 
Modified Ischemia Score 
    0 Auto-amputation of leg 
    1 Leg necrosis 
    2 Foot necrosis 
    3 Discoloration of > two toes 
    4 Discoloration of one toe 
    5 Discoloration of > two nails 
    6 Discoloration of one nail 
    7 No necrosis 
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The murine femoral periarterial cuff model is a validated model of inflammatory-
driven neointima formation and adventitial angiogenesis164. This model is used to induce an 
inflammatory response to vascular injury by placing a non-occlusive polyethylene cuff 
around the femoral artery. Peri-arterial cuff placement induces adventitial inflammation, that 
triggers an influx of proinflammatory cytokines (neutrophils, macrophages) which secrete 
growth factors to the injury site, thereby causing mild endothelial cell damage, SMC 
proliferation and migration & inflammation in the adventitia. 
 In this study, wildtype C57BL/6J and OPG deficient mice were anaesthetised prior to 
surgery by inhalation of 2% isoflurane. Briefly, an incision of approximately 1 cm in length 
was made at the midpoint of the left hindlimb to expose the left femoral artery, and the 
femoral artery was then carefully dissected away from the neurovascular bundle (left femoral 
vein and nerve). Next, a 2.0 mm non-occlusive polyethylene cuff made of PE-50 tubing 
(427410, BD Bioscience, MA, USA) was slit along its length and with the use of forceps was 
opened and placed around the left femoral artery of each mouse. Carefully the cuff was 
secured and tied closed using non-absorbable 6-0 silk sutures, while ensuring blood flow was 
not obstructed (Figure 6.1). The skin was apposed over the cuff with 6-0 sutures and iodine-
based antiseptic solution applied to the wound post-operatively. For post-surgical analgesia, 
buprenorphine (0.1 mg/kg) was administered subcutaneously immediately following surgery 
and day 1 post-surgery for recovery. A sham operation was performed without the 
polyethylene tube placement on the right femoral artery as a control. 21 days post-surgery, 
mice were anaesthetized by inhalation of isoflurane and euthanized by cardiac exsanguination 
21 days post-surgery. The heart was perfused with saline (10 ml) via the left ventricle and 
both the cuffed femoral artery, and the sham were excised for immunohistochemical analysis 
(IHC). An additional cohort (n = 6 per group) was used to assess changes in mRNA 
 77 
expression of key angiogenesis and inflammation genes in cuffed and non-cuffed arteries 






Figure 2.3: Polyethylene Cuff Placed Around Mouse Femoral Artery. 
 
2.3.10 Histology 
2.3.10.1 Sample Preparation 
Femoral arteries were excised following cuff implantation and were placed into 10% 
(v/v) formalin for 24 hours and then into 70% (v/v) ethanol until they could be processed 
further. All collected arteries were embedded in 3% (w/v) agarose to prevent loss of these 
samples from the tissue cassettes (CASLID-01, Techno Plas, SA, Australia) during tissue 
processing. The arteries were then paraffin-embedded in blocks using a HistoStarTM 
Embedding Workstation (ThermoFisher Scientific) and stored at room temperature prior to 
microtome sectioning.  Tissues were sectioned at 5 μm on the M325 Microtome (Thermo 
Fischer Scientific) and were dried for 4 nights at 60°C.  
2.3.10.2 Immunohistochemistry  
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IHC was used to detect the angiogenic response from cuff placement. Samples were 
probed for CD31 adventitial neovessels, α-SMA to detect adventitial arterioles, and CD68 to 
assess macrophage infiltration. Prior to staining, slides were first deparaffinised by incubating 
with xylene (FNNJJ028, Fronine, Riverstone, NSW, Australia) for 5 minutes, then 1 minute, 
followed by decreasing ethanol concentrations of 100% for 2 x 1 minute, 95% (v/v) ethanol 
for 2 x 1 minute, 70% (v/v) ethanol for 1 minute followed by distilled water for 1 minute. All 
sections were then microwaved at a high-power setting (P70) in sodium citrate buffer for 
antigen retrieval for 20 minutes. Endogenous peroxidase was blocked by incubating in 
hydrogen peroxide solution (0.3% H2O2 in methanol) for 20 minutes at room temperature 
(RT), followed by a 1x 5-minute wash in phosphate buffer saline with Tween 20 (PBST; PBS 
with 0.1% (v/v) Tween- 20). Non-specific binding was prevented by blocking in goat serum 
(10% (v/v) goat serum in PBS) for 4 hours at RT for α-SMA and CD1, and 3% Horse serum 
for CD68.  
CD31: Sections were incubated overnight at 4°C with rabbit polyclonal primary 
antibody against CD31 (1:25, ab28364, Abcam) in PBST. Excess antibody was removed by 
washing for 2 × 5 min in PBST before incubating with goat anti-rabbit IgG horseradish 
peroxide (HRP)-conjugated secondary antibody (1:50, NBP2-30348H, Novus Biologicals) 
for 2 hours at room temperature. The slides were washed for 3 × 5 min in PBST, then HRP 
was detected by incubating the sections in the dark for 10 min at room temperature with 
ImmPACT® 3,3’-diaminobenzidine (DAB) Peroxidase Substrate (SK-4105, Vector 
Laboratories), made by adding 1 drop DAB reagent per 1 mL of ImmPACT® DAB diluent. 
The reaction was stopped by immersing the slides in distilled water for 5 min. The sections 
were counterstained with Lillie Mayer’s haematoxylin (AHLM, Australian Biostain, VIC, 
Australia) for 45 seconds, rinsed in distilled water for 1 min, dipped twice in acid-alcohol 
(0.3% [v/v] HCl in 70% [v/v] ethanol) then Scott’s Solution (2% [w/v] MgSO4, 0.35% [w/v] 
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NaHCO3) for 45 seconds, before a final rinse with distilled water for 1 min. The sections 
were dehydrated in increasing concentrations of ethanol by reversing the previous steps for 
hydration, before being cleared in xylene for 5 min and mounted in DPX (06522, Sigma-
Aldrich). 
α-SMA: Sections were incubated overnight with monoclonal primary antibody 
against α-SMA conjugated to alkaline phosphatase (1:100, A5691, Sigma-Aldrich). Tissues 
were washed in 2 x 5 minute in PBST then incubated for 12 minutes with Vector Red 
Alkaline Phosphatase substrate (SK-5100, Vector Laboratories).  Colour change was halted 
by rinsing tissues in distilled water. Sections were counterstained and cover slips were 
applied as stated above.  
CD68: Following antigen retrieval, tissue sections were incubated in 0.3% (w/v) 
hydrogen peroxide in methanol for 30 min, washed in PBST for 5 min, then blocked with 3% 
(v/v) normal horse serum (NHS, S-2000, Vector Laboratories) in PBS for 4 hours at room 
temperature. The sections were incubated overnight at 4°C with rat monoclonal primary 
antibody against CD68 (1:200, MCA1957GA, Bio-Rad) diluted in NHS. Excess antibody 
was removed with 2 × 5 min washes with PBST, followed by incubation with biotinylated 
goat anti-rat IgG secondary antibody (1:250, BA-9401, Vector Laboratories) in NHS for 30 
min at room temperature. The sections were again washed with PBST for 2 × 5 min then 
incubated with PierceTM streptavidin poly-HRP (1:500, 21140, ThermoFisher Scientific) 
diluted in NHS for 15 min at room temperature. Following 2 × 5 min washes in PBST, 
peroxidase activity was detected by incubating with ImmPACT® DAB Peroxidase Substrate 
as above for 10 min, after which the reaction was stopped by immersing in distilled water for 
5 min. The tissue sections were finally counterstained, dehydrated with increasing 
concentrations of alcohol, cleared in xylene and mounted with DPX as for CD31 staining. 
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Masson’s Trichrome Staining was performed using the Trichrome Stain Kit 
(ab150686, Abcam) according to the manufacturer’s instructions. Briefly, the sections were 
deparaffinised first as previously described, then stained with Weigert’s Iron Haematoxylin 
solution for 5 min. The slides were rinsed in running water for 2 min, then immersed in 
Biebrich Scarlet/Acid Fuschsin solution for 15 min, and were rinsed again in distilled water 
for 2 min prior to differentiating in phosphomolybdic/phosphotungstic acid solution for 15 
min. The slides were then immersed in Aniline Blue solution for 10 min, rinsed in distilled 
water for 2 min, then immersed in 1% (v/v) acetic acid solution for 5 min. After this, the 
sections were dehydrated quickly in two changes of 95% (v/v) ethanol then two changes of 
absolute ethanol, before finally clearing in xylene for 5 min and mounting with DPX as 
described previously. 
 
All samples were imaged using a Carl Zeiss Axio microscope and AxioCamER 
camera using the ZEN lite software (Oberkochen, Germany). One high-magnification field of 
view was taken per section for analysis. All analysis was completed using Image J software 
and Image-Pro Premier software (v9.0.4, Media Cybernetics, Rockville, MD, USA). 
 
2.3.11 RNA Extraction, cDNA Synthesis and Quantitative Real-Time PCR 
Quantitative real-time PCR (qRT-PCR) was performed on cDNA in triplicates using 
SSoAdvanced Universal SYBR Green Supermix in a CFX Connect Real Time System (Bio-
Rad). Relative changes in mRNA expression were normalised using the ΔΔCt method to 
housekeeping gene 36B4. Genes of interest included angiogenic markers: HIF-1α, VEGFA, 
VEGFR2, RANKL, Runx2, and inflammatory markers: NF-κB (p65) and CD68 and MCP1. 
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For full extraction protocol and primer sequences, see chapter 2, section 2.3.7-2.3.8, Table 
2.4. 
2.3.12 Plasma Analyses 
Plasma analysis were perfumed using OPG mice plasma for ALP, calcium and OPG. To 
assess alkaline phosphatase activity, an ALP assay (LabAssay ALP, WAKO, 29158601) was 
used according to the manufacturer’s instructions. Calcium concentration was quantified in 
plasma samples using a calcium assay (Calcium Assay, Cayman Chemical, 701220) 
according to the manufacturer’s instructions. To confirm OPG knockdown in the calcification 
mouse model, an OPG ELISA (Quantikine ELISA Mouse Osteoprotegerin/TNFRSF11B 
Immunoassay) was used to measure serum OPG levels in mice that had undergone peri-
arterial cuff surgery. The assay was performed as per manufacturer’s instructions.  
 
2.3.13 Euthanasia 
Mice were anaesthetized by inhalation of isoflurane (SAHMRI SOP1/027) and euthanized by 
cardiac exsanguination post-surgery. The heart was perfused with saline (10 ml) via the left 




2.3.14 Blood Collection 
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At euthanasia, blood was collected in heparin sulphate tubes (Interpath) by right ventricular 
puncture using the 27-gauge needle syringe. Blood was kept on ice until centrifugation at 
5,000 rpm for 5 minutes. Plasma was stored in 100 μL aliquots at -80°C. 
 
2.3.15 Histology 
2.3.15.1 Immunohistochemistry  
2.3.15.1.1 Sample Preparation 
Femoral arteries excised following cuff implantation were fixed in 10% formalin (v/v) and 
paraffin embedded. Tissues were sectioned at 5 μm on the M325 Microtome (Thermo Fischer 
Scientific) and were baked for 2 nights at 60°C. Samples were either probed for neovessels 
(CD31+), arterioles (smooth muscle α-actin) and macrophages (CD68). Slides were first 
deparaffinised in incubations of xylene and rehydrated in decreasing ethanol concentrations 
of 100%, 95% and 70%. 
 
2.3.15.2 CD31, CD68 and Smooth Muscle a-actin Staining  
To determine capillaries, CD31 immunohistochemical staining was performed on paraffin 
embedded tissue sections from the peri-arterial cuff. Tissue sections were submerged in 
sodium citrate buffer for antigen retrieval and were microwaved at 80 high-power setting. 
Endogenous peroxidase was blocked by incubation in hydrogen peroxide solution (0.3% 
H2O2 in methanol) for 20 minutes at room temperature (RT), followed by a phosphate buffer 
saline with Tween 20 (PBST) wash (PBS with 0.1% (v/v) Tween- 20). To prevent non-
specific binding, goat serum (10% (v/v in PBS) was used for blocking for  4 hours at RT. 
Slides were then incubated overnight with primary antibodies for CD31 (1:25; ab28364; 
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Abcam), smooth muscle a-actin conjugated to alkaline phosphatase (1:100, A5691, Sigma-
Aldrich); and CD68 (ab31630, 1:100) respectively at 4°C. Subsequently, CD31 slides were 
incubated with horseradish peroxidase (HRP) secondary antibody (1:100, goat anti-rabbit 
NBP2-30348H, Novus) for 2 hours at RT. For CD68, this was coupled with 
biotinylatedanti0mouse HRP antibody (DETAILS), followed by incubation with streptavidin 
peroxidase (DETAILS) for 15 minutes. For both, HRP enzyme was detected using 3,3′-
Diaminobenzidine (DAB) substrate (Vector Laboratories, Burlingame, CA, USA) for 12 
minutes. Smooth muscle a-actin slides were incubated with Vector Red alkaline phosphatase 
substrate (SK-5100, Vector Laboratories) for 12 minutes. Slides were counterstained with 
haematoxylin, dehydrated and mounted with DPX. 
 
2.3.15.3 Imaging and Analysis  
Samples were imaged using a Carl Zeiss Axio microscope and AxioCamER camera using the 
ZEN lite software (Oberkochen, Germany). One high-magnification field of view was taken 
per section for analysis. 
 
2.3.15.4 Immunofluorescence Triple Staining 
The gastrocnemius muscles from ischemic and non-ischemic hindlimbs were harvested and 
embedded in OCT (Sakura Finetek, Torrance, CA, USA). OCT-embedded tissues were then 
sectioned at 5 μm on the Shandon Cryotome E Cryostat (Thermo Fisher Scientific, MA, 
USA) and allowed to dry overnight at room temperature prior to staining. The following day, 
tissue samples were fixed in 2% paraformaldehyde and washed in PBST (PBS with 0.1% 
(v/v) Tween-20). To target non-specific binding, goat serum (10% (v/v) goat serum in PBS) 
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was used for blocking tissues for 1 hour at RT. Tissues were then incubated with primary 
antibodies for 1 hour, probing for CD31 (1:50; ab28364; Abcam, Cambridge, UK) to assess 
CD31+ neovessels, smooth muscle a-actin (1:1000; F3777; Sigma-Aldrich, St. Louis, MO, 
USA) to assess arterioles and laminin (1:200; MAB1905; Merck Millipore, Burlington, MA, 
USA) to assess myocytes. Tissues were then incubated with secondary antibodies for 1 hour 
at room temperature respectively using Alexa FluorÒ 555 (1:1000; A-21434; Invitrogen, 
Carlsbad, CA, USA) and Alexa FluorÒ 647 (1:500; A-32733; Life Technologies, Carlsbad, 
CA, USA). Samples were imaged on the Nikon Eclipse Ni-U microscope using NIS-
Element’s software (Melville, NY, USA) with five high-magnification fields of view taken 
for each section for analysis.  
 
2.3.16 Calcium Assay 
Calcium concentration was quantified in plasma samples using a calcium assay (Calcium 
Assay, Cayman Chemical, 701220) according to the manufacturer’s instructions. In this 
colorimetric assay, in an alkaline environment, calcium reacts with o-Cresolphthalein 
Complexone to form a complex with a purple colour that absorbs between 560 and 590 nm. 
The intensity of the colour is directly proportional to the concentration of calcium in the 
sample. To begin the assay, calcium standards with final concentration of 0, 0.5, 1, 2, 4, 6, 8 
10 mg/dl were performed. Subsequently, to set up the 96 well plate, 10 μl of calcium standard 
were added to standard wells. 10 μl samples were added in duplicates to the 96 well plate. 
Finally, 200 μl of Working Detector Reagent was added to all wells, and plate was gently 
shaken for 20-30 seconds. The 96 well plate was incubated at room temperature for five 
minutes, and absorbance was measured at 570-590 nm using the BIO-RAD iMark™ 
Microplate Reader. Data was normalised to protein via a BCA Protein Assay. Averages of 
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duplicates were recorded using Microsoft Excel (2016), and R2 value was used to calculate 
the concentration of ALP in each sample.   
 
2.3.17 ALP Assay  
Alkaline Phosphatase (ALP) is an important hallmark for physiological phenomena as 
osteogenesis. To assess alkaline phosphatase activity, an ALP assay (LabAssay ALP, 
WAKO, 29158601) was used according to the manufacturer’s instructions. HCAECs were 
cultured and harvested as previously described and were plated in a 96 well plate at a density 
of 1x105. Following treatment for 24 h, cell culture medium from each sample were collected 
and stored at 20 °C. For plasma samples, a 1:10 dilution was performed prior to conducting 
the assay. To prepare the buffer solution, 1 ALP substrate tablet was dissolved into 5 mL of 
buffer solution. Standard solutions of 0.5, 0.25, 0.125, 0.0625 mmol/L. were prepared by 
diluting with distilled water. The assay was performed in a 96 well plate, whereby 100 µL of 
working assay solution was added to 100 µL of standard and 20 µL sample.  The 96 well 
plate was then agitated on a plate mixer for 1 minute then incubated at 37°C for 15 minutes. 
Subsequently, 80 µL of stop solution was added to all wells and plate was placed on the plate 
mixer for 1 minute, and absorbance was measured at 405 nm wavelength using the BIO-RAD 
iMark™ Microplate Reader. Data was normalised to protein via a BCA Protein Assay. 
Averages of duplicates were recorded using Microsoft Excel (2016), and R2 value was used 
to calculate the concentration of ALP in each sample. 
 
2.3.18 Tissue RNA Extraction  
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RNA was isolated from gastrocnemius muscle and femoral arteries of mice post- hindlimb 
and peri-arterial cuff surgery, respectively. Tissues were homogenised, and total RNA was 
extracted using TRI reagent (Sigma-Aldrich) and quantified spectrophotometrically as 
previously described.  Following quantification, RNA samples were normalised to 100 
ng/mL and were reverse transcribed to generate complimentary cDNA using iSCRIPT cDNA 
synthesis kit (Bio-Rad, Hercules, CA, USA).  
 
2.3.19 Quantitative Real-Time PCR  
Quantitative real-time PCR (qRT-PCR) was performed on cDNA in triplicates using 
SSoAdvanced Universal SYBR Green Supermix in a CFX Connect Real Time System (Bio-
Rad). Relative changes in mRNA expression were normalised using the ΔΔCt method to 
housekeeping gene 36b4. Genes of interest included angiogenic markers: Hif-1α, Vegfa, 
Vegfr2, Rankl, Runx2, and inflammatory markers: NF-Κb (P65) and Cd68, Icam, Vcam and 






Table 2.5: Murine Mouse Primers used for qRT-PCR 
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2.3.20 Statistical Analysis  
Analyses were performed using PRISM software (GraphPad Prism). All data were quantified 
using imageJ and ImagePro Premier and analysed for statistical significance by an unpaired t-
test amongst the independent groups of data. A value of p<0.05 was deemed significant. One-
way ANOVA test was also conducted, and using Bonferroni’s multiple comparison test, all 
treatment groups were compared to control groups. All data was represented as mean ± SEM 






Gene Forward Primer 5’-3’ Reverse Primer 5’-3’ 
12 36b4 CAACGGCAGCATTTATAACCC CCCATTGATGATGGAGTGTGG 
13 Vegfa  GGCTGCTGTAACGATGAAG CTCTCTATGTGCTGGCTTTG 
14 Vegfr2 GCCCAGACTGTGTCCCGCAG AGCGCAAGACCGGGGAGAGC 
15 HIF1-α TCCCTTGCTCTTTGTGGTTGGGT AACGTAAGCGCTGACCCAGG 
16 Rankl CCAGCTATGATGGAAGGCTCA ACCGAAGATAATGGACATGC 
17 Runx2 AACGATCTGATTTGTGGCC CCTGCGTGGGATTTCTTGGTT 
18 Bmp2 GGGACCCGCTGTCTTCTAGT TCAACTCAAATTCGCTGAGGAC 
19 Siah1 GACTGCTACAGCATTACCCACT GTTGGATGCAGTTGTGCCG 
20 Siah2 CTAACGCCCAGCATCAGGAA GAACAGCCCGTGGTAGCATA 
21 Phd1 TAAGGTGCATGGCGGCCTGC TGGCTGCTGCCCGTTCCTTG 
22 Phd2 ATCACCTGGATCGAGGGCAA CGTTCGGCCGTTTATCCTGT 
23 Mcp1 GCTGGAGCATCCACGTGTT ATCTTGCTGGTGAATGAGTAGCA 
24 Cd68 GGACAGCTTACCTTTGGATTCAA CTGTGGGAAGGACACATTGTATTC 




CHAPTER 3:             
HIGH CALCIUM IMPAIRS 
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3. Introduction  
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Angiogenesis is a fundamental process that describes the formation of new blood 
vessels from pre-existing capillary beds, and is severely impaired in pathological diseases such 
as peripheral arterial disease7. VC is a phenomenon of soft tissue calcification that occurs due 
to the deposition of hydroxyapatite in the form of calcium phosphate within the arterial wall 15, 
100, 105, 165. The pathogenesis of lower extremity PAD remains poorly described but is regarded 
secondary to atherosclerosis due to fatty plaque build-up within the arterial wall15. Therapies 
for PAD are centred around alleviating stenosis and promoting tissue revascularization 
following ischemia15, and while atherosclerosis is recognised as the main cause of PAD, acute 
or chronic limb ischemia may be the result of various other cardiovascular risk factors 15.  
Recent literature has implicated vascular calcification as a potential driver of 
angiogenesis in PAD 15. There are several lines of evidence that bone-related osteogenic 
markers are involved in regulating vascular calcification in VSMCs, although lacking in the 
context of ECs126, 129, 131, 145, 166-171. These regulators include members of the TNF superfamily 
of cytokines, receptor activator of nuclear factor ĸappa-B (RANK) and its ligand (RANKL); 
and its soluble decoy receptor osteoprotegerin (OPG); and other bone regulatory factors such 
as runt related transcription factor 2 (runx2); the main transcriptional regulator of 
osteogenesis; bone morphogenetic protein 2 (BMP2); a strong inducer of bone formation, and 
alkaline phosphatase (ALP), an key early diagnostic marker of VC126, 131, 169, 170. The 
mechanism underlying VC pathology suggests the differentiation of VSMCs towards an 
osteoblastic phenotype, as demonstrated in numerous in vitro studies showing VSMC 
mineralization when cultured in a pro-calcific enviroment86, 172-174. 
Additionally, the OPG/RANK/RANKL pathway known to drive bone formation has 
been suggested to regulate angiogenesis51, 62,150. RANKL treatment  has been reported to 
stimulate angiogenesis both in vivo and in vitro by acting as a chemostatic factor for ECs 
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and inducing their migration and proliferation150,129, 151; increased vascular permeability 
and promoted neoangiogenesis via induction of EC migration and proliferation51, 150, 152. 
However, conflicting studies have reported RANKL to cause a reduction in EC 
proliferation, while inducing EC apoptosis, therefore suggesting RANKL to be an 
inhibitor of angiogenesis, and OPG a promotor.153 In addition, VEGFA has been shown to 
increase the mRNA expression of Rank in human ECs, which upregulated their 
angiogenic response to RANKL51,150,45. Furthermore, OPG was also shown to facilitate an 
increase in EC proliferation and tubule formation in vitro, whilst stimulating 
neovascularization in vivo153, 155. Based on this evidence, the OPG/RANK/RANKL triad 
may have a potential role in regulating angiogenesis.  
While the involvement of bone regulatory genes in angiogenesis has been explored, 
there remains a poor correlation between angiogenic marker expression in the presence of 
elevated calcium levels. Since the endothelium regulates many of the processes involved in 
atherogenesis and other pathological diseases of the vasculature including PAD; the present 
study examined the effects of elevated calcium levels on EC-driven angiogenesis and 
hypothesised that high calcium will attenuate this process.  
To test these hypotheses, the response of HCAECs to calcium/phosphate was assessed 
with measures of proliferation, migration, and tubule formation in vitro. In combination with 
this the expression of both calcification and angiogenic markers were analysed to understand 





 Calcification Medium Increases Calcium Levels and ALP Activity 
in ECs. 
An increase in calcium (Ca2+) has been a key player in the pro-angiogenic pathway in 
ECs175. Increased calcium signaling is induced by growth factor and chemokine activation 
involved in angiogenesis which then stimulates a cascade of events for angiogenesis 
including EC proliferation, migration, and tube formation176. Furthermore, the process of 
vascular calcification occurs due to hydroxyapatite mineral deposition in the form of calcium 
and phosphate. To ensure our calcification medium was indeed eliciting a calcification 
response, calcium levels were measured. Calcium levels in cell culture supernatants of ECs 
treated with CM and were found to be elevated in normoxia compared to controls, 
(414.20±11.52 vs 299.20±15.09, P<0.027, Figure 3.1A). This response was also maintained 
in hypoxia (423.80±30.71 vs 305.80±37.17, P<0.024, Figure 3.1A), suggesting that elevated 
calcium may influence EC activation of calcification-driving markers to help drive vascular 
calcification. 
 
In the early events of calcification, specific osteogenic factors are released to initiate 
the process of mineralisation; including ALP105.  Changes in ALP levels are a prominent 
feature bone diseases, CKD and cardiovascular diseases, specifically atherosclerotic lesions 
with vascular calcification100. The role of ALP in angiogenesis has been well explored in 
bone cells; with VEGFA reported to stimulate ALP activity117,  and hypoxia shown to 
increase ALP activity118. ALP activity was measured in cell culture supernatants of ECs 
treated with CM. ALP activity was upregulated by CM compared to untreated ECs in both 
normoxia (6.90±0.72 vs 4.09±0.45, P<0.023 Figure 3.1B) and hypoxia (6.12±0.45 vs 
4.06±0.26, P<0.114, Figure 3.1B), though not reaching statistical significance. This data may 



























































Figure 3.1: Calcification Medium Upregulates Calcium Levels and ALP Activity in ECs. 
HCAECs cultured and treated with calcification medium containing 2.0mM HNa2PO4 and 2.7mM 
CaCl2 for 24h, in normoxia (37° C humidified atmosphere with 5% CO2) and hypoxia (37° C 
humidified atmosphere with 1.2% O2/5% CO2) conditions. Calcium Assay (Cayman, Calcium Assay) 
and ALP Assay (Wako, Lab Assay) were used to quantify ALP and calcium concentrations in cell 
culture supernatants following treatment. A) ALP Activity, (B) Calcium Levels All data is represented 
as mean ± SEM; One-Way ANOVA with Bonferroni’s multiple comparisons test, (n=3), *P<0.05). 
HCAEC, human coronary artery endothelial cells, M199, medium 199 (Sigma-Aldrich), ALP, alkaline 
phosphatase, EC, endothelial cell.  
 
 Calcification Medium Increases EC Viability in Normoxia.  
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Ischemia occurs when oxygenated blood supply is impaired and is present in disease 
states such as post-MI, PAD and diabetes64. As a result of reduced oxygen supply to tissues, 
cellular and tissue modifications occur often leading to cell death. However, the influence of 
elevated calcium on EC functions or viability during ischemia remain unknown. To 
understand the effects of elevated calcium on EC viability, a WST-1 cell viability assay was 
performed on cells treated for 24 h with CM and conditioned to both normoxic and hypoxic 
stimuli. Treatment with CM for 24 h significantly upregulated EC viability in normoxia 
compared to untreated cells (1.49±0.04 vs 1.04±0.03 P<0.0001) with no change observed in 
hypoxia, (Figure 3.2). However, there was significant decrease in cell viability when 
comparing CM normoxia (1.49±0.04) to CM hypoxia (1.00±.02, P<0.0005); which suggests 















































Figure 3.2: Calcification Medium Increases EC Viability in Normoxia. 
HCAECs cultured and treated with calcification medium containing 2.0mM HNa2PO4 and 2.7mM 
CaCl2 for 24h, in normoxia (37° C humidified atmosphere with 5% CO2) and hypoxia (37° C 
humidified atmosphere with 1.2% O2/5% CO2) conditions. A WST-1 cell viability assay performed. 
All data is represented as percentage of controls, mean ± SEM; One-Way ANOVA with Bonferroni’s 
multiple comparisons test t-test, (n=4/5), ****P<0.0001. HCAEC, human coronary artery 






 Calcification Medium Impairs EC Migration In Vitro. 
EC migration is a crucial step during physiological angiogenesis for the formation of new 
blood vessels, and also during pathological angiogenesis177. In this study, incubation of ECs 
with CM suppressed EC migration in normoxia alone compared to untreated cells 
(202.30±13.37 vs 257.60±10.84, P<0.0085, Figure 3.3). In addition, CM significantly 
reduced migration in cells conditioned to hypoxia relative to normoxia-treated cells 
(110±8.25 vs 202.30±13.37, P<0.0001). Interestingly, hypoxic conditions caused a 
significant reduction in EC migration in untreated cells compared to those in normoxic 
conditions. This is the first study that has looked at the effect of high calcium on EC, and 































Figure 3.3: Figure 3.3.4: Calcification Medium Impairs EC Cell Migration In Vitro  
(A-B) EC migration. HCAECs cultured and treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 for 24h, in normoxia (37° C humidified atmosphere with 5% CO2) and 
hypoxia (37° C humidified atmosphere with 1.2% O2/5% CO2) conditions. Boyden chamber assay 
was performed to assess cell migration. All data is represented as percentage of controls, mean ± 
SEM; One-Way ANOVA with Bonferroni’s multiple comparisons test t-test, (n=4/5), **P<0.01, 









Normoxia Hypoxia  
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 Calcification Medium Impairs EC Tubule Formation In Vitro. 
Tubule formation is the final process of angiogenesis that results in the formation of 
tubular networks and is strictly controlled by different extracellular signals 50, 70, 178. To 
elucidate further mechanisms of CM on angiogenesis and its effects on ECs, functional 
assays of tubulogenesis were carried out in vitro. In this study, incubation of ECs with CM 
further supressed EC tubule formation in normoxia compared to untreated cells (0.98±0.05 vs 
1.26±0.06, P<0.0001, Figure 3.4). There was however no difference observed for number of 
tubules formed in hypoxia with CM and untreated cells. Together, this result highlights the 


























Figure 3.4: Calcification Medium Impairs EC Tubule Formation in Normoxia. 
(A-B) EC Tubule formation. HCAECs cultured and treated with calcification medium containing 
2.0mM HNa2PO4 and 2.7mM CaCl2 for 24h, in normoxia (37° C humidified atmosphere with 5% 
CO2) and hypoxia (37° C humidified atmosphere with 1.2% O2/5% CO2) conditions. Matrigel 
tubulogenesis assay was conducted to assess tubule formation at 4h. All data is represented as 
percentage of controls, mean ± SEM; One-Way ANOVA with Bonferroni’s multiple comparisons test 
t-test, (n=4/5), *P<0.05, **P<0.01, ***P<0.001. HCAEC, human coronary artery endothelial cells, 








Normoxia Hypoxia  
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 Calcification Medium Differentially Regulates the Expression of 
Calcification Markers. 
Runx2 is the main transcription factor of vascular calcification and its role in both 
osteogenesis and vascular calcification have been well established93, 120, 123. A previous study 
has shown that angiogenic cytokines upregulated Runx1 and Runx2 expression in murine EC 
model179. However, little is known about the regulation of Runx2 expression in EC following 
calcification stimulus. In this study, gene expression and protein levels of Runx2 were 
analysed. CM had no effect in regulating Runx2 mRNA expression in normoxia or hypoxia 
conditions (Figure 3.5 A). Interestingly, RUNX2 protein expression was significantly 
downregulated in normoxia with CM treatment compared to untreated cells (64.59±6.82 vs 
93.80±2.97, P<0.0079, Figure 3.5 B); with further downregulation observed in hypoxia 
(71.49±6.77 vs 105.50±5.32, P<0.0039, Figure 3.5 B).  
Bone morphogenetic proteins (BMPs) are a group of secreted growth factors from the 
TGF-β superfamily of cytokines that possess significant osteogenic capacity and play an 
essential roles in vascular disease180, osteoblastic differentiation and bone formation181. 
CM significantly upregulated the mRNA expression of Bmp2 in normoxia compared to 
untreated cells (240.40±32.43 vs 100.70±3.66, P<0.0108 Figure 3.5C). Conversely, 
stimulation of ECs with hypoxia decreased Bmp2 gene expression when treated with CM 
(96.10±13.13.93 vs 281.20±75.83, P<0.0073, Figure 3.5C). In addition, CM treatment 
increased BMP2 protein expression in normoxia conditions (121.90±12.52 vs 100.70±0.65, 
Figure 3.5D) though not statistically significant. Hypoxia stimulation also decreased Bmp2 
expression with CM treatment (56.22±11.84 vs 99.31±1.22, P<0.05, Figure 3.5 D). though 
not statistically significant. Since BMP2 is expressed in ECs, and is known to drive the 
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activation of Runx2, together this data suggests a potential mechanistic pathway by ECs to 

















Figure 3.5: Calcification medium differentially regulates the mRNA expression of osteoblastic differentiation factor 
Runx2 and BMP2. (A) Runx2 mRNA expression, (B) RUNX2 protein expression, (C) Bmp2 mRNA expression, (D) BMP2 
protein expression. HCAECs cultured and treated with calcification medium containing 2.0mM HNa2PO4 and 2.7mM CaCl2 
for 24h, in normoxia (37° C humidified atmosphere with 5% CO2) and hypoxia (37° C humidified atmosphere with 1.2% 
O2/5% CO2) conditions. RNA extracted using Trizol, and. RNA was reverse transcribed into cDNA using iSCRIPT buffer. 
Real-time PCR was performed using universal SYBR© Green Supermix. Relative changes in mRNA expression were 
calculated using the ∆∆Ct method.  Whole cell lysates extracted for to measure immunoblotting. All data is represented as 
mean ± SEM; One-Way ANOVA with Bonferroni’s multiple comparisons test, (n=3/4), *P<0.05, **P<0.01. HCAEC, 
human coronary artery endothelial cells, M199, medium 199 (Sigma-Aldrich), Runx2: runx2 related transcription factor, 
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 Calcification Medium Differentially Regulates the OPG-RANK-
RANKL axis in ECs.    
The RANK-RANKL-OPG cytokine pathway comprises of members of the TNF 
superfamily of ligands and are highly associated with vascular calcification and stimulate 
mineral deposition in VSMCs138, 153. Previous studies investigating this pathway have 
consistently been evaluated in VMSCs182, however, the role of calcium-phosphate on EC is 
still yet to be established. In this study, CM treatment had no significant effect in regulating 
Rankl mRNA expression in normoxia. However, hypoxia stimulation downregulated Rankl 
mRNA expression with CM treatment compared to untreated cells (52.69±8.00 vs 
107.50±14.82, P<0.0158 Figure 3.6B). When RANKL protein was assessed, CM had no 
effect on RANKL protein expression in normoxia whilst decreasing its expression with 
hypoxia stimulation (80.22±12.95 vs 163.80±40.09, P<0.0357, Figure 3.6B).  
 
CM increased Rank receptor mRNA expression in normoxia relative to untreated cells 
(CM: 152.80±9.34 vs 100.60±3.41, P<0.0001); which was further decreased with hypoxia 
stimulation following CM treatment (40.86±6.01 vs 104±13.53, P<0.0001, Figure 3.6C).  
 
OPG is a soluble decoy receptor for RANKL, expressed in the heart, arteries and 
veins, and is secreted by ECs183. OPG is a physiological and pharmacological inhibitor of 
bone resorption and is highly elevated in cardiovascular disease, obesity and diabetes184, 
185, 30. Gene expression for Opg was significantly upregulated with CM treatment in 
normoxia (181.10±32.96 vs 104.60±8.94, P<0.0371, Figure 3.6D), and was significantly 
downregulated with hypoxia stimulation (62.80±12.79 vs 158.80±34.60, P<0.0455, Figure 
3.6D). Though the protective role of OPG against calcification is well known, such increased 
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expression in ECs in normoxia presumably reflects a vascular defense that helps to 
prevent excessive RANKL signaling via a negative feedback regulation. Together, this 










































Figure 3.6: Calcification Medium Differentially Regulates RANK-RANKL axis in ECs.  
Rank mRNA expression (B) RANKL protein expression, (C) Rankl mRNA expression. HCAECs 
cultured in MesoEndo medium, serum starved in 10% FBS M199 medium, then treated with 
calcification medium containing 2.0mM HNa2PO4 and 2.7mM CaCl2 for 24h. RNA extracted using 
Trizol, and. RNA was reverse transcribed into cDNA using iSCRIPT buffer. Real-time PCR was 
performed using universal SYBR© Green Supermix. Relative changes in mRNA expression were 
calculated using the ∆∆Ct method.  Whole cell lysates extracted for to measure immunoblotting. All 
data is represented as mean ± SEM; One-Way ANOVA with Bonferroni’s multiple comparisons test, 
(n=3/4). HCAECs, human coronary artery endothelial cell, RANKL, receptor activator of nuclear 
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 CM-Induced Upregulation of HIF-1a Gene Expression.  
HIF-a is a pivotal driver of angiogenesis both under physiological and pathological 
conditions, particularly in response to ischemia. During hypoxia, HIF-1a translocates to the 
nucleus where it complexes with the HIF-1b subunit and binds to the hypoxia response 
element (HRE)67. This drives the expression of pro-angiogenic mediators such as VEGFA that 
drive angiogenesis. Previously, hypoxia stimulation was shown to enhance phosphate-induced 
VSMC calcification and transdifferentiation186, however there is a paucity of data investigating 
high calcium effects on EC expression of HIF-1a in angiogenesis. In this study, EC incubation 
with CM had no effect in regulating Hif-1α gene expression in normoxia (Figure 3.7 A). 
Because HIF-1a is post-translationally regulated, protein expression was measured and 
significant upregulation was observed in normoxia with CM treatment (507.10±59.70 vs 
113.80±13.80, P<0.0001, Figure 3.7 B). HIF-1a protein expression was however significantly 
downregulated when comparing normoxia CM (507.10±59.70) vs hypoxia CM (118.30±14.74, 





















Figure 3.7: Hypoxia Upregulates CM-Induced Gene Expression of HIF-1a in Normoxia 
Only. 
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. RNA extracted using Trizol, and. 
RNA was reverse transcribed into cDNA using iSCRIPT buffer. Real-time PCR was performed using 
universal SYBR© Green Supermix. Relative changes in mRNA expression were calculated using the 
∆∆Ct method. Whole cell lysates were extracted to measure protein expr3ession via immunoblotting 
technique. Even protein loading was confirmed by a-Tubulin.   All data is represented as mean ± 
SEM; One-Way ANOVA with Bonferroni’s multiple comparisons test, (n=3/4), *P<0.05, 
***P<0.001. HCAEC, human coronary artery endothelial cells, M199, medium 199 (Sigma-Aldrich), 
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 Calcification Medium Regulation of Upstream Signalling Pathways 
for HIF-1a to Drive Angiogenesis.  
HIF-1a is post-translationally modulated, and under normoxic conditions, propyl 
hydroxylase domain proteins (PHD1/2) hydroxylate the proline residues of HIF-1a allowing 
the Von-Hippel Lindau ubiquitin ligase complex to target HIF-1a for proteasomal 
degradation46, 67, as depicted in Figure 1.4 (chapter 1).  Currently, very little is known of the 
effects of elevated calcium on PHD regulation in calcification. To understand the regulation 
of HIF-1a, PHD2 and PHD3 protein expression were measured. CM had no effect in 
regulating PHD2 protein expression in normoxia or hypoxia conditions relative to untreated 
cells Figure 8 A). however as expected, PHD2 protein expression was significantly 
downregulated when comparing normoxia CM (308.60±46.92) versus hypoxia CM 
(139.20±29.71, P<0.0337, Figure 3.8 A). Similarly, no change was observed with PHD3 
protein expression in both normoxia of hypoxia conditions (Figure 3.8 B). This data may 














Figure 3.8: Normoxia Upregulates PHD2 and PHD3 Protein expression in ECS.  
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Whole cell lysates were extracted 
to measure protein expression via immunoblotting technique. Even protein loading was confirmed by 
a-Tubulin. All data is represented as mean ± SEM; One-Way ANOVA with Bonferroni’s multiple 
comparisons test, (n=3/4). HCAEC, human coronary artery endothelial cells, M199, medium 199 
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Furthermore, in hypoxic conditions, the PI3/Akt signalling pathway is activated 
resulting in the induction of E3 ubiquitin ligases Siah 1 & Siah 2. These target and promote 
degradation of PHDs,  which leads to HIF-1a stabilisation, allowing HIF-1a translocation to 
the nucleus where it complexes with the HIF-1b subunit and binds to the hypoxia response 
element (HRE)67 as depicted in Figure 1.4 (chapter 1). In this study, normoxic conditions had 
no effect in regulating Siah1 and Siah2 mRNA expression with CM treatment. However, 
when ECs were stimulated with hypoxia, CM caused significant downregulation in Siah1 
mRNA expression compared to control cells (46.10±10.62 vs 107.40±2.24, P<0.0207, Figure 
3.9 A); and Siah 2 mRNA expression (59.99±11.31 vs 101.0±0.30, P<0.1737 Figure 3.9 B).  
 
Collectively, this data illustrates CM-induced downregulation of PHD and Siah 
activity in ECs following hypoxia stimulation. It however remains unclear as to how CM 
regulates PHD and Siah expression in ECs and thus further studies are warranted to fully 





































Figure 3.9: Hypoxia Decreases Siah 1 and Siah 2 Expression in ECS.  
HCAECs cultured in MesoEndo medium, serum starved in 10% FBS M199 medium, then treated with 
calcification medium containing 2.0mM HNa2PO4 and 2.7mM CaCl2 for 24h. RNA extracted using 
Trizol, and. RNA was reverse transcribed into cDNA using iSCRIPT buffer. Real-time PCR was 
performed using universal SYBR© Green Supermix. Relative changes in mRNA expression were 
calculated using the ∆∆Ct method. All data is represented as mean ± SEM; One-Way ANOVA with 
Bonferroni’s multiple comparisons test, (n=3/4), **P<0.01. HCAEC, human coronary artery 





 CM Upregulates Angiogenesis via the VEGFA-VEGFR2 axis.  
During angiogenesis, HIF-1α modulates the expression of downstream targets by 
regulating the transcription of VEGF, the principle regulator of angiogenesis 50, 70. VEGFA 
protein expression was significantly upregulated in normoxia with CM treatment relative to 
untreated cells (849.40±197.60 vs 116.50±16.55, P<0.0001); with no effect seen in hypoxia 
conditions (Figure 3.10 B). However, when comparing normoxia CM vs hypoxia CM, 
VEGFA protein expression was decreased (74.47±7.66 vs 849.40±197.60, P<0.0001, Figure 
3.10 B). Vegfr2 mRNA expression remained unchanged in both normoxia and hypoxia 
(Figure 3.10 C). Furthermore, CM had no effect on phosphorylated VEGFR2 protein 
expression compared to untreated cells in normoxia or hypoxia (Figure 10 D). Collectively, 
based on this data, upregulation of VEGFA in normoxia proposes a compensatory 

























Figure 3.10: CM Upregulates Angiogenesis via the VEGFA-VEGFR2 Axis 
HCAECs cultured and treated with calcification medium containing 2.0mM HNa2PO4 and 2.7mM CaCl2 for 
24h, in normoxia (37° C humidified atmosphere with 5% CO2) and hypoxia (37° C humidified atmosphere with 
1.2% O2/5% CO2) conditions. RNA extracted using Trizol, and. RNA was reverse transcribed into cDNA using 
iSCRIPT buffer. Real-time PCR was performed using universal SYBR© Green Supermix. Relative changes in 
mRNA expression were calculated using the ∆∆Ct method. Whole cell lysates were extracted to measure total 
and phosphorylated protein expression via immunoblotting technique. Even protein loading was confirmed by 
a-Tubulin. (A) vegfa mRNA expression, (B) VEGFA protein expression, (C) vegfr2 mRNA expression, (D) 
phosphorylated VEGFR2 (pVEGFR2) and total VEGFR2 (VEGFR2T). All data is represented as mean ± SEM; 
One-Way ANOVA with multiple comparisons, Bonferroni test, (n=4/5), *P<0.05, **P<0.001. HCAEC, human 
coronary artery endothelial cells, VEGFA, vascular endothelial growth factor and receptor, VEGFR2, vascular 
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 Calcification Medium Negatively Affects Angiogenesis via 
Suppression of eNOS. 
To further determine the mechanism of calcification medium in driving angiogenesis, 
downstream signalling pathways were assessed. Endothelial nitric oxide (eNOS) is located 
downstream of the HIF-1a-VEGFA pathway71. During hypoxia, eNOS produces nitric oxide 
(NO) to help enhance EC proliferation, migration and to increase VEGFA expression; which 
ultimately increases angiogenesis72. In this study, EC incubation with CM significantly 
mitigated eNOS phosphorylation in both normoxia (66.75±7.86 vs 112.9±6.78, P<0.0151); 
and hypoxia (49.44±9.78 vs 92.75±11.62, P<0.0208, Figure 3.11).  In line with previous data 
from Figure 3.4 where significant reduction in EC tubule formation and cell migration were 
observed with CM; this reduction in eNOS expression may suggest a downstream signalling 


















































Figure 3.11: Calcification Medium Negatively Affects Angiogenesis via Suppression of eNOS.  
HCAECs cultured and treated with calcification medium containing 2.0mM HNa2PO4 and 2.7mM 
CaCl2 for 24h, in normoxia (37° C humidified atmosphere with 5% CO2) and hypoxia (37° C 
humidified atmosphere with 1.2% O2/5% CO2) conditions. Whole cell lysates were extracted to 
measure total and phosphorylated protein expression via immunoblotting technique. Even protein 
loading was confirmed by a-Tubulin. All data is represented as mean ± SEM; One-Way ANOVA with 
multiple comparisons, Bonferroni test, (n=4), *P<0.05, **P<0.001. HCAEC, human coronary artery 
endothelial cells, eNOS, endothelial nitric oxide synthase.  
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 Discussion  
Vascular calcification (VC) is associated with atherosclerotic lesions and is thought to 
be a potential driver of PAD by affecting limb revascularization following ischemia100. In this 
case, angiogenesis or blood vessel formation is affected by the presence of calcific 
lesions within the peripheral arteries. These studies report for the first time that high levels of 
calcium impair endothelial cell angiogenesis in vitro. CM treatment attenuated the ability of 
ECs to form tubes and migrate, suggesting potential inhibition of angiogenesis, despite the 
increased cell viability that was observed in normoxia.  
Previous studies have reported that incubation of human umbilical vein EC 
(HUVECs) with hypoxia showed resistance to hypoxia-induced cell death, with 98% cell 
viability after 24 h and 55% viability after 48 h of continuous exposure187, thus suggesting 
that chronic hypoxia is necessary for EC viability. However, despite this result, there remains 
limited studies showing the effect of elevated calcium-phosphate on EC viability in hypoxia 
conditions. Furthermore, another study reported significant proliferative activity of 
mesenchymal stem cells and bone marrow mesenchymal stem cells treated with calcium 
concentrations above 1.8mM188. This is however the first study to explore the effect of high 
calcium on EC proliferation, placing a great need for future studies to fully understand its 
interactions.  
There exist several lines of evidence that bone-related osteogenic markers are 
involved in regulating vascular calcification in VSMCs, although lacking in the context of 
ECs. These regulators include members of the TNF superfamily of cytokines,  RANK and its 
ligand (RANKL); and its soluble decoy receptor OPG; and other bone regulatory factors such 
runx2, BMP2 and ALP189. In this study, these calcification markers were evaluated and were 
found to be elevated with CM treatment in normoxia conditions, thus highlighting the 
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presence or initiation of a calcification process. However, when cells were stimulated with 
hypoxia, this response was negated. A previous study conducted in human periodontal cells 
demonstrated that hypoxia stimulated the expression of Rankl mRNA and protein expression 
at 12 h, 24 h and 48 h while downregulating Opg mRNA and protein expression190. In a 
different study, hypoxia enhanced the expression of both RANKL and RANK in breast 
cancer cells, via activation of the HIF-1a known to drive angiogenesis191. Collectively, these 
studies suggest chronic hypoxia regulates these calcification markers, and because of the lack 
of studies conducted in ECs, further research is required to fully understand this.  
 
Additionally, there lies extensive work to address the potential role of BMP2 in 
angiogenesis. In previous published work, BMP2 enhanced and stimulated blood vessel 
formation in developing tumours, to increase neovascularization192. Furthermore, in this same 
study, recombinant BMP2 induced tubule formation in human aortic EC (HAEC) and 
HUVECs, whilst also stimulating proliferation of HAECs. BMP2 regulation of endothelial 
cell processes is proposed to be modulated mechanistically via phosphorylation of ERK 1/2 
and SMAD pathways192.  In line with this, data from this study demonstrated that treatment 
of ECs with CM increased mRNA expression of Bmp2 in normoxia, which coincides with 
increased cell viability (Figure 3.13). Previous studies however have reported conflicting 
results whereby hypoxia  up-regulated Bmp2 mRNA and protein expression in bovine 
capillary EC and human microvascular ECs, a result that was also enhanced with VEGF 
treatment after 24h and 48h of treatment193.  In other cell types such as osteoblasts, hypoxia 
also stimulated upregulation of Bmp2 mRNA and protein expression181. There lie arguments 
suggesting that different ECs will respond differently.  
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OPG is highly elevated in cardiovascular disease, obesity and diabetes184, 185, 30, 
and while this clinical finding is not well understood it is possible the increased levels 
act as a compensatory mechanism for protection against disease154, 194. Our findings 
demonstrate that a calcification milieu is capable of upregulating both the drivers 
(RANKL, Runx2, BMP2) and the inhibitor (OPG) of calcification with detrimental effects on 
proliferation, cell migration and tubule formation, all hallmark measures of angiogenesis 
(Figure 3.13). 
 
Ischemia is a potent stimulus for hypoxia-driven angiogenesis in pathological 
conditions of MI, stroke and peripheral arterial disease. In clinical settings, hypoxia increases 
HIF-1a which further promotes VEGFA and VEGFR2 signalling to promote angiogenesis46. 
Interestingly, this study demonstrated that this calcification milieu also promotes the release 
of key angiogenic markers HIF-1a and VEGFA; which may, at least in part be a 
compensatory mechanism by the cells to counteract this mineral imbalance, thus favouring 
angiogenic protein synthesis; suggesting that this is not occurring via the HIF-1a pathway, 
and may be occurring via alternative mechanisms. Furthermore, based on data from section 
3.3.10, where CM treatment to ECs increased Siah 1 & Siah 2 mRNA expression in hypoxia; 
this study confirms the role of Siah 1 and Siah 2 in suppressing PHDs activity in hypoxia, to 
therefore increase HIF-1a stability. These results thereby suggest a plausible role of calcium 
phosphate in driving angiogenesis via upregulation of HIF-1a in normoxia conditions, 
though further analysis is required to fully understand these interactions.   
 
 Both HIF-1a and Runx2 are transiently expressed in vascular endothelial cells, which 
may elude to their potential role in the regulation of angiogenesis123. HIF-1a is expressed 
early in embryonic development and is necessary for bone development195, while Runx2 is 
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also expressed throughout skeletal development and is crucial for vascular invasion119. 
Deficiency in Runx2 is reported to result in vascularization defects, mainly due to reduced 
VEGF expression, a key growth factor essential for angiogenesis 120, 121.  Runx2 has also been 
shown to increase HIF-1a protein expression, mainly because it stabilises and protects HIF-
1a from degradation, in both normoxic and hypoxic conditions121. Overexpression of Runx2 
is also associated with significant increases in Vegfa mRNA expression, and vice versa. This 
is thought to occur due to physical interactions of Runx2 and HIF-1a on the Runx2/RUNT 
domain122 and possibly through binding of Runx2 on the VEGF promotor region120.  
From these results, suppression of angiogenesis was also associated with upregulation 
of angiogenic markers HIF-1a and VEGFA and its receptor VEGFR2 in normoxia. Since 
Runx2 is expressed in ECs of developing blood vessels123, this may explain its role in 
regulating angiogenesis, and highlights the need for further studies to expand our 
understanding of this relationship. Additionally, the time of exposure of cells to hypoxia may 
influence the angiogenic response. Previous studies have reported that ECs exposed to 24 h 
of hypoxia attenuated VEGF-induced EC migration, proliferation and tubule formation;  
demonstrating the negative effect of chronic hypoxia on angiogenesis71. In this study, cells 
were conditioned to hypoxia for only 4 hours, reflecting acute hypoxia, and may therefore 
help explain the increase in angiogenic marker expression (HIF-1a and VEGF). Based on 
these results, I propose a potential mechanistic link in our study, where treatment of ECs with 
CaPO4 increased the expression of both Runx2, and HIF-1a. Therefore, it is clear that both 
factors can interact to regulate VEGFA angiogenic signalling, which also showed increased 
expression with CaPO4 treatment.  
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There are a myriad of approaches for calcifying cells in cell culture with calcification 
medium. The commonly used form of calcification medium is supplemented with inorganic 
(sodium phosphate 1-5mM) or organic (β-glycerophosphate e.g., 10 mM) phosphate196. 
Dexamethasone is a steroid that is often used to stimulate calcification in vitro. However, 
these readily available methods do not recapitulate hyperphosphatemia, hypercalcemia, 
inflammation or a calcification environment as seen in the human body196. This thesis utilised 
the method of supplementing calcium and phosphate to cells as means to induce a 
physiological high calcific environment in these cells. A limitation that exists across all 
studies in calcification is the lack of consensus on which calcification stimulus is the most 
effective and for what purpose. The use of calcium phosphate in these studies does not 
preclude the results observed elsewhere, it only highlights the need for a standardised 
approach 
 
 Conclusion  
Overall, observations from this study found that CM impaired EC angiogenesis in 
normoxia, as demonstrated in the functional assays for tubule formation and cell migration. 
When evaluated mechanistically, I observed decreased expression of downstream signalling 
pathways of eNOS, a known to drive EC angiogenesis. Furthermore, I observed upregulation 
of key calcification markers in both normoxia and hypoxia conditions, which coincided with 
upregulation of key pro-angiogenic factors HIF-1a and VEGFA, suggesting a compensatory 




Figure 3.13 : In Vitro Ischemia Summary diagram.  
EC: Endothelial Cell,  HIF-1α: Hypoxia-inducible factor-1 alpha,  VEGFA: Vascular endothelial 
growth factor, VEGFR2: Vascular endothelial growth factor  receptor 2, BMP2: Bone morphogenetic 
protein 2, Runx2: Runx2 related transcription factor, RANK/RANKL: Receptor activator of nuclear 






























2.1 Introduction  
Ischemia reperfusion occurs in various pathologies post-MI, due to occlusion and 
obstruction of major arteries that block the flow of oxygenated blood from reaching the 
tissue175. A major consequence of chronic ischemia is irreversible injuries to affected cells, 
resulting in cell death. One other risk factor known to result to chronic ischemia is the 
presence of calcified lower extremity vessels as observed in diabetic and PAD patients33, 34, 37, 
197. Arterial calcification is highly associated with increased risk of limb amputations, 
however the causal link between calcification in lower extremity arteries and the severity of 
ischemia remains unclear.  
Findings from chapter 3 showed differential regulation of ischemia-driven 
angiogenesis with calcification medium (CM) in vitro. There was upregulation of 
transcription markers for calcification with CM, and functionally, CM decreased angiogenic 
processes of tubule formation and cell migration, which was accompanied by increased 
expression of pro-angiogenic markers as a compensatory mechanism for angiogenesis.  
To further understand the relationship between high calcium in regulating 
angiogenesis, in vivo mouse studies were employed. In disease, ischemic tissue stimulates the 
growth of new blood vessels as an important strategy to revascularize the damaged area. The 
presence of calcification and a highly calcific environment has not been studied as a deterrent 
of this angiogenic process. The aim of this study was to assess the effects of vascular 
calcification on ischemia-driven angiogenesis using murine models of both angiogenesis and 
vascular calcification. The osteoprotegerin (OPG) knockout mouse is a well validated model 
used to study vascular calcification and has been shown to exhibit calcification in their aortas 
and renal arteries145. In this study, OPG–/– mice were compared against their WT counterparts 
(C57BL6/J) using a well-validated model of physiological angiogenesis, namely the hindlimb 
ischemia model (HLI), which is primarily driven by hypoxia. Since both peripheral arterial 
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disease and vascular calcification are age-associated diseases, two different aged cohorts 
were utilised:  8-10wk (young)- and 24wk (aged). 
 
2.2 Results  
2.2.1 Confirmed Absence of OPG using an assay OPG ELISA 
assay to measure plasma OPG levels in mice following peri-arterial cuff and 
HLI surgeries.  
OPG deficient mice showed reduced plasma OPG levels compared to C57BL6/J wildtype 







Figure 4.1: The loss of OPG was confirmed using an assay OPG ELISA assay to measure 
plasma OPG levels in mice following peri-arterial cuff and HLI surgeries. Results are 




2.2.2 OPG-/- Mice Have Significantly Elevated Serum Calcium and ALP 
Activity Post-HLI. 
Alkaline phosphatase (ALP) is a well-used diagnostic marker for vascular 























were measured in blood plasma collected from both C57BL6/J and OPG knockout mice. 
Calcium levels were elevated in the OPG deficient mice compared to C57BL6/J controls 
(12.90 ±1.30 vs 6.60 ±1.60, P<0.0108 Figure 4.2 A). Plasma analysis also demonstrated 
significantly elevated ALP activity in the OPG deficient mice compared to C57BL6/J 
controls (2.80 ± 0.18 vs 1.14 ± 0.15, P<0.001, Figure 4.2 B). These results are consistent 
with previous studies where serum ALP  levels have been shown to be elevated in OPG–/–
mice than in WT mice145, 198, 199, showing significant differences in serum concentrations of 




























































Figure 4.2: Calcification Milieu In OPG-/- Mice Upregulates Calcium and ALP Activity In 8wk Old 
Mice. Femoral artery ligation was performed on 8wk old C57Bl6/J mice (controls) and OPG-/- mice. 
(A) Circulating calcium (B) ALP activity. Blood plasma was isolated 14 days post-HLI surgery, and 
calcium concentration was measured using a calcium assay (Cayman Chemical) and ALP activity 
using ALP assay (Wako, ALP Lab assay). Data is represented as mean ± SEM, *P<0.05, 
***P<0.001, (n=9/group). Statistical analysis was performed using a Mann-Whitney t-test, OPG
-/-: 













2.2.3 High Calcium Impairs Blood Flow Reperfusion In OPG-/- Mice Post-HLI. 
Laser Doppler Perfusion Imaging (LDPI) was used to assess blood perfusion as a 
marker of angiogenesis in control C57BL/6 mice compared to the OPG knockout mice. The 
LDPI ratio was determined as a ratio of the ischemic leg compared to the non-ischemic leg 
for each mouse. In this study, LDPI following unilateral femoral artery ligation showed 
striking reductions in blood flow reperfusion of 8wk old OPG-/- mice compared to C57BL/6 
at day 6 (013±0.04 vs 0.37±0.06, P<0.0024); day 10 (0.18±0.03 vs 0.40±0.04, P<0.0088) and 
day 14 (0.21±0.02 vs 0.45±0.08, P<0.0083) post HLI (Figure 4.3 A). Furthermore, OPG 
deficient mice played necrotic toes at day 14 post-HLI surgery, an observation that wasn’t 
seen in wildtype C57BL6/J (Figure 4.3 B). Collectively, this data demonstrates that elevated 
calcification milieu present in the OPG deficient mice is associated with decreased limb 


























Figure 4.3: High Calcium Impairs Blood Flow Reperfusion In 8-Wk Old OPG-/- Mice Post-HLI At 
Days 6, 10 And 14. Ischemia-driven neovascularization: femoral artery ligation was performed on 
8wk old male C57Bl6/J mice (controls) and OPG-/- mice (n=9/group). Blood flow perfusion was 
measured non-invasively using Laser Doppler Perfusion Imaging (LDPI). Representative laser 
doppler perfusion images, images show high (red) to low (blue) blood flow at day 14. Perfusion unit 
C57BL/6 
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ratio was determined based in the ratio of ischemic (ISC) to non-ischemic (NON-ISC) hindlimb. (C) 
OPG deficient mice displayed necrotic toes at day 14 post-HLI surgery. Data is represented as mean 
± SEM, *P<0.05, **P<0.01. Statistical analysis was performed using an unpaired student t-test and a 
two-way ANOVA with Bonferroni’s multiple comparison test. OPG-/-, osteoprotegerin deficient mice. 
 
2.2.4 High Calcium Reduces Neovessel and Arteriole in Gastrocnemius Muscle 
Tissues of OPG-/- Mice Following HLI.  
The effect of high calcium on neovascularisation was assessed in the gastrocnemius 
muscle sections by measuring capillary density (CD31+ neovessels) and arteriole density 
(smooth muscle a-actin positive arterioles); which were quantified as number of vessels 
(CD31+ per myocyte) using laminin staining (Figure 4.4 A). Consistent with the blood flow 
perfusion data, OPG-/- mice showed significantly decreased capillary density as shown by 
CD31+ neovessels relative to C57BL6/J wild-type (0.80±0.08 vs 1.37±0.15, P<0.0052, 
Figure 4.4 B). Conversely, OPG-/- mice showed increased arteriolar density compared to 


























Figure 4.4: High calcium Reduces Neovessel and Arteriole Formation in Gastrocnemius Tissues of 
OPG-/- Mice Following HLI   
Ischemia-driven neovascularization: femoral artery ligation was performed on 8wk old male 
C57Bl6/J mice (controls) and OPG-/- mice. Blood flow perfusion was measured invasively using Laser 
Doppler Perfusion Imaging (LDPI). (A) Photomicrographs representing Immunocytochemistry 
staining performed on OCT frozen gastrocnemius muscle sections to detect (B) CD31+ neovessels 
(red staining), and (C) smooth muscle a-actin positive arterioles (green staining), which was 
quantified as number of vessels (CD31+ per myocyte) using laminin staining (blue staining) (n=10-
12/group). Data is represented as mean ± SEM, *P<0.05, **P<0.01. Statistical analysis was 
performed using a Mann-Whitney t-test, Scale bars represent 50 µm. OPG-/-: osteoprotegerin 












2.2.5 Calcification Milieu Regulates Gene Expression of Angiogenic Genes in 
Ischemic Limbs Of OPG-/- Mice Following HLI. 
Ischemia-driven angiogenesis is regulated by the key transcription factor HIF-1α, 
which is post-translationally regulated by the E3 ubiquitin ligases, Siah1 and Siah2 and the 
propyl hydroxylase family (PHD 1-3). During hypoxia, Siahs 1 and 2 supress PHDs (PHD 1-
3) which render HIF-1a for ubiquitination and degradation72. The effect of OPG deficiency on 
mRNA expression of these pro-angiogenic regulators was assessed. Elevated calcium levels as 
observed in OPG deficient mice had no effects on Siah1 and Siah 2 mRNA expression in both 
the ischemic and non-ischemic limbs of OPG-/- mice compared to C57BL6/J controls (Figure 
4.5 A-B). However, PHD levels were decreased in ischemic limbs of OPG deficient mice 
compared to C57BL6/J controls; for both PHD1 (55.82±14.95 vs 139.60±19.52, P<0.0279, 
Figure 4.5 C), and PHD2 (48.38±13.73 vs 146.10±14.14, P<0.0329, Figure 4.5 D). Together, 
these findings demonstrate how a calcific environment can upregulate pro-angiogenic markers 











































Figure 4.5: Calcification Milieu Regulates Gene Expression of Angiogenic Genes in Ischemic 
Limbs OPG-/- mice following HLI. Real-time PCR was performed to assess mRNA expression of (A) 
Siah1, (B) Siah2, (C) Phd1, (D) Phd2 in gastrocnemius muscle of both C57Bl6/J and OPG
-/-
 mice (n 
= 5 per group). Data is represented as non- ischemic (Non-Isc) for control hindlimb, and ischemic 
(Isc) and surgical hindlimb. Data is represented as percentage of controls, mean ± SEM; One-way 
ANOVA with Bonferroni’s Multiple comparisons test, *P<0.05, **P<0.01. OPG-/-: osteoprotegerin 









2.2.6 High Calcium Differentially Upregulates mRNA Expression of Pro-
Angiogenic HIF-1a, VEGFA and VEGFR2 In Ischemic Limbs OPG-/-Mice.  
HIF-1a is the pivotal driver of ischemia-driven angiogenesis following occlusion of 
vessels during diseases of PAD and post-MI. To understand its regulation in OPG deficient 
mice following hind-limb ischemic insult, I measured its gene expression. As expected, 
ischemic limbs of OPG deficient mice had significant upregulation of Hif-1a mRNA 
expression compared to wildtype controls (332.50±72.05 vs 94.75±12.69, P<0.0056, Figure 
4.6 A). Furthermore, OPG deficient mice had higher expression of total Hif-1a relative to 
wildtype controls when expressed as a ratio of the non-ischemic to ischemic hindlimb 
(3.57±0.69 vs 0.99±.27, P<0.0286, Figure 4.6 B).  
The downstream effects of HIF-1a involve upregulation of VEGFA to drive 
angiogenesis during ischemia. In this study, there was no significant change in Vegfa gene 
expression in ischemic limbs of OPG deficient mice compared to wildtype controls (Figure 
4.6 C); with no change also observed for its receptor Vegfr2 (Figure 4.6 E); and when 
expressed as a ratio, Vegfa or Vegfr2 gene expression remained unchanged (Figure 4.6 D-F). 
In this study, increased expression of angiogenic markers suggests a compensatory mechanism 




































Figure 4.6: Calcification Milieu Upregulates Gene Expression of Pro-Angiogenic Markers HIF-
1a, VEGFA and VEGFR2 In Ischemic Limbs OPG-/- Mice. Real-time PCR was performed to assess 
gene expression of (A-B) Hif-1a and (C-D) Vegfa, (E-F) Vegfr2 in gastrocnemius muscle of both 
C57Bl6/J and OPG
-/-
 mice (n = 6 per group). Data is presented as non- ischemic (Non-Isc) for 
control hindlimb, and ischemic (Isc) and surgical hindlimb. Data is represented as percentage of 
controls, mean ± SEM; One-way ANOVA with Bonferroni’s Multiple comparisons test, Mann-
Whitney t-test, *P<0.05. OPG-/-: osteoprotegerin deficient mice. HIF-1a: hypoxia-inducible factor-1 
alpha, VEGF: vascular endothelial growth factor, VEGFR: vascular endothelial growth factor 








2.2.7 OPG-/-show increased mRNA expression of calcification-regulating genes in 
ischemic limbs following HLI.  
There is growing evidence highlighting the role of the Runx2, RANKL and BMP2 as 
regulators of vascular calcification and in cardiovascular and metabolic disease states138, 198. 
To further evaluate calcification in these mice, I assessed Runx2 gene expression, a key 
transcription factor involved in the initiation of vascular calcification; and RANKL, a known 
driver of calcification. There were no significant differences in Rankl mRNA expression in the 
ischemic limbs of OPG deficient mice compared to C57BL6/J controls (Figure 4.7 A). 
Furthermore, Rankl expression appeared to be more elevated in OPG deficient mice compared 
to wildtype controls when expressed as a ratio of the non-ischemic to ischemic hindlimb 
(2.28±0.92 vs 0.74±0.21, P<0.2222 Figure 4.7 B) though not statistically significant.  
 
There were no significant differences in Runx2 gene expression in the non-ischemic 
limbs versus ischemic limbs of C57BL6/J. Furthermore, when comparing the ischemic and 
non-ischemic limbs of the OPG-/- mice alone, there was significant upregulation in Runx2 gene 
(525.80 ±91.40 vs 62.04 ±10.37, P<0.0002, Figure 4.7 C). In addition, when comparing 
ischemic limbs of C57BL6/J versus ischemic limbs of OPG deficient mice, Runx2 gene 
expression was significantly upregulated (525.80 ±91.40 vs 120.00±32.32, P<0.0003, Figure 
4.7 C). This increase in Runx2 expression was further reflected when the data was expressed 
as a ratio of the non-ischemic to ischemic hindlimb (5.12±0.92 vs 1.79±0.62, P<0.0159, 
Figure 4.7 D).  
 
Bmp2 gene expression was significantly upregulated in OPG deficient mice, when 
comparing the ischemic limbs versus the non-ischemic limbs (1722±470.80 vs 271.40±103.40, 
P<0.0068, Figure 4.7 E). Furthermore, Bmp2 gene expression was upregulated when 
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comparing ischemic limbs of OPG deficient mice versus those of wildtype C57BL6/J mice, 
(1722±470.80 vs 34.46±11.72, P<0.01, Figure 4.7 E). When the data was expressed as a ratio 
of ischemic/non-ischemic, Bmp2 mRNA expression was increased (P<0.0635, Figure 4.7 F) 
though not statistically significant.  
In combination with our blood flow reperfusion data and neovessel/arteriole data, 
these findings highlight the presence of a calcific milieu in the OPG deficient mice, which 
clearly has negative effects in regulating angiogenesis. However, while there is upregulation of 
calcification makers, data from figure 4.5 demonstrated increased expression of angiogenic 





































Figure 4.7: OPG-/-Show Increased mRNA Expression of Calcification-Regulating Genes in 
Ischemic Limbs Following HLI. Real-time PCR was performed to assess gene expression of (A-B) 
Rankl, (B-C) Runx2, (E-F) Bmp2 in gastrocnemius muscle of both C57Bl6/J and OPG
-/-
 mice (n=5 
per group). Data is represented as non- ischemic (Non-Isc) for control hindlimb, and ischemic (Isc) 
and surgical hindlimb. Data is represented as percentage of controls, mean ± SEM; One-way ANOVA 
with Bonferroni’s Multiple comparisons test, Mann-Whitney t-test, *P<0.05, **P<0.01. OPG-/-: 
osteoprotegerin deficient mice, Runx2: runx2 related transcription factor, RANKL, receptor activator 





2.2.8 Aged OPG-/- Mice Exhibit Elevated Serum ALP Activity Following HLI.  
Both VC and PAD are age-associated diseases and therefore I studied the effects of elevated 
calcium in an aged cohort of mice. Interestingly, there was no difference in calcium levels in 
the aged OPG deficient mice compared to the C57BL6/J mice (Figure 4.8 A), which could 
indicate a saturation or plateau effect as a result of calcium uptake by tissues. In line with the 
previous data from the 8wk-old study, OPG deficient mice had significantly elevated ALP 























Figure 4.8: Aged OPG-/- Mice Exhibit Elevated Serum ALP Activity Following HLI 
Ischemia-driven neovascularization: femoral artery ligation was performed on 8wk old C57Bl6/J 
mice (controls) and OPG
-/-
 mice (n=9/group). (A) Circulating calcium (B) ALP activity. Blood 
plasma was isolated 14 days post-HLI surgery, and calcium concentration was measured using a 
calcium assay (Cayman Chemical) and ALP activity using ALP assay (Wako, ALP Lab assay). Data 
is represented as mean ± SEM, Mann-Whitney t-test, ****P<0.0001. Statistical analysis was 
performed using a Mann-Whitney t-test. OPG










2.2.9 Calcification Milieu Impairs Blood Flow Recovery in Aged OPG-/- Mice 
Post-HLI. 
The effects of high calcium on neovascularization were also assessed in an aged 
cohort of mice following hind-limb ischemia surgery. As expected, the aged model of 
calcification showed exacerbated effects on angiogenesis. Consistent with the younger 
cohort, aged OPG-/- mice showed striking reductions in blood flow as measured by LDPI 
compared to C57BL6/J wildtype controls, particularly at day 10 (0.14±0.03 vs 0.31±0.03, 













            



































Figure 4.9:  High Calcium Impairs Blood Flow Reperfusion In 24-Wk Old OPG-/- Mice Post-HLI. 
Ischemia-driven neovascularization: femoral artery ligation was performed on 24wk old C57Bl6/J 
mice (controls) and OPG
-/-
 mice (n=9/group). Blood flow perfusion was measured invasively using 
Laser Doppler Perfusion Imaging (LDPI), (A-B) Representative laser doppler perfusion images, 
images show high (red) to low (blue) blood flow at day 14. Perfusion unit ratio was determined based 
in the ratio of ischemic (ISC) to non-ischemic (NON-ISC) hindlimb. Data is represented as mean ± 
SEM, **P<0.01, ***P<0.001. Statistical analysis was performed using a two-way ANOVA with 
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2.2.10 High Calcium Impairs Reduces Neovessel Formation in Gastrocnemius 
Muscle Tissues Of OPG-/- Mice Following HLI. 
The effects of high calcium on neovascularisation were further evaluated in an aged 
murine model of angiogenesis. Consistent with data from the 8wk-old study, aged OPG 
deficient mice also had decreased capillary density (CD31+ neovessels) (0.47±0.10 vs 
0.80±0.09, P<0.0186, Figure 4.10 A); which were quantified as number of vessels (CD31+ per 
myocyte) using laminin staining. Furthermore, OPG deficient mice showed decreased arteriole 
density (smooth muscle a-actin positive arterioles) (0.48±0.31 vs 1.77±0.41, P<0.0255, 


































Figure 4.10: High Calcium Impairs Reduces Neovessel Formation in Gastrocnemius Muscle 
Tissues Of OPG-/- Mice Following HLI. Ischemia-driven neovascularization: femoral artery ligation 
was performed on 8wk old C57Bl6/J mice (controls) and OPG
-/-
 mice (n=9/group). Blood flow 
perfusion was measure invasively using Laser Doppler Perfusion Imaging (LDPI), (A) 
Photomicrographs representing Immunocytochemistry staining performed on OCT frozen 
gastrocnemius muscle sections to detect (B) CD31
+
 neovessels (red staining), and (C) smooth muscle 
a-actin positive arterioles (green staining); which was quantified as number of vessels (CD31
+
 per 
myocyte) using laminin staining (blue staining) (n=6/group). Data is represented as mean ± SEM, 
*P<0.05, ***P<0.001, ****P<0.0001. Statistical analysis was performed using a Mann-Whitney t-

















2.2.11 Aged OPG-/- Mice Show Impaired Tissue Ischemia and Limb Function, 
And Severe Foot Necrosis in Ischemic Limbs Following HLI Compared to 
Controls. 
To functionally evaluate decreased angiogenesis in OPG deficient mice compared to 
wildtype C57BL/6J mice, tissue ischemia and limb function were assessed in these mice 
using a modified version of the well-established Tarlov Scoring System as previously 
described163. Tarlov scoring revealed significantly worse outcomes for both tissue ischemia 
(177 vs 95, P<0.0001, Figure 4.11 B) and limb functions (126 vs 72, P<0.0004, Figure 4.11 
C) (with higher scoring indicating a worse prognosis) in the OPG-/- mice compared to 
controls (Table 4.1). This was associated with severe amputations and higher level of foot 
necrosis as demonstrated in Figure 4.11. A.  So far, the doppler perfusion data from both the 
8wk and aged study have shown that OPG deficiency leads to significant impairment in 
blood flow reperfusion, decreased capillary and arteriole density in the ischemic tissues of 











































Table 4.1: Tarlov Scores for Limb Function and Tissue Ischemia In 24 Wk-Old OPG-/- Mice 
Following HLI. Ischemia-driven neovascularization: femoral artery ligation was performed on 24wk 
old C57Bl6/J mice (controls) and OPG
-/-
 mice (n=12/group). Tarlov Scoring System163 was used to 
assess limb function (scores 0-3) and Tissue ischemia (scores 0-8), with a higher value indicating 
poor prognosis for both. Mice were monitored and photos were taken at each doppler time point for 
identification of toe necrosis and amputations. Excel was used to tally all scores. OPG-/-: 





































Figure 4.11: Aged OPG-/- Mice Show Impaired Tissue Ischemia and Limb Function, And Severe 
Foot Necrosis in Ischemic Limbs Following HLI Compared to Controls.  
Ischemia-driven neovascularization: femoral artery ligation was performed on 24wk old C57Bl6/J 
mice (controls) and OPG
-/-
 mice (n=12/group). Tarlov Scoring System163 was used to assess (A) tissue 
ischemia (scores 0-3) and (B) tissue ischemia (scores 0-8); with a higher value indicating poor 
prognosis for both. Mice were monitored and photos were taken at each doppler time point for 
identification of toe necrosis and amputations. Excel was used to tally all scores. Data is represented 
as mean ± SEM, *P<0.05, ***P<0.001. Statistical analysis was performed using a Mann-Whitney t-




NON-ISC ISC ISC NON-ISC 




This data demonstrated that a highly calcific environment in the OPG deficient mouse 
model resulted in severe loss of revascularisation with observed differences in neovessel 
formation in OPG deficient mice compared to controls. Furthermore, calcific milieu resulted 
in significant impairment in tissue ischemia and limb function, with OPG mice demonstrating 
toe necrosis and amputations.  
Patients with PAD often present with multilevel disease, characterised by fatty plaque 
build-up and high levels of diffused calcium deposits in the media of their peripheral 
arteries83. In addition, lower extremity arterial calcification predicts poor cardiovascular 
outcomes and is highly associated with limb amputations15, 34, 84-87, and is reported in 
peripheral arteries of diabetic and chronic kidney disease (CKD) patients, suggesting an 
association between arterial calcification and PAD34, 84, 85. Because calcification affects limb 
vascularization, it is therefore considered a limiting factor for the treatment of PAD and a 
potential driver of PAD15. 
 
The most prominent type of calcification that occurs in the lower extremity is medial 
calcification, very distinct from intimal calcification occuring in the coronary arteries, 
although both may co-exist in diseases such as atherosclerosis37. Calcification in PAD is 
proposed to affect limb vascularization due to reduced vessel compliance, increased arterial 
stiffening and reduced coronary perfusion 37, 82.  In a previous study, tibial artery calcification 
(TAC) score was used to assess the associations of calcification with the severity of symptoms 
in PAD patients following computed tomography (CT). This study found that patients with 
elevated TAC scores had a much higher incidence of PAD symptoms and increased risk of 
limb amputations compared to those with lower scores34. In a different study, assesment of 
human femoralpopliteal arteries showed that calcified arteries had larger diameters, thicker 
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walls, thinner tunica media; with more discontinuous elastic fibres compared to healthy 
arteries36. This therefore suggests that the extent of calcification in lower exremity arteries 
may influence the severity of symptoms in PAD patients.  
 
Indeed, OPG is known to be essential for angiogenesis in vitro184,  however, to date 
no studies have reported this critical observation in vivo. The calcific milieu present in this 
model was a unique opportunity to assess the effects of elevated calcium and the resulting 
detrimental consequences. Furthermore, the presence of calcification and a highly calcific 
environment has not been studied as a deterrent of this angiogenic process. Here I used an 
OPG-deficient mouse model, as these mice develop extensive vascular calcification in their 
aorta and renal arteries145. Utilising this model, ischemia-induced angiogenesis was assessed in 
vivo and demonstrated a profound detrimental suppression of vascularisation, with significant 
elevation of calcification markers (Runx2 and RANKL). The association of calcification on 
angiogenesis and ischemia however remains unclear, though it’s been proposed that new blood 
vessels may arise within atherosclerotic plaques as a result of cross-talk and coordinated 
interplay by ECs, SMCs, pericytes, osteoblasts and other osteoprogenitor cells residing within 
the vessel wall, which may therefore drive the differentiation of ECs into bone-like cells to 
induce vascular calcification61.  
 
In this study, I utilised the OPG knockout mice as a calcification model to mimic high 
calcific environment. OPG has been shown to have numerous functions in both physiological 
and pathological processes. Clinical studies have reported that higher levels of serum OPG is 
associated with poor cardiovascular outcomes in coronary artery disease, chronic kidney 
disease and rheumatoid arthritis137, 139, 141, 149. Additionally, the pro-angiogenic role of OPG 
was reported in a study whereby OPG stimulated the recruitment of endothelial colony 
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forming cells from the bone marrow to sites of neovascularization during vasculogenesis153. 
Furthermore, while OPG deficient mice result in greater calcium level, and have been 
validated as a vascular calcification model, it cannot be discounted that the dramatic 
ischemia-related effects could be due to the loss of OPG itself. This serves as a limitation in 
this study as there are other available models used to study vascular calcification. Therefore 
further investigation is required to fully understand the role of OPG in angiogenesis, however 
some in vitro  studies have reported the “protective effects” of OPG, where OPG enhanced 
the pro-angiogenic properties of endothelial colony forming cells which are recruited from 
the bone marrow to sites of revascularisation during vasculogenesis153. Therefore, it still 
remains unclear that the presence of calcification is detrimental to the progression of 
angiogenesis and PAD. 
Ageing plays a crucial role in endothelial dysfunction and the progression of 
calcification200. Our aged cohort of OPG-deficient mice displayed significant loss of 
angiogenic ability in concert with extensive tissue ischemia and impaired limb function with 
decreases in capillary and arteriole density compared to control mice (Figure 4.12). The 
combination of increased age and severe calcification in these mice created a largely 
unfavourable environment for revascularisation, similar to the consequences observed in 
patients with PAD. PAD patients presenting with femoral calcification often have reduced 
coronary perfusion and are at a higher risk for amputations37, 82. In a different published study 
using mice deficient in osteopontin, another known inhibitor of vascular calcification, 
OPN−/− demonstrated decreased running abilities compared to control wildtype mice 7 days 
post hind-limb ischemia108. 
The angiogenic process or development of collateral vessels originates from co-
existing blood vessels in the vicinity of an ischemic insult to bypass sistes of obstruction, and 
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to restore blood flow and preserve tissue fucntion47. During an ischemic environment, the 
initial step is activation of endothelial cells to stimualte proliferation and migration by growth 
factors. An ischemic environment induces HIF-1α which further stimulates VEGF synthesis 
to drive neovascularization to rescue blood flow in the affected area. Data from this study 
demonstrated that following the induction of ischemia by femoral artery ligation, there was 
an attempt to increase pro-angiogenic marker expression for HIF-1 alpha, VEGFA and its 
receptor VEGFR2 in ischemic limbs of OPG deficient mice compared to wildtype controls 
(Figure 4.12). This may explain the increased arteriole formation observed with the 8wk-old 
mice where there is increase in arteriolar density in OPG deficient mice compared to 
wildtype mice. Furthermore, while OPG deficient mice result in greater calcium level, and 
have been validated as a vascular calcification model, futher investigation is required to fully 
understand the role of OPG in angiogenesis.  
 
2.4 Conclusion 
This study provides important insights into the mechanisms of high calcium in 
regulating angiogenesis. I found that high calcium environment impairs ischemia-driven 
angiogenesis and upregulates ALP and calcification markers. While the mechanisms 
underlying the effects of calcification on angiogenesis are still not clear, this study has 
provided some evidence to identify how elevated calcium levels may have devastating effects 
on revascularisation. The degree of calcification in patients with PAD can often be a limiting 
factor when providing standard therapies and these findings may have implications for the 







Figure 4.12:  Summary Schematic for the Effects of Calcification Milieu on Ischemia-Driven 



















CHAPTER 5:                 
THE INTERACTION BETWEEN 
INFLAMMATION AND 










VC is now considered to be surrogate marker for the burden of atherosclerotic disease 
and a potential contributor to disease progression. Angiogenesis is a multi-step process that 
occurs in several well-defined stages of atherosclerosis and involves a complex orchestration 
of growth factors, cytokines, signalling cascades and cellular events46. Depending on the 
pathophysiological context, angiogenesis is driven by two distinctly different, yet partially 
overlapping, pathways64, 67. In contrast to ischemia-driven angiogenesis which is primarily 
modulated by the main hypoxic transcription factor, HIF-1α; NF-κB, a pivotal transcription 
factor for inflammatory-driven angiogenesis66. Inflammatory-driven pathological 
angiogenesis is implicated in several inflammatory disease processes such as atherosclerosis, 
cancer and peripheral vascular diseases46.   
Inflammatory-driven angiogenesis can be triggered by direct or indirect stimulation. 
Direct stimulation involves increased expression of inflammatory cytokines on endothelial 
cells (EC) to regulate EC proliferation and migration, leading to angiogenesis67. In contrast, 
indirect stimulation involves the release and recruitment of macrophages to the inflamed site 
in response to an inflammatory stimulus, which then triggers the secretion of a host of pro-
angiogenic factors including vascular endothelial growth factor (VEGFA), tumour necrosis 
factor-α  (TNF-α), basic fibroblast growth factor (bFGF) and  interferon gamma (IFNg) to 
promote angiogenesis67. This effect is however not beneficial as it enhances plaque growth 
making them more prone to rupture. Other key promoters of inflammatory-driven 
angiogenesis include TNF-α, NF-kB, cell adhesion molecules (CAMs) including vascular 
cell adhesion molecule (VCAM), intracellular adhesion molecule (VCAM) and monocyte 
chemoattractant protein-1 (MCP1)66, 67. Notably, VEGF is an important stimulator of 
angiogenesis in both ischemia and inflammatory conditions; modulated by HIF-1α and NF-
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κB, respectively. VEGF is known to possess a response element for both NF-κB and HIF-1α 
in its promoter region; thus, allowing for conditional regulation via activation of both 
signalling pathways independently.  
TNF-α is a well-studied pleiotropic cytokine, that has been shown to play a role in 
vascular pathologies relating to angiogenesis, and also in bone pathophysiology91. 
Inflammatory mediators derived from monocyte-macrophages such as TNF-α, have been 
reported to contribute in the progression of VC by promoting osteoblastic differentiation of 
VSMCs, leading to mineralisation91, 201. Furthermore, calcium phosphate mineral deposition 
is known to elicit an inflammatory response, by stimulating TNF production by 
macrophages160, 161. In other studies, exposure of macrophages to calcium or phosphate 
nanocrystals resulted in a change from M0 to M1 polarization, which was followed by TNF-α 
release202. Macrophages may contribute to the vicious cycle of inflammation and calcification 
in the vessel wall through paracrine activation of VSMCs, and by ingesting calcium-
phosphate deposits (hydroxyapatite) whilst also secreting TNF-α160.  In addition, it has been 
shown that basic calcium-phosphate crystals stimulated the release of TNF-α and other pro-
inflammatory cytokines from differentiated human macrophages161.   
 
Though the mechanisms of TNF-α in regulating VC have been intensely studied, the 
understanding of its effects on inflammatory-driven angiogenesis in ECs is incomplete. In 
this study, I aimed to investigate the effect of calcification medium on TNF-α-induced 
responses on ECs, and its effect on angiogenesis. I hypothesised that calcification stimuli will 





5.2 Results  
5.2.1 Calcification Medium Upregulates Calcium Levels and ALP 
Activity Following TNF-a Stimulation. 
The physiological importance of both calcium and phosphate are well established for 
their roles in muscle contractions, mineralisation of skeletal bones and nerve transmissions203. 
Calcium phosphate homeostasis is well regulated in the vasculature, however disrupted 
balance in both can lead to vascular calcification commonly seen in CKD101, 105, 204. To 
understand the effect of inflammation on ECs, cells were stimulated with and without 
inflammatory mediator TNF-a. Consistent with the previous data in chapter 3, cells treated 
with calcification media alone demonstrated elevated levels of calcium secretion compared to 
control cells (341.4±48.65 vs 288.20±28.61, Figure 5.1 A). When cells were stimulated with 
TNF-a , this had no effect on calcium levels; however, when cells were co-treated with both 
TNF-a and CM, there was a significant elevation in calcium secretion by endothelial cells 
(454.60±47.06 vs (305.30±26.23, P<0.0197, Figure 5.1 A).  
Alkaline Phosphatase (ALP) is an early marker of osteogenic activity that plays an 
important role in the initiation of mineralisation in bone osteogenesis and also during VC105. 
Previously, ALP secretion was upregulated via hypoxia signalling in endothelial cells 
following incubation with CM. To further delineate its role in inflammatory-driven 
angiogenesis, ALP activity was measured in ECs following CM treatment and co-incubation 
with TNF-a. In this study, CM upregulated ALP secretion in ECs relative to un-treated cells 
(6.53±0.56 vs 4.96±0.27, P<0.0337, Figure 5.1 B). Subsequent exposure of ECs with both 
TNF-a and CM also stimulated increase in ALP secretion and activity (6.79±.37 vs 
5.29±0.31, P<0.0138, Figure 5.1 B). This data supports previous findings in ECs where 
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TNF-α promoted calcifying vascular cell mineralization; via increasing the expression of 




















Figure 5.1: CM Raises Calcium Levels and ALP Activity Despite the Presence of TNF-a . 
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. (A) Circulating calcium (Cayman, Calcium Assay) and 
(B) ALP activity (WAKO, ALP LabAssay) were used to quantify calcium concentrations in cell culture 
supernatants following treatment. All data is represented as mean ± SEM; One-way ANOVA with 













5.2.2 Calcification Medium Effects on Angiogenic Assays With TNF-a  
Stimulus. 
The effect of calcification medium in driving endothelial cell viability, migration and 
tubule formation was assessed under the influence of inflammation. Incubation of ECs with 
CM stimulated an increase in cell viability compared to untreated cells (2.13±0.09 vs 
1.16±0.11, P<0.0065, Figure 5.2). In addition, co-incubation of ECs with TNF-a and CM 
demonstrated a significant increase in cell viability when compared to cells unstimulated with 












Figure 5.2: CM Induces Change in Cell Viability Despite TNF-a Presence  
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. WST-1 cell viability reagent was added to cells and 
incubated for 4h to assess total cell viability. All data is represented as percentage of controls, mean 
± SEM; One-way ANOVA with Bonferroni’s Multiple comparisons test, (n=6), HCAEC, human 






When assessed for migratory effect, CM significantly reduced endothelial cell 
migration relative to non-treated cells (44.85±3.74 vs 75.87±9.60, P<0.0062, Figure 5.3). 
Stimulation with TNF-a also significantly decreased cell migration compared to untreated 
cells.  Interestingly however, when cells were co-incubated with both TNF-a and CM, cell 
migration was significantly increased compared to cells treated with TNF-a alone 
(58.47±6.73 vs 39.52±3.14, P<0.0289 Figure 5.3). Taken together this data demonstrates 
differential regulation of cell migration by both CM and TNF-a and may therefore suggest 








































































Figure 5.3: TNF-a Drives CM-Induced Increase in Endothelial Cell Migration. 
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. Boyden cell migration assay was conducted. All data is 
represented as percentage of controls, mean ± SEM; One-way ANOVA with Bonferroni’s Multiple 
comparisons test, (n=6), *P<0.05, **P<0.01, HCAEC, human coronary artery endothelial cells, 














Tubule formation is the final stage of angiogenesis, regulated by numerous pro-
angiogenic factors. Consistent with data from previous chapters, CM supressed endothelial 
tubule formation when compared to control cells (15.50±3.59 vs 48.61±5.38, P<0.0001, 
Figure 5.4). Stimulation with TNF-a had no effect on ECs tubule formation capacity when 
compared to untreated cells (53.89±4.30 vs 48.61±5.38). However, when cells were co-
incubated with both CM and TNF-α, there was a significant increase in the number of tubules 
formed when compared to cells treated with CM alone (45.61±4.35 vs 15.50±3.59, P<0.0001, 
Figure 5.4). This indicates that stimulation with TNF-α in this instance overrode the ability 







































































Figure 5.4: Inflammation Has No Effect on EC Tubule Formation. HCAECs cultured in MesoEndo 
medium then treated with calcification medium containing 2.0mM HNa2PO4 and 2.7mM CaCl2 in 
10% FBS M199 medium for 24h. Cells were then treated with a concentration of 1 ng/mL of TNF-a 
for 4h. Matrigel Tubulogenesis assay was performed to assess number of tubes formed over 4 h. All 
data is represented as percentage ratio of controls, mean ± SEM; One-way ANOVA with Bonferroni’s 
Multiple comparisons test, (n=9), ****P<0.0001, n=9. HCAEC, human coronary artery endothelial 













5.2.3 Inflammation Had No Effect on Pro-Angiogenic Marker HIF-1a 
Expression  
The HIF-1a pathway is known to be a key regulator of angiogenesis and is 
conditionally regulated by both ischemia and inflammatory stimulus46. However, the role of 
calcification in driving HIF-1a-upregulation in inflammatory-driven angiogenesis has not 
been explored. In this study, treatment of ECs with CM alone upregulated Hif-1a mRNA 
expression compared to non-treated cells (152.80±26.10 vs 96.71±6.80, P<0.0355 (Figure 
5.5). When cells were treated with TNF-a, there was no change in HIF-1a expression when 
compared to non-TNF-a treated cells (Figure 5.5), with no effect also seen with co-
incubation with both CM and TNF-a. These findings collectively imply that CM may have 














































Figure 5.5: CM Alone Drives TNF-a -Induced Hif-1a expression.  
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. RNA extracted after 24 h, reverse transcribed into cDNA, 
then real-time PCR performed. mRNA was normalised to human 18s. All data is represented as 
percentage of controls, mean ± SEM; One-way ANOVA with Bonferroni’s Multiple comparisons test, 
(n=4-8), *P<0.05. HCAEC, human coronary artery endothelial cells, M199, medium 199 (Sigma-











5.2.4 Inflammation Differentially Effects The Vegfa-Vegfr2 Signalling 
Pathway to Regulate Angiogenesis.  
The VEGFA-VEGFR2 axis is well regulated in angiogenesis. Very little is known 
about the regulation of this pathway by calcification, particularly in its ability to influence 
angiogenesis. In this study, treatment of ECs with CM upregulated Vegfa mRNA expression 
in the absence of an inflammatory stimulus (134.40±19.67 vs 90.72±5.97, P<0.0438, Figure 
5.6 A). However, when cells were treated with TNF-a, there was significant upregulation in 
Vegfa mRNA expression compared to non-treated cells (176.90±15.04 vs 90.72±15.04, 
P<0.035, Figure 5.6 A). However, there was no change in VEGFA protein expression with 
CM treatment alone and when cells were co-incubated with both CM and TNF-a when 
compared to non-treated cells (Figure 5.6 C).  
Based on these findings and to understand the mechanisms further, Vegfr2 expression 
was measured following CM and TNF-a treatment. CM alone had no effect on Vegfr2 
mRNA expression when compared to non-treated cells (Figure 5.6 C).  When cells were 
treated with TNF-a, this elicited no change on Vegfr2 mRNA expression (Figure 5.6 C). 
Furthermore, the addition of TNF-a alone had no effect on Vegfa gene expression (Figure 
5.6 C).  
These findings collectively demonstrate differential regulation of the VEGFA-
VEGFR2 axis at both the transcriptional and translational level by CM and TNF-a, 
potentially implicating alternative regulatory mechanisms to be involved. This data also 
suggests that CM may elicit more striking effects on VEGFA expression at the translational 










































Figure 5.6: CM Differentially Regulates Vegfa-Vegfr2 Axis With TNF-a  Stimulation.  
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. RNA extracted after 24 h, reverse transcribed into cDNA, 
then real-time PCR performed. mRNA was normalised to human 18s. All data is represented as 
percentage of controls, mean ± SEM; One-way ANOVA with Bonferroni’s Multiple comparisons test, 
(n=4-8), *P<0.05, **P<0.01 HCAEC, human coronary artery endothelial cells, M199, medium 199 
(Sigma-Aldrich), VEGFA, vascular endothelial growth factor, VEGFR2, vascular endothelial growth 
factor receptor 2. 
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5.2.5 CM Elicits No Change on Runx2 Expression Following TNF-a 
Treatment.  
Runx2 is an important transcription factor involved in the calcification process, that 
regulates the expression of a cascade of mineralization regulating proteins such as alkaline 
phosphatase, osteopontin and osteocalcin89. In chapter 3, CM decreased Runx2 mRNA 
expression in ECs in hypoxia compared to normoxia. In this chapter, the role of Runx2 in 
inflammatory-driven angiogenesis was explored. ECs treated with CM showed no change in 
Runx2 mRNA expression compared to control cells. Furthermore, co-incubation of ECs with 
both CM and TNF-a did not appear to have any effect on Runx2 mRNA expression (Figure 














Figure 5.7: CM Has No Effect in Regulating Runx2 Expression Following TNF-a  Treatment in ECs  
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. RNA extracted after 24 h, reverse transcribed into cDNA, then 
real-time PCR performed. mRNA was normalised to human 18s. All data is represented as percentage of 
controls, mean ± SEM; One-way ANOVA with Bonferroni’s Multiple comparisons test, (n=5-8). HCAEC, 




5.2.6 TNF-a  and Calcification Medium Upregulated Osteogenic 
Marker BMP2 Expression. 
Bone morphogenetic proteins (BMPs) are potent osteogenic differentiation mediators 
of bone formation; and their role as inducers of VC has been well established124, 125. In this 
study, treatment of ECs with CM induced upregulation of Bmp2 mRNA expression compared 
to non-treated cells (225.30±52.30 vs 104.10±9.67, P<0.0290); a response that was further 
increased with TNFα treatment (557.20±83.76, P<0.0001, Figure 5.8). Likewise, co-
incubation of ECs with both CM and TNF-a showed further elevation in Bmp2 mRNA 
expression compared to CM treated cells (599.40±126 vs 225.30±52.30, P<0.0131). 
Although there was no change compared to cells treated with TNF-a alone, elevated Bmp2 
expression suggests a proinflammatory effect of TNF-a in driving calcification marker 








Figure 5.8: CM Upregulates Bmp2 Expression With TNF-a -Treatment in ECs.  
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. RNA extracted after 24 h, reverse transcribed into cDNA, 
then real-time PCR performed. mRNA was normalised to human 18s. All data is represented as 
percentage of controls, mean ± SEM; One-way ANOVA with Bonferroni’s Multiple comparisons test, 
(n=5-9, *P<0.05, **P<0.01. HCAEC, human coronary artery endothelial cells, M199, medium 199 
(Sigma-Aldrich), BMP2, bone morphogenetic protein 2.  
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5.2.7 CM Differentially Regulates the RANK-RANKL-OPG Axis Under 
Inflammatory Conditions. 
There is growing evidence that ectopic calcification of blood vessels and cardiac 
valves are associated with angiogenesis51, 62,150. Several processes have been proposed to 
regulate calcification, including the RANK/RANKL/OPG signalling pathway129, 166, 169. 
Treatment of ECs with CM upregulated Rankl mRNA expression compared to non-treated 
cells (372.80±90.09 vs 113.30±20.99, P<0.0026, Figure 5.9 A). When cells were stimulated 
with TNF-a, there was no effect on Rankl expression. Co-incubation with TNF-a and CM 
also had no effect on Rankl mRNA expression (Figure 5.9 A).  CM also upregulated Rank 
mRNA levels compared to non-treated cells (136.50±14.22 vs 98.02±9.77, P<0.0308, Figure 
5.9 B). However, all other treatments had no effects in regulating Rank gene expression 
(Figure 5.9 B). The only effect on the pro-calcific mediators of this axis came from 
calcification treatment with no additive effects from inflammation.  
 
OPG is a known decoy receptor and has protective role in preventing vascular 
calcification. EC stimulation with TNF-α is known to stimulate the release of OPG under 
basal conditions205. Consistent with previous data, treatment of ECs with CM significantly 
upregulated Opg mRNA expression compared to non-treated cells (187.30±44 vs 
111.70±11.09, P<0.0360, Figure 5.9 C). TNF-a alone had negligible effects on Opg 
expression, however when ECs were co-incubated with both TNF-a and CM, there was a 
significant reduction in Opg mRNA expression compared to cells treated with CM alone 






















Figure 5.9: CM Differentially Regulates the Rankl/Rank/Opg Axis Under Inflammatory 
Conditions. 
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. RNA extracted after 24 h, reverse transcribed into cDNA, 
then real-time PCR performed. mRNA was normalised to human 18s. All data is represented as 
percentage of controls, mean ± SEM; One-way ANOVA with Bonferroni’s Multiple comparisons test, 
(n=5-9), *P<0.05. HCAEC, human coronary artery endothelial cells, M199, medium 199 (Sigma-







5.2.8 Calcification Medium Upregulates NF-kB Activation 
Under Inflammatory Response.  
The transcription factor NF-kB is a key driver of inflammatory-driven angiogenesis65. 
The effects of elevated calcium levels in combination with inflammation and the subsequent 
effects on NF- κB (p65), however have not been fully characterised. CM treatment had no 
significant effect on NF-κB (P65) protein expression compared to non-treated cells (Figure 
5.10); however when ECs were stimulated with TNF-a, there appeared to be an increase in 
NF-κB (P65) compared to non-treated cells (825±421.2 vs 99.20±3.6) though not statistically 
significant. Co-incubation of ECs with both CM and TNF-a increased NF-κB (P65) protein 
expression relative compared to cells treated with CM alone (3028±2939 vs 158±32.29, 
P<0.0049, Figure 5.10). These findings suggest a pro-inflammatory effect of high calcium on 















































Figure 5.10: CM Drives NF-B (P65) Activation Under Inflammatory Response.  
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. Nuclear protein was extracted measure protein expression 
via immunoblotting technique. Even protein loading was confirmed by Lamin B 1 Nuclear Envelope 
Marker. All data is represented as percentage of controls, mean ± SEM; One-way ANOVA with 
Bonferroni’s Multiple comparisons test, (n=3-9). HCAEC, human coronary artery endothelial cells, 
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5.2.9 CM Drives Upregulation of Inflammatory Markers 
ICAM, VCAM and . MCP1 
 ICAM-1 is a well-studied acute inflammatory marker that is highly expressed in 
endothelial cells. ICAM-1 expression is known to be stimulated by various stimuli including 
TNF-a, interleukins (IL-1beta, IL-6), lipopolysaccharide (LPS) and oxidised low-density 
lipoproteins (oxLDL). ICAM-1 activation is also dependent on the transcription factor NF-
κB206, 207. Currently, little data is currently available to highlight the effect of a calcification 
stimuli on ICAM-1 expression in ECs, particularly in the regulation of inflammatory-driven 
angiogenesis. In this study, treatment of ECs with CM significantly upregulated Icam-1 
mRNA expression compared to non-treated cells (234±46.90 vs 106.30±14.16, P<0.0191, 
Figure 5.10 A). Additionally, when cells were stimulated with TNF-a, there was striking 
increase in Icam-1 mRNA expression compared to non-treated cells (2364±408.30 vs 
106.30±14.16, P<0.0001). Furthermore, while co-incubation with both TNF-a and CM had 
no additional effects on Icam-1 expression relative to TNF-a only treated cells, they 
remained substantially elevated when compared to CM alone (2006±388 vs 106.30±14.16; 
P<0.0002, Figure 5.10 A).   
 
VCAM-1 is also expressed on the luminal surface of endothelial cells208. Unlike 
ICAM-1, VCAM-1 expression is not normally present in basal conditions, only following 
stimulation with pro-inflammatory cytokines such as TNF-a and IL-1β and IL-6208. VCAM-1 
expression is also regulated by NF-κB, namely its two subunits p65 and p50. CM 
significantly upregulated Vcam-1 mRNA expression compared to non-treated cells 
(317±58.94 vs 105.30±13.0, P<0.0014, Figure 5.10 B). When cells were stimulated with 
TNF-a, there was a striking elevation in Vcam-1 expression compared to non-treated cells 
 171 
(4389±754.4 vs 105.30±13.10, P<0.0001, Figure 5.10 B). Once again, co-incubation with 
both TNF-a and CM showed no additional effects on TNFα stimulated Vcam-1 expression 
but significantly increased it compared to CM alone (3389±835.40 vs 105.30±13.10, 
P<0.0035, Figure 5.10 B). 
 
MCP-1 is a chemokine secreted by numerous cell types including endothelial cells, 
fibroblasts, smooth muscle cells, monocytes and macrophages209. Regulation of MCP-1 
occurs via NF-κB and the mitogen activated protein kinase (MAPK) signalling pathways.210 
In this study, treatment of ECs with CM significantly upregulated Mcp-1 mRNA expression 
compared to non-treated cells (289.90±49.03 vs 125.30±11.67, P<0.0151, Figure 5.10 C) and 
when cells were stimulated with TNF-a, this resulted in a marked increase in Mcp-1 
expression compared to non-treated cells (1450±285.3 vs 125.30±11.67, P<0.0022, Figure 
5.10 C). Consistent with the data above, co-incubation with both TNF-a and CM had no 
additional effects on Mcp-1 expression compared to TNFα alone but elevated the expression 
seen with CM treatment (1857±389.80 vs 125.30±11.67, P<0.0002, Figure 5.10 C). Taken 
together, these findings demonstrate a pro-inflammatory effect of elevated calcium on 












































Figure 5.11: CM Upregulates Icam, Vcam and Mcp1 Expression.  
HCAECs cultured in MesoEndo medium then treated with calcification medium containing 2.0mM 
HNa2PO4 and 2.7mM CaCl2 in 10% FBS M199 medium for 24h. Cells were then treated with a 
concentration of 1 ng/mL of TNF-a for 4h. RNA extracted after 24 h, reverse transcribed into cDNA, 
then real-time PCR performed. mRNA was normalised to human 18s. All data is represented as 
percentage of controls, mean ± SEM; One-way ANOVA with Bonferroni’s Multiple comparisons test, 
(n=3-9). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. HCAEC, human coronary artery 
endothelial cells, M199, medium 199 (Sigma-Aldrich), ICAM, intracellular adhesion molecule, 







This study demonstrated consistent upregulation of inflammatory markers with 
calcification treatment, while treatment with TNF-α had little effect on both angiogenic and 
calcification markers. It was also clear that a combination of calcification with inflammation 
had additive effects for inflammatory markers. However, as a result of the discrepant effects 
of the combination treatment on the angiogenic markers the precise mechanism for the role of 
calcification in inflammatory-induced angiogenesis remains unknown.  
Inflammatory macrophages colocalise with basic calcium phosphate crystals/deposits 
in developing atherosclerosis lesions and can promote VC through the release of TNF-α161. 
Our data appears to oppose this idea because when cells were co-incubated with both TNF-α 
and CM, this was unable to drive gene expression for osteogenic markers (Figure 5.12). 
Furthermore, when comparing CM treatment alone with the combination treatment, there was 
significant downregulation in expression of protective factor OPG and RANKL. It therefore 
remains unclear whether calcification is purely a pathological response or simply represents 
an adaptive protective mechanism by the vasculature. Based on data collected from previous 
studies by Aikawa et al.211, 212, not all calcification is proinflammatory, as medial calcification 
occurs in the absence of macrophage infiltration. This is an area that requires further 
investigation particularly in the regulation of endothelial cell angiogenesis. 
 
This study demonstrated significant upregulation of NF-κB (P65) protein expression 
with co-incubation with both TNFα and CM; therefore, suggesting a pro-inflammatory role 
of CM in driving inflammatory driven angiogenesis (Figure 5.12). This was supported by a 
previous study with human fibroblasts where treatment with hydroxyapatite caused a striking 
increase in NF-κB activation213. The functional studies in this thesis demonstrated increases 
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in endothelial cell migration following TNF-α treatment and during angiogenesis, BMP2 
along with other angiogenic factors such as VEGF have been shown to induce EC migration 
and proliferation61, 62. Furthermore, in other literature, TNF-α has been shown to upregulate 
EC expression for BMP2 through activation of the NF-kB pathway, which causes nuclear 
translocation of NF-kB, suggesting that NF-kB activation is required for BMP2 activation 
and expression214. In addition, TNF-α and interleukin-1 beta (IL-1β) were shown to induce 
endothelial-to-mesenchymal transitions in human aortic-endothelial cells and promoted 
BMP-mediated osteogenic expression and mineralisation215. Therefore, in line this with, our 
data demonstrates a potential mechanistic pathway involving both BMP2 and the NF-kB 
pathway and provides a potential avenue for future research.  
 
Based on previous results from chapter 3, it was demonstrated that Runx2 may play a 
role in driving HIF-1α expression in ECs in normoxia. In this study TNF-α stimulation 
decreased Runx2 expression, findings similar to those of previous studies which have shown 
TNF-α inhibited Runx2 expression, but increased ALP activity and mineralisation of 
mesenchymal stem cells216. Other results have also demonstrated similar findings of TNF-α 
inhibition of Runx2 expression217, 218. There was however no observed change in HIF-1α 
expression with TNF-α treatment. Interestingly, co-incubation with both TNF-α and CM 
upregulated Runx2 expression whilst downregulating HIF-1α expression (Figure 5.12). Data 
from a previous study showed that TNF-α treatment stimulated an increased in BMP2 
expression in a time-dependent manner at 2 h and 8 h, with significant increases seen 
following TNF-α treatment, though no changes were observed at 24 h63. Data from our study 
corresponds in with this as cells were treated with TNF-α for 4 hours, and I observed 
increased BMP2 expression with TNF-α treatment; an effect which was further increased 
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with the combination treatment. This therefore proposes a role of BMP2 in driving 
inflammatory cytokine TNF-α to potentially drive angiogenesis in disease.  
  Calcification-induced expression of inflammatory markers was observed in this study, 
with calcification treatment significantly upregulating key inflammatory markers ICAM-1, 
VCAM-1 and MCP-1 (Figure 5.12). It is important to note that very little is known regarding 
the expression of inflammatory markers during vascular calcification. During atherogenesis, 
lipids, particularly cholesterol delivered by low-density lipoprotein (LDL) particles 
accumulate and are deposited into the sub-endothelial lumen. Oxidation occurs by reactive 
oxygen species (ROS) which cause modification of LDL to be oxidised (oxLDL), driving the 
inflammatory response seen in atherosclerosis. So, while very little is known regarding the 
role of ICAM-1, VCAM-1 and MCP1 in vascular calcification, due to their well-established 
role in plaque atherogenesis, it is likely that they may also play a role in regulating 
calcification-induced inflammatory-driven angiogenesis.  
 
Functional angiogenic assays demonstrated that TNF-a treatment increased 
endothelial cell viability. A similar trend was reported in a previous study, where HUVECs 
exposed to TNF-a with different concentrations of 100, 20, 10 and 1 ng/ml showed 
significantly increased cell proliferation activity at the concentration above 1 ng/ml as 
compared with the control group219. In addition, tubule formation reflects the final stage of 
endothelial cell angiogenesis and in this study, calcification dampened the ability of ECs to 
form tubule networks. More interesting, stimulation of cells with TNF-a had no additional 
effect on EC tubule formation, however with combination treatment there were greater 
number of tubules formed. These results demonstrated that the combination treatment was 
not sufficient to drive angiogenesis or the expression of calcification markers, thus 
highlighting inflammation to be a sole regulator.   However, very little is known of the 
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association between calcium-phosphate crystals and TNF-a-induced inflammation. 
Nevertheless, the present findings demonstrated that high calcium may be acting via 
alternative pathways to drive EC tube formation; thus, warranting further studies. As 
previously stated in chapters 3, the same limitations also apply to this study; including the use 
of one mode of calcification stimulus, thus warranting future studies to test out other 
calcification-inducing approaches in vitro.  
 





CHAPTER 6:         
THE EFFECT OF CALCIFIC 










As outlined in previous chapters, angiogenesis is defined as the formation of new 
blood vessels from pre-existing capillary beds46, 62. This process is tightly controlled by 
specific growth and inhibiting factors which create a delicate balance between blood vessel 
formation and inhibition. Impairment in this balance from either excessive or insufficient 
blood vessel growth; can exarcabate and lead to the pahotlogical form of angiogenesis as 
seen in cancer and cardiovascular atherosclerotic diseases46. New blood vessel formation is 
however beneficial for tissue neovascularisation in response to ischemia such as that 
following a MI, peripheral vascular diseases and wound healing. Neovacularisation however 
is detrimental in the setting of atheroslerosis or cancer as it may exacerbate inflammatory-
driven angiogenesis, therefore accelerating the progression of disease64. 
The studies in chapter 5 demonstrated that stimulation of ECs with TNF-α alone had 
no effect in driving the expression of calcification and angiogenic markers. However, these in 
vitro results demonstrated a combination effect of calcification medium and TNF-α in 
stimulating the expression of calcification markers BMP2 and inflammatory markers VCAM-
1, ICAM-1, MCP1 and NF-κB (P65); whilst driving EC viability and migration. 
As previously stated in chapter 1, atherosclerosis is a chronic inflammatory disease 
that occurs in the vessel wall. During this process, there is involvement of different cell types 
including ECs, VSMCs, fibroblasts, monocytes/macrophages and adipocytes from the tunica 
intima, media and adventitia which all play a role in driving this inflammatory response via 
multiple intricate pathways. During atherogenesis, LDL accumulates within the vessel wall 
and becomes oxidised to ox-LDL. Ox-LDL drives the recruitment of inflammatory mediators 
ICAM-1, VCAM-1 and MCP1, which further stimulates monocyte recruitment and 
differentiation into macrophages, a main event during atherogenesis. As a result, these 
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cascades of inflammatory responses promote atherosclerotic plaque growth. Furthermore, 
cardiovascular calcification most commonly occurs within inflamed plaques and is 
characterized by lipid deposition and macrophage accumulation. Monocyte-derived 
macrophages located in atherosclerotic lesions display osteoclast-like functions and can 
present with a heterogeneous phenotype, from classical proinflammatory M1 to alternative 
anti-inflammatory M2 macrophages. In one study, macrophages were observed to surround 
calcium deposits in atherosclerotic plaques220. In the same study, monocytes/macrophages 
were capable of undergoing osteoclastogenesis when treated with RANKL and colony-
stimulating factor in vitro220. In addition, numerous studies have demonstrated that 
macrophage-derived proinflammatory cytokines ( IL-1β, IL-6, IL-8, TNF-α) promote 
atherosclerosis-associated calcification by regulating the differentiation of calcifying VSMCs 
within the vessel wall91, 221.  
 
 Based on this, the present studies sought to assess whether these striking in vitro 
findings could be extended to an in vivo model of inflammatory-driven angiogenesis. Based 
on results from chapter 3 where in vivo studies showed significant impairment in ischemia-
driven angiogenesis in OPG deficient mice compared to wildtype controls, this study 
evaluated the functional role of a calcification milieu on inflammatory-driven angiogenesis in 







 OPG Deficient Mice Exhibit Elevated Serum Calcium Level 
Following Peri-Arterial Femoral Cuff Surgery.  
To establish the presence of a calcification milieu, both calcium and ALP levels were 
measured in blood plasma collected from both C57BL/6J and OPG deficient mice following 
peri-arterial femoral cuff surgery. Plasma analysis demonstrated no change in ALP activity in 
the OPG deficient mice compared to C57BL/6J controls (Figure 6.2 A). Calcium levels were 
however elevated in the OPG deficient mice compared to C57BL/6J controls (44.80±7.48 vs 
24.04±3.09, P<0.0196, Figure 6.1 B). These results are consistent with previous studies 
























Figure 6.1: OPG Deficient Mice Exhibit Elevated Serum Calcium Levels Following Peri-Arterial 
Femoral Cuff Surgery. C57BL/6J and OPG-/- mice underwent peri-arterial femoral cuff surgery, 
mice were culled 21 days post-surgery and blood plasma collected for analyses. ALP and calcium 
assays were carried out to measure circulating calcium and ALP activity in these mice. (A) ALP 
Activity (B) Calcium concentration. Data is represented as mean ± SEM, *P<0.05, (n=8-10/group). 
Statistical analysis was performed using an unpaired student a Mann Whitney t-test. OPG
-/-, 





 OPG Deficiency Affects Adventitial Neovascularisation, Arteriole 
Formation and Macrophage Infiltration Following Peri-Arterial Cuff 
Placement.  
Neovessels and arterioles were determined by histological staining for CD31 
(endothelial cells in neovessels) and smooth muscle α-actin (smooth muscle in arterioles). 
Neovessels indicate vessels in the early stage of development whilst arterioles represent the 
more advanced vessels that contain a smooth muscle cell outerlayer. In this peri-arterial 
femoral cuff model, OPG-/- mice demonstrated no change in CD31 positive neovessels 
(Figure 6.2) or arterioles (Figure 6.3) as quantified by α-SMA staining in the cuffed arteries 
when compared to wildtypes. This may be attributed to sample size and variability as two 
contributing factors.  
 
Moreover, when macrophage infiltration into the adventitia was assessed following 
peri-arterial cuff placement using CD68 macrophage staining, there was no change in CD68 
expression in cuffed arteries of OPG deficient mice (152%, 329.30±138.90 vs 130.40±25.63) 
when compared to their WT littermates (Figure 6.4). It’s important to note that this result is 
being driven by a couple of outliers with quite variable results, therefore in future if sample 
size was increased, this may help improve the statistics.   
 
 In addition, intima-to-media thickness was assessed using the massons trichrome 
staining, which allows visualisation of the 3 layers of the artery wall. In this study, there OPG 
deficient mice appeared to have a greater intima-to-media thickness compared to wildtype 
control mice (183±57.07 vs 62.85±24.59, Figure 6.5), although a larger sample size is 

















Figure 6.2: OPG Deficiency Affects Adventitial Neovascularisation Following Peri-Arterial Cuff 
Placement. C57BL/6J and OPG-/- mice underwent peri-arterial femoral cuff surgery, and mice were 
culled 21 days post-surgery.  (A) Representative images of neovessels as detected by CD31 staining 
(brown) in the femoral artery adventitia of OPG deficient and C57BL/6J wildtype mice following 
surgery. Negative control panel were tissues not treated with primary antibody (B) Number of 
neovessels were determined as CD31+ cells in the adventitia. Scale bars represent 50 µm. Data is 
represented as mean ± SEM, (n=4-5/group). OPG
-/-, osteoprotegerin deficient mice. 













































Figure 6.3: OPG Deficient Affects Adventitial Arteriole Formation Following Peri-Arterial Cuff 
Placement. C57BL/6J and OPG-/- mice underwent peri-arterial femoral cuff surgery, and mice were 
culled 21 days post-surgery.  (A) Representative images of arterioles identified by α-actin staining 
(pink) in the femoral artery adventitia of OPG deficient and C57BL/6J wildtype mice following 
surgery. Negative control panel were tissues not treated with primary antibody (B) Number of 
arterioles were determined as α-actin+ staining in the adventitia. Scale bars represent 50 µm. Data is 
represented as mean ± SEM, (n=6/group). OPG
















































Figure 6.4: Macrophage infiltration is increased in OPG deficient mice following peri-arterial cuff 
surgery. C57BL/6J and OPG-/- mice underwent peri-arterial femoral cuff surgery, and mice were 
culled 21 days post-surgery.  (A) Representative images and quantification of CD68+ macrophages 
in the adventitia of cuffed arteries from WT and OPG deficient mice, normalised to WT C57BL/6J 
mice. Adventitial macrophages detected by CD68 staining (arrowheads). Negative control panel were 
tissues not treated with primary antibody. (B) CD68+ macrophages were quantified. Scale bars 
represent 50 µm. Data is represented as mean ± SEM, (n=5-6/group). OPG
-/-, osteoprotegerin 
deficient mice. 





















































Figure 6.5: OPG Deficient Mice Display Greater Intima-Medial Thickness Compared to WT 
controls. C57BL/6J and OPG-/- mice underwent peri-arterial femoral cuff surgery, and mice were 
culled 21 days post-surgery.  Representative images and quantification of CD68+ macrophages in the 
adventitia of cuffed arteries from WT and OPG deficient mice, normalised to WT C57BL6/J mice. 
adventitial macrophages detected by CD68 staining (arrowheads). Scale bars represent 50 µm. Data 
is represented as mean ± SEM, (n=5/group). OPG
















 Peri-Arterial Cuff Placement Differentially Regulates mRNA 
Expression of Key Inflammatory Mediators.  
Previously in chapter 5, in vitro data demonstrated that inflammatory stimulus TNF-α 
upregulated inflammatory and calcification markers in ECs. To assess this further in in vivo, 
mRNA was isolated from both non-cuffed and cuffed femoral arteries in wildtype C57BL/6J 
and OPG deficient mice following peri-arterial cuff placement, and inflammation markers 
were assessed.  
Inflammatory-driven angiogenesis is primarily regulated by activation of the 
transcription factor NF-κB, which is responsible for the recruitment of monocytes and 
macrophages to the inflamed site. Nf-κb (p65) activity was downregulated in cuffed arteries 
of C57BL/6J mice compared to non-cuffed arteries following femoral cuff placement 
(24.82±11.85 vs 94.48±10.71, P<0.05, Figure 6.5A). Nf-κb (p65) activity was further 
downregulated in cuffed arteries of OPG deficient mice compared to non-cuffed arteries 
(71.99±6.34 vs 381.10±187.6, Figure 6.5A), though not statistically significant (P<0.06). 
Interestingly, as expected, cuffed arteries of OPG deficient mice exhibited greater expression 
of Nf-κb (p65) activity compared to cuffed arteries of C57BL/6J mice (71.99±6.34 vs 
25.82±11.85, P<0.01, Figure 6.5A).  
Analysis of Cd68 mRNA expression showed significant increase in cuffed arteries 
compared to non-cuffed arteries of wildtype C57BL/6J mice (499.90±64.60 vs 112.80±34.19, 
P<0.01, Figure 6.5C). Consistent with this, OPG deficient mice showed increase in Cd68 
mRNA expression in cuffed arteries compared to non-cuffed arteries (2013±490.90 vs 
341.50±122.20, P<0.05, Figure 6.5C). Furthermore, Cd68 mRNA expression was markedly 
increased in cuffed arteries of OPG deficient mice compared to cuffed arteries of wildtype 
C57BL/6J mice (2013±490.90 vs 499.90±64.60, P<0.05, Figure 6.5B).  
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Monocyte chemoattractant protein (MCP1) is regarded as an important marker of 
inflammation as it is responsible for the transmigration of monocytes into the intima at sites 
of arterial injury. Following periarterial cuff placement on the femoral artery, Mcp1 mRNA 
expression was significantly upregulated in cuffed arteries compared to non-cuffed arteries of 
wildtype C57BL6/J mice (349.30±64.30 vs 132.20±55.69, P<0.05, Figure 6.5E), an effect 
that was further increased in OPG deficient mice (1268±252.60 vs 222.90±91.16, P<0.01, 
Figure 6.5E). Mcp1 expression was also upregulated in cuffed arteries of OPG deficient mice 
compared to cuffed arteries of C57BL6/J mice (1268±252.60 vs 349.30±64.30, P<0.01, 
Figure 6.5E).  
Taken together, these findings show that periarterial cuff placement on the femoral 






















Figure 6.5: Peri-Arterial Cuff Placement Differentially Regulates mRNA Expression of Key 
Inflammatory Mediators. C57BL/6J and OPG-/- mice underwent peri-arterial femoral cuff surgery, mice 
were culled 21 days post-surgery and Real-time PCR was performed to assess gene expression. (A) Nf-κb 
(P65), (B) Cd68, (C) Mcp1.  Data is represented as mean ± SEM, *P<0.05, **P<0.01, (n=5-6/group). 
Statistical analysis was performed using a One-way ANOVA with Bonferroni’s multiple comparison test 
and an unpaired student a Mann Whitney t-test. OPG--/: osteoprotegerin deficient mice, NF-kB (P65): 







6.2.4 OPG Deficiency Inhibits the Expression of Key Angiogenic Factors 
Following Peri-Arterial Cuff Placement. 
To further understand the role of elevated calcium on inflammatory-driven 
angiogenesis, angiogenic factors Hif-1a, Vegfa and its receptor Vegfr2 mRNA levels were 
examined following peri-arterial cuff placement. There was no significant change in Hif-1a  
mRNA expression in cuffed arteries compared to non-cuffed arteries of wildtype C57BL/6J 
and OPG deficient mice (Figure 6.6A); with no change also observed when expressed as a 
ratio of cuffed versus non-cuffed (Figure 6.6B)   
Similarly, there was no change in Vefga mRNA expression in wildtype C57BL/6J 
mice between non-cuffed and cuffed arteries, even when expressed as a ratio of cuffed: non-
cuffed (Figure 6.6D). In addition, Peri-arterial cuff placement had no effects on Vegfr2 
mRNA expression in non-cuffed and cuffed arteries of wildtype C57BL/6J mice (Figure 
6.6E); and the same response was also evident when expressed as a ratio of cuffed: non-















Figure 6.6: OPG Deficiency Inhibits the Expression of Key Angiogenic Factors Following Peri-
Arterial Cuff Placement. C57BL/6J and OPG-/- mice underwent peri-arterial femoral cuff surgery, 
mice were culled 21 days post-surgery and Real-time PCR was performed to assess gene expression. 
(A-B) Hif-1a,, (C-D) Vegfa, (E-F) Vegfr2.  Data is represented as mean ± SEM, (n=5-6/group). 
Statistical analysis was performed using a One-way ANOVA with Bonferroni’s multiple comparison 
test and an unpaired student a Mann Whitney t-test. OPG
--/: osteoprotegerin deficient mice, HIF-1a, 
hypoxia-inducible factor-1 alpha, VEGF, vascular endothelial growth factor, VEGFR, vascular 








6.2.5 OPG Deficiency Inhibits the Expression of Calcification 
Transcription Factors. 
To better understand the role of calcification on inflammatory-driven angiogenesis, I 
examined the expression of key transcription factors Runx2 and RANKL following peri-
arterial cuff placement. While there was no change in Runx2 mRNA expression in cuffed vs 
non-cuffed arteries compared of C57BL/6J mice, cuff placement resulted in significant 
reductions in Runx2 mRNA expression compared to non-cuffed arteries in OPG deficient 
mice (46.11±26.48 vs 186.90±36.22, P<0.05, Figure 6.7A). When expressed as a ratio of 
cuffed versus non-cuffed, this effect was lost (Figure 6.5 B).  
 Rankl expression was significantly downregulated in cuffed arteries of wildtype 
C57BL6/J compared to non-cuffed arteries (39.09±12.20 vs 241.50±72.11, P<0.05, Figure 
6.7C), a response that was also present in OPG deficient mice (22.11±6.88 vs 540.60±195.50, 
P<0.05, Figure 6.7C. Additionally, Rankl mRNA expression was also reduced in OPG 
deficient mice compared to C57BL6/J mice when expressed as a ratio of cuffed: non-cuffed 
(Figure 6.5 D) though not statistically significant.  
Altogether, the gene expression analyses indicate that while the placement of the cuff on the 
femoral arteries caused an inflammatory response evidenced by an increase in inflammatory 
markers, this did not cause any downstream activation of angiogenic markers. Interestingly 
expression of calcification markers was reduced suggesting that high calcium present in the 
OPG model may act alone to drive inflammation independently via other unknown 
alternative pathways.  
 














Figure 6.7: OPG Deficiency Inhibits the Expression of Calcification Transcription Factors. 
C57BL/6J and OPG-/- mice underwent peri-arterial femoral cuff surgery, mice were culled 21 days 
post-surgery and Real-time PCR was performed to assess gene expression. (A-B) Runx2, (C-D) 
Rankl. Data is represented as mean ± SEM, (n=5-6/group). Statistical analysis was performed using 
a One-way ANOVA with Bonferroni’s multiple comparison test and an unpaired student a Mann 
Whitney t-test, *P<0.05. OPG
--/: osteoprotegerin deficient mice, Runx2: runt related transcription 








The present study was designed to further understand the role of calcification on 
inflammatory-driven angiogenesis in vivo. While calcification is known to be associated with 
inflammation very little is known regarding its effect in driving the pathological form of 
angiogenesis.  It is important to note that no previous literature has reported any known role 
for the regulation of calcification genes during inflammation. However, there are evidence 
for the association of inflammation in vascular calcification. Chronic inflammation is a 
central factor in soft tissue calcification and is a common site for atherosclerotic calcification 
in mice222. Oxidation of lipids from atherosclerotic plaques can induce RANKL expression to 
drive calcification223, 224. Therefore, based on this evidence, calcification may therefore 
contribute in regulating inflammatory-driven angiogenesis.  
The peri-arterial cuff model was used to stimulate inflammatory-driven angiogenesis 
in OPG and C57BL/6J mice. This murine model involved placing a cuff around the femoral 
artery to stimulate a localised inflammatory response which triggers the recruitment of 
macrophages and the release of pro-inflammatory cytokines and growth factors that drive 
increased neovessel formation at the site of injury. To assess angiogenesis, histological 
staining was performed to measure CD31+ endothelial cells (neovessels) and α-actin+ for 
smooth muscle cells (arterioles), which represent early and late neovessels. Cuff placement 
caused a reduction in the number of neovessels within the adventitial space, while increasing 
the number of arterioles in the adventitia in OPG deficient mice compared to wildtype 
C57BL/6J mice (Figure 6.8). It is important to also note that cuff placement had no effect in 
regulating pro-angiogenic factor expression for HIF-1a or VEGFA, and may therefore 
demonstrate differential effects of high calcium on inflammatory-driven angiogenesis 
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Macrophages play a key role in the regulation of inflammatory-driven angiogenesis 
and are known to secrete pro-angiogenic cytokines and growth factors to regulate this 
process. In this study, placement of the peri-arterial cuff around the femoral artery stimulated 
an increase in inflammation as demonstrated by increased Cd68 and Mcp1 mRNA 
expression, responses that were see in both wildtype C57BL/6J mice and further increased in 
OPG deficient mice Figure 6.8); highlighting that a calcification milieu may drive a greater 
inflammatory response. While there was increased pro-inflammatory marker expression, 
there was also concomitant decrease in the expression of calcification markers Runx2 and 
Rankl in cuffed arteries of OPG knockout mice. This effect could be attributable to other 
mechanisms independent of inflammation and is an area that requires further investigation. 
Therefore, it is likely that the mechanism by which cuff placement exerts its inflammatory 
effects may be occurring via modulation of the NF-κB signalling pathway and may explain 
the results observed in this study.  
 
VEGFA is an important regulator of angiogenesis under both ischemic and 
inflammatory conditions, as it contains both hypoxia (HIF-1a) and inflammatory (NF-κB) 
response elements in its promoter region. As a result, VEGFA can drive both physiological 
ischemia-driven angiogenesis and pathological inflammatory-driven angiogenesis, thus 
allowing conditional regulation of the two processes. In this study, when key pro-angiogenic 
markers were assessed, cuff placement elicited no significant change in Hif-1a and Vegfa 
mRNA expression in OPG knockout mice, a trend that was also observed in wildtype 
C57BL/6 J mice. This response in pro-angiogenic marker expression may suggest increased 
regulation of pathological angiogenesis, though a greater sample size is required to fully 
confirm this response.  Interestingly, Nf-κb (p65) mRNA expression was decreased in cuffed 
arteries of both C57BL6/J and OPG deficient mice following cuff placement, a response that 
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was unexpected. This decrease in Nf-κb (p65) expression in cuffed arteries of OPG deficient 
mice may reflect alternative mechanisms that may be suppressing Nf-κb activation during 
inflammation, thus warranting further studies.  
 
Additionally, RANKL signalling involves activation of NF-κB located downstream of 
the RANK receptor. This is known to result in the activation and initiation of osteogenic 
differentiation, and release of transcription factor Runx2 which drives vascular calcification. 
In this study, decreased Nf-κb signalling coincides with decreased Rankl and Runx2 
expression in cuffed arteries of OPG deficient mice. Therefore, potentially, the inhibition of 
Rankl may subsequently inhibit the expression of inflammatory marker Nf-κb (p65), which 
suggests other downstream pathways to be involved.  
As previously stated in chapters 4, the same limitations also apply to this study. OPG 
deficient mice have been validated as a vascular calcification model and therefore it cannot 
be discounted that the response seen is due to the loss of OPG itself. Furthermore, a small 
sample size is another limitation, and thus increasing sample size will increase statistical 
significance in future studies.   
 
In conclusion, data from this study has provided evidence that high calcification 
milieu may help drive pathological inflammatory-driven angiogenesis, a response that isn’t 








Figure 6.8: Summary Schematic for the Effect of High Calcium on Inflammatory-Driven 
















7.1 Introduction  
PAD and CAD are increasingly recognized as two major causes of mortality, 
affecting  approximately 200 million individuals worldwide33. During the course of disease 
progression, reduced tissue perfusion of the limbs results in ischemic ulcerations and gangrene 
formation; which increases the risk of developing limb amputations, also known as critical 
limb ischemia (CLI) 9. In response to ischemia, the body works to compensate this via 
increasing the development of collateral vessels to bypass and alleviate stenosis, and thus 
restore blood flow to preserve tissue function, a process that is regulated by both hypoxia and 
inflammatory processes. However, the formation of collateral vessels is dependent on the 
environment. In patients with PAD, the ability to form collateral vessels is suboptimal or 
impaired due to many factors, one of them being the presence of calcification within the vessel 
wall15, 33, 34, 225, 226. As a result, most treatment options for patients suffering from PAD are 
limited to lifestyle and surgical interventions which are not always effective especially in 
severe/chronic cases where limb amputations are required. Therefore, it is crucial to 
understand the mechanisms to promote new collateral vessel formation, as this will lead to 
potential non-surgical therapeutic approaches to treat patients with PAD. 
 
7.2 Purpose of Thesis and Summary of Results 
This study sought to understand how calcification regulates essential processes of 
neovascularisation. In endothelial cells the effect of calcium/phosphate on angiogenesis172, 227,  
has demonstrated conflicting results with one study reported to increase proliferation66, while 
inhibiting proliferation in another65. Because of the myriad of effects that both calcium and 
phosphate have in regulating physiological processes and cell signalling within the body, it 
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remains unclear the exact mechanism by which calcium/phosphate may regulate angiogenesis 
in ECs. In an attempt to understand the mechanisms driving EC-angiogenesis in response to 
calcification, in vitro studies were conducted to investigate the effect of high calcium on two 
mechanisms known to regulate neovascularisation: ischemia-driven angiogenesis and 
inflammatory-driven angiogenesis. In vivo studies utilised a pre-clinical calcification model 
using OPG knockout mice to mimic a high calcific environment against wildtype C57BL6/J 
mice. These mice were subjected to two models of angiogenesis namely the hind-limb 
ischemia model to induce hypoxia-driven angiogenesis, and the peri-arterial femoral cuff 
model to induce inflammatory-driven angiogenesis.  
Based on data from Chapter 3, treatment with calcification medium (CM) in vitro 
significantly reduced key functional angiogenic assays when subjected to normoxic conditions 
but had very little to no effect in hypoxic conditions. Mechanistically, in vitro studies 
demonstrated that CM downregulated angiogenesis in ECs, via reductions in tubule formation 
and cell migration; whilst mitigating the phosphorylation of key pathways for eNOS, P38 
MAPK, and ERK1/2 signalling that are known to drive angiogenesis (Figure 7.1). 
Furthermore, in vivo data presented in Chapter 4 demonstrated significant impairment of 
ischemia-driven angiogenesis following hind-limb ischemia surgery in our calcification model 
using OPG deficient mice. The negative effects of high calcium were further demonstrated as 
OPG-/- mice experienced severe impairment in blood flow reperfusion following HLI surgery, 
with decreased capillary and neovessel formation. OPG-/- mice also developed necrosis and 
spontaneous foot amputations following HLI, and as a result had impaired tissue and limb 
function which was exacerbated with age (Figure 7.1). 
In vitro data presented in Chapter 5 showed that stimulation of ECs with TNF-α 
resulted in CM-induced upregulation in key inflammatory markers of MCP1, ICAM-1, 
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VCAM-1 and NF-κB (P65). These results coincided with significant upregulation of key 
calcification markers of BMP2, Runx2 and ALP (Figure 7.2).  In vivo data from Chapter 6 
demonstrated that following peri-arterial femoral cuff placement, there was no effect on 
inflammatory-induced angiogenesis in OPG deficient mice compared to controls. Cuff 
placement however induced the expression of inflammatory markers Nf-κb (p65) and Mcp1; 
whist decreasing both Runx2 and Rankl gene expression in OPG deficient mice relative to 
controls (Figure 7.2). Overall, the data presented in these chapters highlights the idea that high 
calcium may drive inflammation alone independent of effects on angiogenesis. 
Physiological angiogenesis is a crucial process that occurs post-ischemia following a 
myocardial infarct, stroke or in PAD. Impairment in pro-angiogenic pathways can exacerbate 
and lead to pathological form of angiogenesis, that occurs in atherosclerosis and cancer tumour 
growth. Following assessment of both forms of angiogenesis, collectively, this data has 
demonstrated negative regulation of ischemia-driven angiogenesis with a calcification milieu 
both in vitro and in vivo; while having very little effect in regulating inflammatory-driven 
angiogenesis.  
 
7.3 Effect of High Calcium on The Endothelium  
This study utilised endothelial cells as the primary model to study angiogenesis in 
vitro. These cells were chosen because as they are the primary cells that line the vessel wall, 
they are responsible for regulating key angiogenic processes of proliferation, migration and 
tubule formation; whilst also mediating a range of reparative responses including 
inflammation  in response to injury56. ECs are the first cell targets to be involved following 
ischemia-induced responses in different organs, and their functions are immediately impaired 
by ischemia175. It is important to note that this is the first study that has assessed the direct role 
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of calcium-phosphate on EC angiogenesis. Majority of studies relating to calcification have 
been conducted on VSMCs as these cells are capable of osteoblast-differentiation98. 
Furthermore, to date, only one study has evaluated the role of endothelium in VC, which 
involved the knockdown of calcification inhibitor matrix-gla protein. This study reported that 
the vascular endothelium may act as a source of multipotent cells that contribute to VC in 
states of high BMP activity228. Furthermore, based on the in vivo data, it would be interesting 
to assess OPG knockdown in endothelial cells to fully to confirm the results obtained from this 
study and to see whether the absence of OPG a compounding for the regulation of 
angiogenesis, as OPG has been shown to drive EC angiogenesis in published in vitro 
studies153.   
 
7.4 The Effect Calcification on Hypoxia-Driven Angiogenesis  
Results from the in vitro studies demonstrated that hypoxia had no effect in driving 
angiogenic processes of cell viability, migration, or tubule formation. CM however induced 
upregulation of pro-angiogenic markers HIF-1α and VEGFA in both normoxia and hypoxia 
conditions, despite reduced angiogenesis. It is plausible that this effect is dependent on the 
incubation time and exposure to hypoxia, as in this study, cells were incubated in hypoxia for 
only 4 hours. In previous studies, human umbilical vein endothelial cells (HUVECs) exposed 
to hypoxia showed resistance to cell death with only a 2% reduction in viability at 24 h and 
45% reduction in viability at 48 h187. Studies in chapter 3 showed that hypoxia had no effects 
on EC viability, and based on this evidence, future studies should be conducted at longer time 
points such as 48 h.  
The interplay between calcium (Ca2+) and reactive oxygen species (ROS) signalling 
pathways is an important determinant in normal physiology and in several pathophysiologies. 
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Ca2+ modulates reactive oxygen species (ROS) homeostasis by regulating ROS generation in 
both the mitochondria and cytosol229. In addition, calcium phosphate is known to regulate cell 
signalling in the body and are coupled with oxygen availability. During hypoxia, the 
reduction of oxygen molecule results in the formation of reactive oxygen species (ROS). So it 
is likely that decreased O2 via hypoxia may affect the cells ability to function and thus affect 
their ability to regulate calcium signalling in order to drive cellular processes. Furthermore, 
ROS have been reported to be important in processes of physiological ischemia-induced 
angiogenesis and wound healing in vivo. In one study, mice lacking Superoxide dismutase 
displayed significant inhibition in ischemia-induced increase in blood flow recovery, 
collateral vessel formation, and capillary density230. This data support findings from our 
study where eNOS phosphorylation is significantly decreased in vitro following incubation 
with calcification medium. However, in futures, eNOS activity could be further investigated 
in our in vivo model of calcification to fully understand these interactions.  
In angiogenesis, ROS production stimulates VEGFA expression to augment 
angiogenesis in endothelial cells231. There are various sources involved in producing ROS in 
ECs, including xanthine oxidase, NADPH oxidase, mitochondrial electron transport chain, 
eNOS uncoupling and cytochrome P450. During angiogenesis, eNOS is important and is 
located downstream of the HIF-1α signalling pathway and helps to enhance angiogenesis 
following an ischemic insult. In this study, CM treatment significantly mitigated eNOS 
phosphorylation in ECs compared to untreated cells in both normoxia and hypoxia 
conditions, despite an increase in HIF-1α in normoxic conditions. This reduction in eNOS 
expression suggests a downstream signalling effect of high calcium in supressing 
angiogenesis. Since calcification is highly associated with aging, as is the role of oxidative 
stress - the correlation between VC and vascular aging has been well established. Aging 
induces mitochondrial dysfunction and augments ROS production, which plays an important 
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role in regulating cell signalling pathways during senescence and contributes to extracellular 
vesicle formation during calcification232. ROS production has opposing effects in 
calcification, as oxidative stress stimulates calcification by activating specific signalling 
cascades to increase Runx2 transcription factor expression. Interestingly, Runx2 expression is 
maintained by ROS production, particularly by hydrogen peroxide233. Furthermore, BMP2 
activates NADPH oxidases to increase VC. Therefore, based on results obtained from this 
study where CM reduces eNOS phosphorylation, this suggests the involvement of ROS and 
potentially alternate sources of ROS including NADPH oxidase, xanthine oxidase and 
mitochondria should be investigated to fully understand their role in calcification-induced 
angiogenesis232.  
The hindlimb ischaemia model employed in Chapter 4 is a well-established model of 
ischaemia-driven neovascularisation that is commonly used to study PAD in vivo; and allows 
both angiogenesis and arteriogenesis to be investigated. Data from Chapter 4 demonstrated 
that a calcification milieu caused striking reductions in revascularisation in OPG deficient 
mice compared to controls in an 8wk old cohort, as illustrated by reductions in CD31 positive 
neovessels in the gastrocnemius muscle of these mice. Surprisingly, there was significantly 
increased smooth muscle alpha actin-positive arterioles in the gastrocnemius muscle of OPG 
deficient mice following HLI. This increase may demonstrate late stage remodelling or 
arteriogenesis, as arterioles demonstrate more mature vessels compared to those seen in 
angiogenesis. Furthermore, OPG deficient mice demonstrated significant increases in 
circulating calcium and ALP levels relative to wildtype C57BL6/J mice. Moreover, because 
both PAD and calcification are age-associated diseases, OPG-/- mice were aged and 
angiogenesis was assessed. Aged OPG-/- mice demonstrated significantly exacerbated effects 
as demonstrated by the doppler perfusion data, where there was impairment in angiogenesis 
and revascularisation following HLI. OPG-/- mice surprisingly self-amputated following HLI, 
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which was associated with decreased limb function and tissue ischemia. However due to the 
clinically reported effects of OPG139, 143, 146, 234 , it remains unclear whether the response 
observed in this study is due to the absence of OPG or the increased calcium in this OPG 
model; an observation that needs to be investigated further.  
 




7.5 The Effect Calcification on Inflammatory-Driven Angiogenesis  
The pathophysiology of PAD is often considered secondary to atherosclerosis and is 
characterised by fatty plaque build-up within the peripheral arteries of the vessel wall. In the 
vessel wall there are two types of calcifications; intimal calcification which is associated with 
atherosclerosis alongside lipid deposition and inflammation; and medial calcification that 
occurs independently of atherosclerosis in the medial layer due to differentiation of VSMCs 
towards osteoblast-like cells. Numerous risk factors such as smoking, high cholesterol, 
oxidative stress, aging and high blood pressure drive the process of calcification and 
inflammation in atherosclerosis.  
In Chapter 5, ECs treated with CM and TNF-α exhibited increased ALP activity and 
calcium secretion in cells; as well as increased expression of inflammatory markers of ICAM-
1, VCAM-1, MCP1 and transcription factor NF-κB (P65); a response that coincided with 
increased cell migration, cell viability and tubule formation following treatment with both CM 
and TNF-α (Figure 7.2). This was also associated with increased expression of calcification 
markers BMP2 and Runx2. While very little is known regarding the effect of calcification on 
ICAM-1, VCAM-1 and MCP1, because of their well-established role in plaque atherogenesis 
it is likely that calcification may regulate their expression in inflammatory-driven 
angiogenesis.  
During early atherogenesis, a network of microvessels within the adventitial and outer 
medial layer stimulate neovascularisation to deliver oxygen and nutrients to support plaque 
growth, resulting in expansion of the vaso vasorum. In this study, CD31 neovessels were non-
significantly decreased following cuff placement in OPG mice compared to C57BL6/J mice.   
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Previously, data by Collett and Canfield24, reported that differentiation of VSMCs 
is brought about by an inflammatory stimulus, which triggers activation of specific 
osteogenic signals such as BMP2. This subsequently stimulates differentiation of VSMCs 
into osteoblast-like cells, a well proposed mechanism of vascular calcification 61, 62, 157. In 
addition, studies have proposed OPG as a marker of endothelial dysfunction during 
inflammatory disease processes. Previous findings reported that OPG induced the expression 
of intercellular adhesion molecules, such as VCAM-1 and E-selectin in ECs, and promoted 
leukocyte adhesion, an early step in EC dysfunction, thus supporting a pro-inflammatory role 
for OPG184, 205. In a different study, treatment of HUVECs with 5 ng/ml of TNF-α over 24 h 
increased OPG expression235. In this study, data from Chapter 5 demonstrated that OPG 
expression remained unchanged when cells were stimulated with TNF-a alone compared to 
untreated cells; however, when cells were co-incubated with both TNF-a and calcification 
medium, OPG expression was significantly downregulated. There currently lies much 
controversy regarding the role of OPG, particularly since elevated OPG is considered a 
predictive biomarker of cardiovascular disease mortality and morbidity137, 149, 153, 235.  
Inflammatory-driven angiogenesis is primarily regulated by the NF-κB signalling 
pathway. Moreover, VEGFA is also a regulator of inflammatory-driven angiogenesis as it 
contains a NF-κB response element in its promotor region. Data from Chapter 5 demonstrated 
no change in expression of VEGFA, with TNF-a and calcification medium co-incubation, 
while NF-κB (P65) protein expression was increased (Figure 7.2). Since VEGFA can promote 
both ischemia and inflammatory-driven angiogenesis, HIF-1a expression was also assessed 
with calcification medium treatment, and no change was observed. In other studies, with 
smooth muscle cells, TNF-a enhanced HIF-1a mRNA expression levels in both normoxic and 
hypoxic conditions236. Additionally, using human adenocarcinoma cells, TNF-a treatment 
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increased HIF-1a expression, whilst also inhibiting cell viability191. Furthermore, it was 
previously shown that TNF-α induced accumulation of HIF-1α in normoxic cells requires 
activation of NF-kB pathway237. To date, there are no studies demonstrating the expression of 
HIF-1a in response to calcification stimulus with or without inflammatory stimuli, thus further 

























Figure 7.2: Summary schematic illustrating the effects of calcification stimuli on 
inflammatory-driven angiogenesis.  
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7.6 Future directions  
Damage to the endothelium is one of the earliest responses in the development of 
CVD, and occurs due to changes in vasoactive mediators which promote vasosonstricion189. 
Given the organisation of the vessel wall with the endothelium being in close proximity to the 
medial layer containing smooth muscle cells, crosstalk between ECs and VSMCs contributes 
to the progression of disease. The mechanisms accounting for the link between angiogenesis 
and calcification are multifactorial as these processes involve the coordinated interplay of 
many different cell types expressed within the vessel wall including ECs, VSMCs, pericytes, 
circulating and resident osteoprogenitors, as well as osteoblastic cells. The three known 
primary cell drivers of angiogenesis are ECs, VSMCs and pericytes 23, 24, 238. While these 
studies utilised ECs, the other cells involved could also be utilised for future studies in 
vascular calcification. As discussed earlier, endothelial cell migration and proliferation are 
critical processes required for angiogenesis. A subpopulation of  SMCs have been identified 
within the vessel wall and termed calcifying vascular cells (CVCs), accounting for 
approximately 20-30% of the total VSMC population61, 80 239. These cells have high expression 
of ALP and are able to calcify and form large nodules when maintained in culture for extended 
periods of time. CVCs also have the potential for undergoing multiple mesenchymal lineages 
for osteoblasts61. Furthermore, it has been suggested that osteogenic signals or osteogenic 
precursor cells may be delivered into the arterial wall by collateral vessels that develop in 
response to inflammatory signals; a theory that is based on the known relationship between 
angiogenesis and the progression of atherosclerotic plaques. Therefore, it has been proposed 
that the development of collaterals within the adventitia during atherosclerosis allows 
migration of multipotent adventitial myofibroblasts and other cells types including pericytes 
into the intima and medial layer of the vessel wall, where they are able to differentiate into 
osteoblast-like cells through signalling mechanisms regulated by BMP2, Runx2 and OPG33.   
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Pericytes are resident cells that are expressed in the vessel wall that are involved in 
regulating angiogenesis. Pericyte migration and activation is an important step in the later 
stages of angiogenesis as demonstrated in Figure 1.3. Pericytes are often proposed to be 
mesenchymal progenitor cells that are capable of undergoing cell differentiation towards other 
several lineages including osteogenic (osteoblasts) and chondrogenic (chondrocytes); and are 
therefore proposed to be involved in regulating vascular calcification processes239. 
Furthermore, pericytes also produce nodules of cells and ECM in long-term culture, which 
contain calcification markers of type I collagen, OPN, MGP and osteocalcin. Therefore based 
on this , pericyte activation within the vessel wall may provide a source of osteoprogenitors 
and thus help drive VC61. Based on results obtained from this study, I suspect that calcium 
phosphate may regulate angiogenesis by mechanisms other than directly stimulating 
endothelial cells. Co-culture experiments with other cell types such as pericytes, VSMCs 
and/or endothelial progenitor cells would be beneficial to fully understand any potential 
autocrine/paracrine effects of calcium-phosphate-induced angiogenesis.  
The involvement of Tie-2 and angiopoietin have been suggested to play potential 
roles in driving calcification. This is because elevated expression of growth factors such as 
VEGFA and angiopoietins are associated with increased cholesterol and OPG, which are two 
known mediators of inflammation189. Its therefore suggested that there is possible binding of 
VEGFR1/2 and Tie-2 to ECs which may then drive increased calcification. Future studies 
could therefore be employed to study the relationship between Tie-2 in driving angiogenesis. 
In addition, it would be interesting to cross OPG mice with Tie-2 mice to further examine the 
specific effects of calcification on endothelial cells.  
In Chapter 3, CM had differential effects on EC angiogenesis, where HIF-1α was 
upregulated with CM treatment, despite upregulation of calcification marker Runx2. Because 
of the role of Runx2 in its ability to increase HIF-1α expression, this provides a plausible 
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explanation for the regulation of HIF-1α . To fully understand this interaction, future studies 
performing siRNA knockdown for Runx2 in ECs following CM treatment could offset the 
possibility of early compensatory mechanisms for HIF-1α. Furthermore, it would be 
beneficial to measure intracellular calcium for internalisation into the cells, by measuring 
calcium sensing receptor activity. Other future directions for this study could involve 
performing ex-vivo experiments to study angiogenesis in OPG mice.  This would involve 
performing aortic ring assays or Matrigel plug assays to assess angiogenic sprouting in mice 
with elevated calcium. In addition to this, ECs could be extracted from OPG deficient mice 
and cultured in vitro to perform angiogenic assays as previously done in this study.  
 
7.7 Limitations  
This thesis aimed to contribute to the current body of evidence on vascular 
calcification and its effects on angiogenesis both in vitro and in vivo.  Physiologically, 
calcium serves many functions in the body and is ubiquitously available in biological fluids, 
whilst phosphate also serves as a common stimulus for molecular signalling pathways; thus, 
any shift in ion homeostasis for both Ca and phosphate can result in mineralisation. There are 
many cell and animal models to study the molecular processes of vascular calcification. 
Majority of cell lines do not calcify spontaneously in vitro and require stimuli to induce 
calcification. As mentioned in Chapter 3, this study utilised one stimulus for the induction of 
calcification in the cells, using calcium chloride and sodium phosphate as a form of 
calcification medium. Furthermore, while in vitro cell culture experiments are helpful in 
studying signalling pathways of calcification, tissue organisation of cells is lost and processes 
involving the ECM are not represented. Therefore, as an alternative, 3D cell culture models 
could be utilised in future as they mimic the direct physiological environment and thus 
provide a better understanding of mechanisms driving disease progression. There currently 
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exists one 3D model used to study calcific aortic valve disease which resembles human aortic 
calcification196. Based on this, it remains unclear of the most efficient way to stimulate VC in 
vitro and which limits our ability to fully study this in vitro. In Chapter 3, western blotting 
results demonstrated that hypoxia treatment with calcification medium decreased the levels of 
the housekeeping protein alpha-tubulin (loading control), and this may also contribute to the 
lack of significant in the data. Furthermore, the lack of statistical significance observed in this 
study could be due to the smaller sample size, thus future studies should include more n 
values to increase the statistical power.  
 
Preclinical models using rats and mice are readily used to study vascular calcification 
in vivo as they provide a better physiological context. Currently, there are 4 approaches of 
inducing calcification in mice, including models that are naturally occurring, induction of VC 
by operation, substance application/feeding or by genetic modification196. The most 
commonly used models for calcification are genetically modified mouse models, whereby 
medial calcification is induced by disrupting protective mechanisms by inhibiting 
calcification inhibitors. These knockout models include deficiency in MGP, Fetuin-A, OPN 
and OPG196. Furthermore, calcification can be induced by increasing hormonal regulation of 
phosphate, by affecting serum phosphate concentration. This method involves 
supplementation with vitamin D and is often used to study calcification in the setting of 
chronic kidney disease. This model however is not suitable to study angiogenesis as vitamin 
D administration causes physical impairment and promotes weight loss. 
In this study, I utilised the OPG knockout mice as a calcification model to mimic high 
calcific environment. It is therefore important to note that the absence of OPG could be 
responsible for the results obtained in vivo and this requires further investigation. Data from 
Chapter 4 confirmed that our OPG knockout mice indeed had increased circulating calcium 
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levels as measured using a calcium assay. Furthermore, in a different study, osteoprotegerin 
inactivation accelerated atherosclerotic plaque lesion progression and calcification in older 
ApoE-/- mice compared to controls149. Overall, the pre-clinical models used in this thesis 
provide mechanistic insight into how calcification may drive angiogenesis, particularly in the 
context of high calcium. 
Finally, OPG levels in humans are gender specific with women having higher levels 
of OPG than men234. In mice, oestrogen has been shown to increase OPG expression240.  
Therefore, this study utilised male mice only to eliminate the effect of oestrogen on our 
doppler perfusion and inflammatory data. However, this study should be performed using 
both male and female mice to fully understand the effect on calcification milieu in OPG mice 




This study demonstrates that calcification may dampen physiological angiogenesis 
while having no effect on inflammatory-driven angiogenesis. These data suggest that high 
calcium mediates angiogenesis in part by activating endothelial cells and driving increased 
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